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ABSTRACT 
ρ GABAC receptors are membrane receptors that are activated by GABA, the most 
abundant inhibitory neurotransmitter in the vertebrate CNS.   The ρ receptors are 
insensitive to ligands that typically affected both the ionotropic GABAA and 
metabotropic GABAB receptors.  
Structural studies of the ρ GABAC receptor haven’t been undertaken due to difficulties 
in crystallizing the protein. Thus, homology modeling based on the available templates 
would afford the method to gain knowledge about the structure of the GABA binding 
site of ρ GABAC receptors. 
Five sets of ρ1 GABAC homology models were generated based on AChBP, GLIC, 
ELIC, GABAA β3 and GluClα templates. Studies on GABA poses and interactions in 
the orthosteric binding site were performed with models based on each template. Due to 
the higher amino acid sequence identity (36%) and the presence of glutamic acid as a 
co-crystalized ligand, the GluCl based models were found to be the best to represent the 
structure of ρ1 GABAC receptors. The GABA conformation in the selected best model 
supported by QM-polarized ligand docking was used to study molecular interactions in 
the ρ1 GABA binding site. This study identified several residues with potential ligand-
interactions located on loops F and G with their side chains oriented toward the binding 
site such as serine 215 and glutamine 83. The partial agonists muscimol and imidazole-
4-acetic acid (I4AA) were re-docked into the binding site of the most reliable ‘GABA 
bound’ homology model. The potency and efficacy of these partial agonists in 
activating recombinant ρ1 receptors were studied along with their docking results. A set 
of TPMPA bound ρ1 homology models based on the GluClα ‘apo state’ template was 
built in order to study a competitive antagonist in the ρ1 orthosteric binding site. The 
results demonstrated the ability of our model to explain most experimental findings and 
predict potential roles of residues within the orthosteric binding site. 
The three hydrophilic residues Ser168, Ser243 and Thr244, which line the orthosteric 
binding site of ρ1 GABAC receptors were studied by point mutation and tested with 
GABA, some representative partial agonists and antagonists. Thr244 has a hydroxyl 
group essential for GABA activity that is constrained by the threonine methyl group, 
pointing it toward the binding site. Significant decreases in activation effects of studied 
ligands at ρ1 T244S mutant receptors suggest a crucial role of this residue in binding of 
the agonist as an initial step during channel gating by moving loop C towards the 
ligand. ρ1 T244A and ρ1 T244C mutant receptors have minimal sensitivity to GABA at 
high mM concentrations, whereas β-alanine and MTSEA demonstrate higher efficacy 
and potency, respectively, than GABA at these mutant receptors. The Ser243 residue in 
the middle of the loop C has the hydroxyl group partially facing the binding site and 
oriented toward the adjacent subunit. Homology modelling studies predict different 
contacts between the side chain of this residue and the side chains of Arg104 and 
Lys210 residues in the adjacent subunit during the apo state and the open conformation. 
xxxvi 
 
Structural chemistry studies have shown significant decreases in activation and 
additive/inhibition effects of the studied ligands when threonine or cysteine residues are 
introduced at the Ser243 site. Interestingly, 3-APPA is switched from a full antagonist 
to a partial agonist with mixed effects of activation and potentiation at ρ1 S243T and ρ1 
S243C mutant receptors. Results of modelling and electrophysiology studies predict a 
role for Ser243 residue in the inter-subunit interactions that stabilize the closed state or 
the open conformation. Ser168 in loop E has a hydroxyl group oriented toward the 
orthosteric binding site, which is predicted by GABA docking studies to form a H-bond 
with the carboxylate group of GABA. Removing the hydroxyl group at the 168 position 
through mutation to alanine  or replacing the hydroxyl with a thiol group have been 
shown to decrease the activation and inhibition effects of the studied ligands, however 
the magnitude of the co-operative (additive) effects of the studied ligand were shown to 
increase. The results of these studies suggest that the introduced residues at the Ser168 
site have mixed effects in the ligands stabilizing different states. 
Two sets of ρ2 GABAC homology models were generated based on GluCl in open and 
apo conformations using GABA and (R)-ACPBPA as reference ligands, respectively. 
Various interactions between GABA and residues in the binding site were discussed. 
The activation and co-application with GABA effects of three sets of partial agonists 
were discussed in terms of their efficacy and magnitude of additive and inhibitory 
effects. The potent and selective antagonist R-(ACPBPA) at ρ2 GABAC receptors was 
studied in terms of interactions with residues in the binding site. A cation-cation 
interaction was predicted to form between this ligand and a basic residue (Arg230) 
located at loop C. 
The intra-subunit selectivity of the studied partial agonists at ρ1 and ρ2 GABAC 
homomeric receptors was discussed in terms of their efficacy and co-application with 
GABA effects. The glide emodel values and the predicted interactions of ligands with 
residues in the binding site were reported and discussed in terms of stabilizing the apo 
state or the open conformation either when those partial agonists were applied alone or 
co-applied with GABA EC50. 
In this thesis, the residues in the GABA binding site of ρ1 GABAC were discussed in 
terms of identifying their role in the binding site as part of ligand binding and/or 
channel activation. Those residues which were previously experimentally studied have 
been identified and their role was predicted according to the generated models. 
Hydrophilic residues in the binding site were extensively studied by introducing 
mutants at each of sites and many ligands of interest were tested at mutant receptors, the 
different roles of the residues in the binding site were proposed. The co-application of 
partial agonists with GABA EC50 at the homomeric channels receptors was also 
investigated and explanations of the results were proposed. Studying the same partial 
agonists with ρ2 GABAC receptors has interestingly shown inter-selectivity between the 
two very similar receptors in terms of their effect when co-applied with GABA, and the 
effect of their interactions with various residues in the binding site on the overall 
activity (co-operative/inhibition effects).  
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1. Introduction 
1.1 Ligand-gated ion channel receptors (LGICs) 
Ligand-gated ion channel (LGIC) receptors are membrane proteins that include the 
orthosteric binding site which is linked to a membrane bound pore for ion 
conductivity.
1,2
 The first time that a chemical substance was shown to act in human 
bodies by binding with receptors was more than hundred and fifty years ago when 
Claude Bernard noticed the action of curare in muscle contractions.
3
 Fifty years later 
John Langley introduced the term pharmacological receptor.
4,5
 At this time, Elliot 
proposed that a chemical substance released at nerve endings may transmit a neuronal 
impulse to the periphery,
6
 and Lillie proposed that the nerve signal may be due to 
changes in ionic permeability through a cell membrane.
7
  
This previous work provided an important basis for the future understanding of LGICs. 
In the 1950s del Castillo and Katz were first to describe ligand binding and channel 
activation.
2,8-10
 Changeux and his team were first to employ biochemical techniques to 
purify snake venom toxins.
11,12
 Within the next few years single channel recording was 
used by Neher and Sakmann to confirm LGIC receptors.
13
  
The first receptor belonging to the LGIC family was cloned and sequenced in the early 
1980s,
14-16
 which provided the basis for the molecular study of these receptors. Three 
dimensional crystal structures of the extracellular domain of these receptors were first 
resolved in the 1990s when the homologous acetylcholine binding protein was 
crystalized.
17,18
 However, it was another ten years before the first complete or ‘unified’ 
LGIC receptor structure was resolved.
19-22
 The structural and molecular information we 
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have today afford an important resource for studying the distinctive functionality of 
these receptors and their unique mechanisms of action. 
 
1.1.1 LGIC Superfamilies 
The cDNA sequencing of the genome revealed that there are three major unrelated 
vertebrate superfamilies of LGICs in terms of architecture. The first are pentameric ion 
channel receptors which are also called Cys-loop receptors and include nicotinic 
acetylcholine, GABAA (gamma-aminobutyric acid), ρ GABAC, glycine and 5-HT3 
receptors.
23
 The second are tetrameric nonselective cation (Na
+
, K
+
, Ca
+
) glutamate-
gated receptors (iGluRs).
24
 The last superfamily consists of the trimeric P2X receptors 
(P2XRs) activated by ATP.
25
 
 
1.1.2 Cys-loop Receptors 
The Cys loop superfamily of receptors comprises excitatory, cation selective receptors 
such as nicotinic acetylcholine receptors, 5-HT3 receptors and zinc-activated channels 
and inhibitory, anion-selective receptors such as GABAA and ρ GABAC receptors, 
strychnine-sensitive glycine receptors and invertebrate glutamate-gated chloride 
channels.
26,27
 
Receptors of this superfamily are pentameric, requiring five subunits to assemble a 
single ion channel. The ion channel may be homomeric, formed by five identical 
subunits as is the case for ρ GABAC receptors or heteromeric that are formed by a 
combination of at least two different subunits, such as the GABAA receptors.
28
 Cys-loop 
receptors are analogous to each other in their structure and they are comprised of four 
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domains. The N-terminal extracellular domain is generally formed by ten β-sheets and 
two α-helices (Figure 1.1A). This domain contains the orthosteric binding site and also 
the characteristic loop of 13 residues forming a cys-cys disulfide bond between two 
cysteine residues called the cys loop (also called β6-β7 loop) (Figure 1.1B). This loop is 
conserved across the subunits belonging to this superfamily and is the reason for the 
name Cys-loop receptors.
29
 The second region consists of the four transmembrane α-
helices (TM1-TM4). The TM2 forms the pore of the ion channel, whereas the remaining 
three transmembrane helices form a hydrophobic environment to incorporate the pore 
into the plasma membrane (Figure 1.1A).
30
 The third domain is an intracellular loop 
between TM3 and TM4. The transmembrane domain has little residue conservation 
across different subunits or even within subunits. There is evidence that the intracellular 
domain is involved in modulating the receptor by phosphorylation and binding to other 
intracellular molecules.
31
 The final domain is a short extracellular C terminal.
32
 
Figure 1.1 Cys-loop ion channel receptor. A. A single ion channel showing the main domains (Note: 
Figure does not show the intracellular loop between TM3 and TM4). B. Part of a single subunit showing 
the Cys-Cys disulfide bond in the extracellular domain. The covalent bond is between two cysteine 
residues located at β6-β7 loop. 
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1.2 GABA Receptors 
The GABA receptors are membrane receptors that are activated by GABA, the most 
inhibitory neurotransmitter substance in the vertebrate CNS. The neurotransmitter 
GABA has many general functions in the CNS that were identified through screening of 
ligands. The discovery of selective agents initially revealed two distinct classes of 
GABA receptors, ionotropic GABAA and metabotropic GABAB receptors. The two 
classes are different in their pharmacological, biochemical and electrophysiological 
properties.
33
 A subclass of ligand-gated ion channels were later identified, insensitive to 
ligands that typically affected GABAA and GABAB receptors, these were initially 
classed as GABAC receptors. 
  
1.2.1 GABAA and GABAB Receptors 
GABAA receptors were the first recognized receptors in the CNS belonging to the 
GABA family, and they mediate fast neuronal responses to GABA. These ionotropic 
receptors are chloride-selective channels that are activated when GABA binds to the 
orthosteric binding site in the extracellular domain.
34,35
 On the other hand, GABAB 
receptors cause slow response mediated by GABA and linked via G-proteins to 
potassium or calcium channels.
36,37
  
The ionotropic GABAA receptors lead to enhanced membrane ion conductance when 
activated, are selectively blocked by the alkaloid bicuculline and modulated by a 
number of agents including benzodiazepines, barbiturates and steroids.
38
 The 
metabotropic GABAB receptors are coupled to G-proteins and hence they indirectly 
change membrane ion permeability and enhance the intracellular concentration of 
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second messengers. They are selectively activated by baclofen and antagonized by 
phaclofen.
39,40
 
GABAA receptors require five subunits to form one ion channel. In humans, there are 16 
known isoforms of GABAA subunits, i.e. six α, three β, three γ and one of δ, ε, π, and θ 
subunits.
41
 The predominant GABAA ion channels in brain tissues are formed from two 
α, two β and one γ subunit, for example GABAA α1β2γ. The formation of active 
GABA-gated ion channels requires the presence of at least α and β subunits.42 GABAB 
receptors, on the other hand, have two isoforms (i.e. GABAB1 and GABAB2) which 
assemble together as heterodimers through the intracellular C termini (a prat in GPCRs 
links two dimers together) to form a single transmembrane receptor.
43
 The crystal 
structure of GABAB was recently resolved in a study which revealed a novel 
heteromeric interface between subunits of G-protein coupled receptors.
44
 
 
1.2.2 GABAA and ρ GABAC Receptors  
GABAC and GABAA receptors were initially classified as different members of the 
GABA LGIC family.
45
 There are significant differences between these subfamilies 
based on physiological, pharmacological and biochemical properties.
46
 The amino acid 
sequence identity between various GABAA subunits and GABAC subunits ranges 
between 35% and 45%, but is as high as 75% in the transmembrane region.
47
 GABAC 
ion channels expressed in Xenopus oocytes have different properties to GABAA ion 
channels in terms of potency, channel opening time and receptor desensitization. In 
general, GABA is between ten and one hundredfold more potent at GABAC receptors 
than GABAA receptors, with slow activation and deactivation, and less readily 
desensitized.
48-50
 GABAC receptors express functional homomeric ion channels and 
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some theories suggest pseudoheteromeric channels consisting of different ρ subunits. In 
contrast, GABAA receptors are only functional when expressed as heteromeric ion 
channels of at least two different GABAA subunits. These two subfamilies are reluctant 
to co-express as functional receptors.
45
 
The pharmacological profile of GABAC receptors is distinguished by many ligands 
which are selective at this subfamily over GABAA receptors (Figure 1.2). Attempts to 
explore the GABA conformation responsible for activation of receptors commenced in 
the 1970s.
51
 Hence, conformationally restricted GABA analogues were synthesized and 
it was noted that the analogue CACA which represented a partially folded conformation 
of GABA, depressed the firing of cat spinal neurons with bicuculline insensitive 
properties. This depressant effect is not reproduced by baclofen suggesting 
pharmacologically distinct GABA receptors in the mammalian CNS which are not 
GABAA or GABAB.
52
 CACA is a partial agonist with 70% efficacy compared to GABA 
at ρ1 homomeric receptors expressed in oocytes, but inactive at GABAA receptors. The 
trans-isomer, TACA is also an agonist at GABAC receptors, which is more potent than 
GABA at ρ1 receptors, and is also an agonist at GABAA receptors expressed in 
oocytes.
53-55
  
 
 
Figure 1.2 Chemical 
structures of ligands 
with selectivity 
distinguish GABAA 
receptors from ρ1 
GABAC receptors. 
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Other ligands have been found to distinguish GABAC receptors from other GABA 
receptors such as (+)-CAMP (1S,2R-2-(aminomethyl) cyclopropanecarboxylic acid) 
which selectively activates GABAC receptors,
56
 and THIP (4,5,6,7-
tetrahydroisoxazolo[5,4-c]pyridin-3-ol), which is a partial agonist at GABAA receptors 
and a competitive antagonist at GABAC receptors.
55
 TPMPA has been identified as a 
potent and selective antagonist at GABAC receptors.
57
  
GABAA receptors are well known to be modulated by agents such as benzodiazepines, 
barbiturates and neurosteroids.
48,58
 GABAC receptors are insensitive to these GABAA 
receptor modulators; however, some GABAA modulators can also modulate GABAC, 
such as zinc, lanthanides,
59,60
 and some synthetic neurosteroids.
61
 Moreover, the 
chromosomal locations of coding genes for both subfamilies
62,63
 and the proteins which 
anchor them in the membrane are also different.
64,65
 
Since GABAC ion channels are analogous in sequence and structure to GABAA ion 
channels, and since GABAA and GABAC receptors exhibit similar pharmacology, the 
international union of pharmacology (IUPHAR) have stated that GABAC ρ subunits 
belong to the GABAA superfamily of receptors (GABAA-ρ).
66
  
 
1.3 ρ GABAC Receptors 
After the pharmacological identification of receptors sensitive to the agonist CACA, 
molecular biology provided further information about ρ GABAC subunits. A bovine 
mRNA from retina was expressed in Xenopus oocytes, sensitive to GABA, but 
insensitive to bicuculline and baclofen,
67
 and the novel ρ1 GABAC subunit from a 
human retina cDNA library was cloned in the early 1990s.
68
 The second member of this 
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subfamily, designated ρ2 was cloned from human retina a year later.69 This subunit is 
found in brain tissue such as hippocampus, cerebellum and pituitary, with significant 
abundance.
70
 A third member of this subfamily designated ρ3, has also been detected in 
retina as well as higher brain regions with lower expression levels compared to the 
retinal level.
62,71
 In the retina, ρ3 is found expressed in ganglion neurons of the retina 
while ρ1 and ρ2 are specifically expressed in bipolar and horizontal cells.70,72,73 
Although ρ GABAC receptors are mainly expressed in the CNS, they are also found in 
the peripheral nervous system, for example in the gastrointestinal tract,
74
 and in sperms 
cells.
75
 Members of this ρ subfamily share more than 70% and 95% amino acid identity 
and similarity, respectively (Figure 6.5).
76
 
Studies have suggested the involvement of ρ receptors in the sleep-waking behaviour of 
rats,
77
 learning and memory in chicks and rats,
78
 inhibition of ammonia-induced 
apoptosis in hippocampal neurons,
79
 and hormone release in the pituitary.
80
 Both ρ1 and 
ρ2 GABAC receptors are found in the hippocampus as extra synaptic receptors activated 
by GABA through spillover (the presence of extra GABA),
81
 and are believed to be 
involved in paired-pulse depression (a common form of short-term synaptic plasticity) 
of inhibitory postsynaptic currents.
82
 Behavioural pharmacological studies have shown 
an important role for ρ1 receptors in the inhibitory modulation of the olfactory bulb.83 
ρ1 knockout mouse studies have indicated that ρ1 receptors and possibly also ρ2 and/or 
ρ3 receptors are present in the superior colliculus (a paired structure of the mammalian 
midbrain).
84
 More recently, the GABAC antagonist TPMPA, was shown to improve the 
symptoms of retinitis pigmentosa in rats,
85
 and evidence that ρ1 and ρ2 may be 
important for different specific in vivo effects of ethanol, has been reported.
86
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1.3.1 Structure and Function of ρ1 GABAC Receptors 
Many structure-function studies have been undertaken on ρ1 homomeric receptors. 
However, structural studies with either ρ2 or ρ3 homomeric receptors are extremely 
limited. The structure of ρ1 receptors was first studied by identifying critical residues 
that have direct effects on ligand sensitivity using site-directed mutagenesis and 
substituted cysteine accessibility methods.  
Molecular exploration of the orthosteric binding site (i.e. GABA binding site) of ρ1 
homomeric receptors was facilitated by the cloning of ρ1 receptors. Mutational studies 
on residues equivalent to those residues previously studied in the GABAA β2 subunit,
87
 
showed significant decreases in GABA sensitivity, revealing the importance of residues 
such as Tyr198, Tyr200, Tyr241, Tyr247 and Thr244.
88,89
 Later, mutation of Tyr102 to 
serine was found to produce spontaneously active receptors.
90
 Recently, antagonists 
with varied structures were found to exhibit different effects at these spontaneously 
active receptors suggesting that different antagonists have differing affinities for the 
open and closed state of the receptor.
91
 A study on the equivalent residue (Phe64) in the 
GABAA α1-subunit suggested that this residue may be important for coupling of 
binding and gating during channel openings.
92
 
In a mapping study on three loops (loops A, E and F) within the orthosteric binding site 
of GABAC receptors only a few residues were noted to produce a significant right shift 
of the GABA dose response curve when cysteine was introduced individually at all sites 
within the three loops. These residues are Asp136 in loop A, Leu166, Ser168 and 
Arg170 in loop E and Gln226 in loop F. Interestingly, cysteine mutation of Leu169 in 
loop E resulted in a several fold increase of potency of GABA.
93
 Moreover, a few other 
residues, when individually mutated to cysteine, result in non-functional receptors that 
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are insensitive to high concentrations of GABA. These residues, which are Trp133, 
Pro135 and Phe139 in loop A and Gly160 in loop E, may have critical roles in protein 
stability through intersubunit interactions rather than a direct effect on GABA binding. 
The same study showed that when cysteine replaces Gln160 in loop E, the receptors 
become spontaneously active, which may indicate that this residue is involved in the 
conformational changes that lead to gating.
93
  
Residues within a distance of 7 Å to the carboxylate group of GABA in the orthosteric 
binding site of ρ1 GABAC were studied through various mutations at each site.
94
 This 
study revealed the importance of residues Arg104 and Ser168, which are predicted by 
modelling studies to form a salt bridge and a H-bond interaction, respectively, with 
GABA.
95-98
 Arg158 and Arg170 residues which are close to the carboxylate group of 
GABA are found to be critically important for GABA activity. These arginine residues 
are predicted by modelling to be important for protein stability by inter- or intrasubunit 
interactions.
95-97
  
Aromatic residues in the orthosteric binding site were also investigated by single point 
mutations. The aromaticity of Tyr198, Tyr241 and Tyr247 residues was found to be 
important for the activation by GABA. These residues are predicted by modelling to 
have their functional group oriented toward the binding site and to form an aromatic 
box in order to provide the main source of ligand stability in the binding site. Tyr200 
was also found to be important for GABA activity, however according to modelling, 
this residue has its functional group oriented to the opposite side of the orthosteric 
binding site, which may suggest that this residue is implicated in an intrasubunit 
interaction required for gating.
99
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Thr244 is a residue in loop C with the hydroxyl functional group oriented toward the 
GABA binding site. Mutation of this residue to various amino acids resulted in non-
functional receptors even at high concentrations of GABA, and only the T244S 
mutation resulted in a functional receptor, with a 35-fold decrease in GABA potency.
88
 
Additionally, ρ1 GABAC T244S mutant receptors have recently been studied with 
various ligands. The studied agonists demonstrated many fold decreases in potency, 
whilst the studied antagonists remained unaffected by the mutation.
100
  
The key structural elements for distinctive representative antagonists of ρ1 GABAC 
receptors over GABAA receptors have been studied by individual or combined 
mutations of many residues at ρ1 GABAC to their counterparts in the GABAA α1β2γ 
receptors. Residues Tyr102, Tyr106, Phe138 and Phe240 in ρ1 GABAC receptors were 
found to be major determinants for selective antagonists.
101
  
The non-competitive antagonist picrotoxinin is a channel blocker at GABAA and 
glycine receptors.
102,103
 Interestingly, picrotoxinin has different effects at ρ1 and ρ2 
homomeric GABAC receptors
104
 and also at native GABAC receptors of various 
species.
73,105
 At ρ1 GABAC receptors, picrotoxinin exhibits both competitive and non-
competitive antagonism characteristics.
104
  
Many studies have explored the molecular determinants of picrotoxinin actions in ρ 
receptors. Residues such as Pro309 and Ser319 in the human ρ1 subunit and The314 in 
the rat ρ1 subunit have been found to be critical for picrotoxinin sensitivity.104,106 
Introduction of mutations at sites such as Pro309 and Ser319 in the TM2 domain 
(Figure 1.3) of human ρ1 homomeric receptors expressed in Xenopus oocytes showed 
changes not only in picrotoxinin sensitivity, but also changes in the response of the 
mutant receptors to agonists and partial agonists.
107
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Figure 1.3 The amino acid sequence alignment of the ρ1 and ρ2 subunit transmembrane membrane 
domains. The prediction of secondary structure of transmembrane is predicted by maestro according to 
the generated model. The highlighted residues with dark grey color are conserved in the three receptors. 
The highlighted residues with fair grey color are conserved residues in only two of the three receptors. 
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Mutational studies at the Pro310 residue in ρ1 subunits of rat and perch have suggested 
a critical role of this residue in pharmacology and kinetics of agonist binding (Figure 
1.3). Introducing a serine at the Pro310 site of these ρ1 subunits result in mutant 
receptors with similar pharmacology to human ρ1 P310S receptors.104 In the same way, 
mutating Pro310 to serine in perch ρ1B-subunits produces change in GABA responses 
while deactivation time remains constant.
108
 
Mutating Thr314 or Leu317 to alanine in rat ρ1 afforded mutant receptors which are 
constitutively active (Figure 1.3). Applying low concentrations of GABA led to 
diminished spontaneous currents from both ρ1 T314A and ρ1 L317A receptors, and 
GABA completely suppresses spontaneous current in ρ1 T314A/L317A double mutant 
receptors.
109
 Studies have revealed at least four residues in TM2 that are implicated in 
coupling binding to gating. These residues are oriented toward the channel pore, 
suggesting they contribute physically to receptor gating. Most of these residues are 
conserved among various GABAA and GABAC subunits and due to similar pore sizes of 
these receptor subunits,
49
 that may support their critical role in gating. 
Tryptophan 328 in TM3 of ρ1 receptors is found to be important for pentobarbital 
sensitivity (Figure 1.3). Generally, ρ1 wild type receptors are insensitive to 
pentobarbital, however when W328 is mutated to various hydrophobic residues, ρ1 
mutant receptors become sensitive to pentobarbital.
110
 Moreover, mutation of isoleucine 
323 in TM2 to serine also renders human homomeric ρ1 mutant receptors sensitive to 
barbiturates, which is believed to be due to allosteric effects rather than directly.
111
 
Although ρ1 GABAC receptors are insensitive to many modulators of GABAA 
receptors, two residues in the transmembrane domain of ρ1 subunits were found to be 
critically important for sensitivity toward diazepam. Double mutation of Ile307 and 
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Trp328 residues to serine and methionine in GABAA α1 and β2 subunits, respectively 
rendered a micromolar concentration of diazepam efficacious at potentiation the GABA 
EC5 responses. These double mutation (ρ1 I307S/W328M) GABA receptors still 
resemble ρ1 WT receptors in terms of the pharmacological properties of agonists and 
antagonists.
112
 
Many divalent cations such as Zn
2+
, Ni
2+
 and Cu
2+
 have modulatory actions at ρ1 
receptors.
59,113
 The zinc cation which is present in the synaptic terminal of 
photoreceptors,
60
 is able to reduce GABA responses at ρ1 receptors with an effect that 
depends on the extracellular pH. Due to the effect of pH, the His156 residue in the 
orthosteric binding site was suggested to have a direct role in the zinc modulatory 
effect. Introduction of a tyrosine at this site leads to receptors insensitive to divalent 
cations such as zinc, however other pharmacological and electrophysiological properties 
were the same as for wild type receptors, supporting the involvement of this residue in 
zinc modulation.
59,114
 
 
1.3.2 Intra-selectivity of ρ GABAC Members 
The ρ1 GABAC receptors are the most studied in the GABAC subfamily while ρ2 and 
ρ3 GABAC receptors are much less studied. Although these subunits are highly similar 
in their amino acid sequences across most regions, there are some important differences 
between them that may lead to further distinctive features. The ρ3 subunit has not yet 
been shown to be involved in any disorder or essential role in retina or other brain 
tissues, therefore our modelling and structural studies will focus on the differences 
between ρ1 and ρ2 subunits. 
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Some ligands that bind in the orthosteric ‘GABA’ binding site can differentiate between 
ρ GABAC subunits. Imidazole-4-acetic acid (I4AA) (Figure 1.4) is a partial agonist at 
both ρ1 and ρ2 homomeric receptors expressed in oocytes. This ligand is a weak, low 
efficacy partial agonist (EC50 = 60 µM, Im = 8 %) at ρ1 receptors, while it is potent and 
moderately efficacious (EC50 = 3 µM, Im = 40 %) at ρ2 receptors.
115-117
 Although the 
antagonist effects of I4AA at both ρ subunits have similar potencies with IC50s close to 
1µM, I4AA antagonizes 97% and 20% of GABA responses at ρ1 and ρ2 homomeric 
receptors, respectively (data not published). 
Trans-2-methyl-4-aminocrotic acid (2-MeTACA) (Figure 1.4) is a moderate antagonist 
at both ρ1 (IC50 = 45.5 µM) and ρ2 (EC50 = 101 µM, Im = 34%) receptors.
115
 On the 
other hand, trans-2-aminomethylcyclopropane carboxylic acid (-)-TAMP is a partial 
agonist at both human ρ1 and ρ2 receptors but an antagonist at rat ρ3 receptors.118 
Additionally, regarding the stereoisomers 4-amino-(S)-2-methylbutanoic acid ((S)-
2MeGABA) and 4-amino-(R)-2-methylbutanoic acid ((R)-2MeGABA) (Figure 1.4), the 
(S) isomer is an agonist at ρ1 and ρ2 receptors, while the (R) isomer is an antagonist at 
these receptors. Furthermore, they showed selective potencies at ρ1 and ρ2 receptors as 
(S)-2MeGABA is a more potent agonist at ρ2 whereas (R)-2MeGABA is a more potent 
antagonist at ρ1.119  
 
 
Figure 1.4 Chemical structures of 
ligands that are intra-selective in 
terms of sensitivity to ρ GABAC 
members. 
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(S)- and (R)-Aminocyclopentenyl-butylphosphinic acids ((S)-/(R)-ACPBPA) (Figure 
1.4) are stereoisomeric antagonists with differential selectivity at ρ1 and ρ2 receptors. 
The (S)-ACPBPA ligand is a selective and more potent antagonist at ρ1 receptors, while 
the (R)-ACPBPA ligand is a selective and more potent antagonist at ρ2 receptors (data 
not published).  
The structure of the TM2 of all LGIC receptors is highly similar across species and 
subunits, with variation at only a few sites in the pore.
120
 ρ1 and ρ2 GABAC subunits 
are different at two sites within TM2 regions only, i.e. Pro309 and Ser319 in ρ1 are 
Ser290 and Thr300 in ρ2, respectively (Figure 1.3). Many studies have shown important 
roles for Pro309 in the ion flow,
121,122
 agonist mediation,
123
 antagonist and modulator 
actions,
108
 and the subunit’s kinetic properties such as rate of receptor desensitization.124 
In a mutational study, a reverse mutation switching the two residues between ρ1 and ρ2 
demonstrated that ρ1 P309S mutant receptors produce GABA and picrotoxinin 
responses different to the ρ1 wild type while ρ1 S319T mutant receptors produce similar 
responses to the same ligands at ρ1 wild type.104 
An additional mutational study was done at Thr314 in the TM2 of the rat ρ1 subunit. 
The equivalent residue in the rat ρ2 subunit, methionine (Met299), was introduced at the 
Thr314 site and the resultant mutant receptors have relatively small chloride current 
(Figure 1.3). Both ρ1 and mutant receptors were co-expressed and sensitivity to 
picrotoxinin found to be less relative to the ρ1 wild type and similar to co-expression of 
ρ1 and ρ2 subunits. Rat ρ GABAC receptors are relatively insensitive to picrotoxinin,
50
 
which led to the authors suggesting heteromeric GABAC receptors composed of ρ1 and 
ρ2 subunits in rat.106 
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1.4 GABA 
In the CNS there are significant concentrations of some amino acids such as glutamate 
and γ-aminobutyric acid (GABA). The dicarboxylate amino acids, glutamate and 
aspartate, mediate excitatory responses, on the other hand, the monocarboxylate amino 
acids, GABA and glycine, mediate inhibitory responses.
125
 Overall, the balance between 
excitation and inhibition of the CNS is controlled by balancing the physiological 
activity of the two amino acids i.e. glutamic acid (excitatory) and GABA (inhibitory). 
Hence, ligands able to depress CNS excitability such as hypnotics and anxiolytics are 
either GABA activity enhancers or glutamate activity inhibitors.
126
  
 
1.4.1 GABA as a Neurotransmitter 
The neurotransmitter GABA is biosynthesized in the brain from glutamate and also 
catabolized to glutamate.
125
 The GABA molecule has been known as a metabolite in 
plants since the 18
th
 century, whereas it wasn’t identified as a neurochemical substance 
with chief roles in mammalian CNS tissues until the 1950s.
127,128
 GABA is responsible 
for inhibitory actions at synapses in the brain of vertebrates by binding at recognition 
sites in GABA receptors at pre-, post- and extra-synaptic locations in the neuronal 
plasma membrane. Binding of GABA molecules leads eventually to channel activation 
allowing chloride ions to flow into the cell (e.g. GABAA and GABAC receptors) or 
calcium and/or potassium ions to flow out of cells (e.g. GABAB receptors). This gating 
leads to hyperpolarization of the negative transmembrane potential.
129
 In addition to the 
CNS actions of GABA receptors, they are also present in many peripheral organs and 
tissues such as stomach, kidney, intestine, lung and liver.
130
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1.4.2 Structure and Conformations of GABA 
GABA is a low molecular weight ligand that has three rotatable carbon-carbon bonds, 
which afford flexibility and the ability to adopt many different conformations.
131
 Due to 
variation in binding residues and differing sensitivities of specific subunit combinations 
to GABA, it is believed that GABA may adopt different conformations when it binds at 
the orthosteric binding sites of different GABA receptor sub-types.  
GABA is found as a zwitterion at physiological pH with the carboxylate group 
deprotonated and the amino group protonated. GABA has variable conformations 
depending on the environment as following; it is highly folded in the gas phase, but has 
a more extended conformation with a trans conformation of amino group and a gauche 
conformation of carboxylate group in the solid phase and many different conformations 
in the aqueous state where some are folded and others are extended as a result of 
solvation effects.
131-134
 The presence of GABA in many conformations within aqueous 
environments such as the binding site at the interface between two subunits is important 
for structure-activity studies in order to identify which GABA conformation is most 
selectively active at specific subtypes of receptors and would also help in design and 
discovery of conformationally restricted GABA analogues which are biologically active 
and selective at particular receptor subtypes.  
 
Figure 1.5 Some possible GABA 
conformations.  
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The conformational flexibility of GABA is critically important for the biological 
activity of this neurotransmitter (Figure 1.5). However, the question of the conformation 
of GABA in the binding site at the extracellular domain of the ion channel receptors has 
not yet been fully answered. There is currently no evidence to support whether GABA 
can activate the receptor in only one conformation or more. 
 Experimental methods 
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2. Methods and Materials 
2.1 Homology Modelling and Docking 
2.1.1 Sequence Alignment and Homology Modelling 
The protein sequence of human ρ1 GABAC was obtained from the universal protein 
resources (http://www.uniprot.org/)
135
 and the models were built on templates of the 
AChBP (PDB ID 1UV6), ELIC (PDB ID 2YOE), GLIC (PDB ID 4F8H), GluCl (PDB 
ID 3RIF), GABAA R β3 (PDB ID 4COF) and GluCl ‘apo state’ (PDB ID 4TNV), 
(http://www.rcsb.org/)‎.136 The percent amino acid identity and similarity of the template 
proteins with the ρ1 protein after the structural alignment (Figure 3.1) are given in Table 
3.1. 
Initial sequence alignments were performed using the CLUSTALW program,
137
 after 
careful checking of the non-conserved regions close to the binding pocket and in the 
loop positions, the program produced a moderately correct alignment in many regions, 
manual adjustments were made on the sequence alignment of loop A and C using 
Schrödinger’s Prime 3.2 program,138 50 models of the ρ1 GABAC receptor based on 
each of six templates were built using Prime 3.2 software,
138-140
 with the aim of 
reaching models consistent with most experimental findings. 50 homology models of 
TPMPA bound ρ1 GABAC were built based on GluCl template in apo state using Prime 
v3.7 software. Additionally, 50 homology models of GABA and (R)-ACPBPA bound 
ρ2 GABAC were built based on the GluCl template in an open conformation and apo 
state, respectively. 
No further refinements were done on the generated models, such as loops refinements, 
side chain predictions or structure minimizations. The generated models based on 
 Experimental Methods 
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multiple templates were used in this study to recognize the conserved residues with ρ1 
GABAC in the binding site of extracellular domain. In this study the final model is 
refined by matching the side chains of critical residues with their corresponding 
residues in the templates and their roles where predicted with correlation to the previous 
experimental results. 
% Gaps between ρ1 GABAC and templates is very important in models generation and 
has direct influence in the quality of the built models, so % gaps is also used in the 
assessment of final ‘chosen’ model for molecular basis studies. 
 
2.1.2 Ligand Preparation 
The ligands studied (listed in table 4.1) were first drawn using the 2D sketcher and then 
ligands were manipulated and adjusted for chemical correctness using Schrödinger’s 
Maestro (Maestro, v9.9) interface.
141
 The preparation of all compounds for docking was 
performed by LigPrep (LigPrep v3.1),
142
 which produces 3D low energy structures with 
correct chirality to generate ligands that are optimized for further studies which gave a 
total potential energy OPLS_2005 of -118 kcal/mol for low energy conformations for 
GABA,  -575.8 kcal/mol for muscimol, -343 kcal/mol for imidazole-4-acetic acid and -
755 kcal/mol for TPMPA. Geometry minimizations were performed on all ligand 
conformations using the OPLS_2005
143
 (MacroModel, v10.5) force field and the 
Truncated Newton Conjugate Gradient (TNCG) method. Optimizations were converged 
to a gradient RMSD below 0.05 kJ ⁄mol or continued to a maximum of 5000 iterations, 
at which point there were negligible changes in RMSD gradients. 
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2.1.3 Protein Preparation 
All crystal structure files obtained from the PDB were first prepared by Schrödinger’s 
protein preparation wizard.
144,145
 Briefly, this included deleting crystallographic waters; 
adding hydrogens; adjusting bond orders and formal charges and alleviating potential 
steric clashes via protein minimization with the OPLS_2005 force field. The templates 
thus produced were shown to be accurate structures without need for further manual 
adjustment.  
 
2.1.4 Molecular Docking of Ligands into the Orthosteric Binding Site 
The docking studies of all compounds with the generated models were carried out using 
the default settings (i.e. flexible ligand sampling (sample nitrogen inversions and 
sample ring conformations) and Added Epik State penalties are applied for adopting 
higher-energy states (including those where metals are present). Ligands that do not 
have metals such as the ones in this study are not penalized and therefore their scores 
will be better.
146
 
The shape and properties of the binding site were characterized and set up for docking 
using the receptor grid generation panel using Glide (v6.4)
146-149
 with the templates to 
explore GABA conformations and favourable interactions in the binding sites. The sites 
of these grids were selected either by reference ligands such as GABA and ketamine in 
ELIC and GLIC, respectively, or by residues which are known to form interactions with 
GABA such as Tyr198, Arg104, The244 and Glu196. Generally, the size of grids was 
20 Å unless otherwise stated. A Coulomb-van der Waals (vdW) scaling of 1.0 ⁄ 0.8 was 
set for receptor ⁄ ligand vdW radii, respectively. 
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In addition to the standard flexible docking process, a combined docking of Glide and 
QSite was performed using the Schrodinger QM-polarized ligand docking (QPLD).
150-
152
 The protocol was carried out as follows: flexible docking was first performed using 
Glide; the ligand charges derived from quantum mechanical calculations on the ligand 
in the field of the receptors were calculated with QSite (The charges are calculated from 
the electrostatic potential energy surface of the ligand (uses the 3-21 G basis set, BLYP 
functional, and “Quick” SCF accuracy level), which is generated from a single-point 
calculation using density functional theory for the QM region.),
153
 and the re-docking of 
GABA with the new charges can result in improved docking accuracy.  
GlideScore is an empirical scoring function that was used to approximate binding free 
energy of the GABA poses to select the pose which was considered for further 
studies.
147
 Glide Emodel has a weighting of electrostatic and van der Waals energies 
and was used to compare binding free energies of the studied ligands.
147
 However, 
molecular mechanics using the generalized Born model and solvent accessibility (MM-
GBSA)
154
 method were used to calculate the net free energy change (i.e. sum of a 
comprehensive set of individual energy components) of GABA binding with models 
generated based on all templates.  
The root-mean-square deviation (RMSD) between GABA re-docked in the receptor grid 
of the homology model and GABA in the GluCl template was used to also validate the 
GABA pose after the model was generated in order to study the molecular basis of the 
orthosteric binding site of ρ1 GABAC receptors. 
Z-scoring (standard score) was also undertaken to compare the GlideScore of ligands in 
the current study. In order to calculate Z-scores, all possible conformations of the four 
ligands were generated, docked and considered.  Z-score also known as a K-value, is the 
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positive or negative number of standard deviations an observation is above the mean. 
When Z-score is positive it indicates that it is above the mean and when negative 
indicates below the mean. 
2.2 Molecular Biology 
2.2.1 Material 
Human ρ1 cDNA subcloned into pcDNA1.1 (Invitrogen, San Diego, CA, USA) was 
kindly provided by Dr. George Uh1 (National Institute for Drug Abuse, Baltimore, MD, 
USA). Human ρ2 cDNA sub cloned in PKS (Invitrogen) was a gift from Dr. Garry 
Cutting (Center for Medical Genetics, Johns Hopkins University School of Medicine, 
Baltimore, MD, USA).  
The used chemicals (GABA, 5-aminovaleric acid, β-alanine, glycine, imidazole-4-acetic 
acid, isoguvacine, muscimol, THIP (Gaboxadol)) were purchased from Sigma-Aldrich 
(Sigm-Aldrich Pty Ltd, Castle Hill, NSW 1765 Australia). Gabazine (SR-95531),
155
 
TPMPA,
156
 TACA, CACA,
157
 3-aminopropyl phosphonic acid
158
 and MTSEA
159
 were 
prepared as previously reported. 
 
2.2.2 Site-directed Mutagenesis Protocol 
2.2.2.1 Primer Design 
The UniProt website was searched for GBRR1 (rho1 GABAc) and the sequence of 
amino acids was checked for the particular amino acid for mutation. Using the UniProt 
website, the DNA sequence was obtained. The ExPASy Translate Website (ExPASy-
Translate tool) was used to select a copy of 5’3’ of the GABAc Nucleotide sequence. 
The residue intended to mutate is recognized and the codon bases of five residues before 
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the targeted residue and the codon bases of five residues after the targeted residue were 
selected to design a primer as the following two examples: 
S243TF   ctg  gct   ttc   tac  agc  acc  aca  ggc   tgg  tac  aac (Forward) 
S243TR   gtt   gta  cca  gcc  tgt   ggt  gct   gta   gaa  agc  cag (Reverse Complementary) 
T244CF   gct   ttc  tac  agc  agc  tgt   ggc  tgg   tac   aac  cgt (Forward) 
T244CR  acg   gtt  gta  cca  gcc  aca  gct  gct   gta   gaa  agc (Reverse Complementary) 
Nucleotide bases in red colors indicate the targeted codon bases for the mutation. \ 
 
The pairs of complementary mutagenic oligonucleotide primers (short DNA) were 
designed to introduce the single point mutations at human ρ1 GABAC subunit. The 
primers were made by life technologies (Life Technologies
TM
 Australia Pty Ltd). 
Primers were diluted 1 in 10 times of DNA concentration with nuclease-free water. 
 
2.2.2.2 Point ‘Specific Site’ Mutagenesis 
Site-directed mutagenesis was performed using a QuikChange II site-directed 
mutagenesis kit as described by the manufacturer (Stratagene).
160,161
 The reaction 
mixture contained reaction buffer (5 uL; 100 mM KCl, 100 mM (NH4)2SO4, 200 Mm 
Tris-HCl, PH 8.8, 20 mM MgSO4, 1% Triton X100, 1 mM/ml nuclease-free bovine 
serum albumin (BSA)), ρ1 dsDNA template (5-50 ng), sense and antisense 
oligonucleotides (i.e. primers) (125 ng), dNTP (deoxynucleotide triphosphate) (1 uL) 
and sterile distilled water to make the final volume of 50 uL. Then 1 uL of high-fidelity 
pfuUltra
TM
 ‘DNA’ polymerase enzyme (2.5 U/uL) was added to the mix and a 
polymerase chain reaction (PCR) (The PCR cycle condition according to the 
manufacturer’s instructions is shown in Table 1) was performed using a thermal cycler 
(DNA Engine, MJ Research, Inc., MA, USA) to denature DNA, anneal mutagenic 
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primers containing required mutation and extend primers with pfuUltra DNA 
polymerase.
161
  
Table 2.1 The PCR cycle condition used  
 
The previous reaction generates a relaxed and nicked circular DNA that is followed by 
an enzymatic digestion step of the methylated template DNA by adding 1uL DpnI 
enzyme for one hour (i.e. DpnI is specific enzyme when incubated with the product 
from temperature cycling, it digests methylated parenteral DNA only) to select mutation 
containing DNA.
162
  
The nicked DNA vector containing the required mutation is then transformed into 
Top10 supercompetent cells. 
  
2.2.3 Transformation of Plasmids into Supercompetent Cells 
2.2.3.1 Transformation Protocol 
The desired mutant or plasmid DNAs of ρ1 and ρ2 subunits were transferred into 
TOP10 Chemically Competent E. coli (Invitrogen™)). In brief, competent cells were 
taken out of -80°C and thaw on ice for 30 minutes. Agar plates (containing the 
appropriate antibiotic) were also prepared by warm up to room temperature or place in 
37°C incubator. Then, 1 to 5 μl of DNA (usually 10 ng to 100 ng) was added into 20-50 
μL of competent cells in a falcon tube (Becton Dickinson, Sydney, Australia). The 
Segment Number of cycles Temperature Time 
1 1 95 30 s 
2 18 95 30 s 
  55 1 min. 
  68 6 min. 
3  4 ∞ 
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competent cell/DNA mixture is gently mixed then placed on ice for exactly 30 minutes. 
The transformation tubes were then heat shocked by placing into a 42°C water bath for 
30-60 seconds (depending on the competent cells, generally 45 seconds for heat shock 
with Top10). The tubes were placed back on ice for 2 minutes. 250 μl SOC media 
(without antibiotic) was then added and tubes were placed in 37°C shaking incubator for 
an hour. Finally, 50 μL of the transformation was plated onto an LB agar plate 
containing the appropriate antibiotic and the plates were incubated at 37°C overnight. 
 
2.2.4 Plasmid Preparation 
A plasmid preparation is a method used to extract and purify of plasmid DNA from 
bacteria. This method involves growing of bacterial culture, harvesting and lysis of the 
bacteria then purification of plasmid DNA. 
 
2.2.4.1 Growth of E.Coli Bacterial Culture Containing Desired Plasmid DNA  
Several isolated bacterial colonies were picked and placed in 50 mL falcon tubes 
containing 5-7 mL LB broth and ampicillin (100µg/ml). Inoculated media were then 
incubated in a shaker incubator (225 rpm) at 37 
0
C for 16-20 hours. Glycerol stocks 
were later made from inoculated media containing 20% glycerol. Glycerol stocks were 
snapped frozen using dry ice and ethanol bath and final stock stored at -80 
0
C. 
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2.2.4.2 Harvesting and Lysis of E.Coli 
Cell harvesting was performed using Qiagen Spin Miniprep Kit (Qiagen, VIC, 
Australia) to purify plasmid DNA from E.Coli cells. Cells were first centrifuged in 
microcentrifuge tube (17900* g; Eppendorf Centrifuge 5417R, Hamburg, Germany) for 
3 minutes at room temperature. The supernatant was discarded and the cell pellet was 
re-suspended in cell suspension solution P1 (250 µL; 50mM Tris (PH 8), 10 mM 
EDTA, 100 µg/ml of RNase A), followed by cell lysis solution P2 (250 µL; 200 
mMNaOH, 1% SDS) to lysis the cell membrane. Tubes were gently inverted six times 
to mix content thoroughly. Cell neutralizing solution N3 (350 µL; 4.2 M Gu-HCl, 0.9 M 
CH3COOK, PH 4.8) was then added and tubes gently inverted to mix contents 
thoroughly to precipitate chromosomal DNA and cell membrane.  
 
2.2.4.3 Purification of Plasmid DNA 
Tubes from the previous step were centrifuged for 10 minutes at 13000 rpm to pellet the 
precipitant contents. The clear supernatant containing the plasmid DNA was retrieved 
and purified by QIAprep spin column and then centrifuged for 1 minute at 13000 rpm. 
The flow-through was discarded and the column was subsequently washed by applying 
PB column washing buffer (500 µM; 5 M Gu-HCl, 10 mM Tris-HCl (PH 6.6) and 30% 
ethanol), then was centrifuged for 1 minute at 13000 rpm. Flow-through was discarded 
and column was washed with PE washing buffer (750 µL; 10 mM Tris HCl (PH 7.5) 
and 80% ethanol), then centrifuged for 1 minute at 13000 rpm. The flow through was 
then discarded and the column was centrifuged for an additional minute at 6000 rpm. 
The elution buffer (50 µL; 10 mM Tris-HCl, PH 8.5) was added to the central of 
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column and let it stand for one minute before centrifuging for a minute and the eluent 
collected. 
The quality and quantity of DNA plasmids obtained from the Miniprep were determined 
using Nanodrop Spectrophotometer at absorbance 260-280 nM range (Thermo 
Scientific, Wilmington, DE, USA). The plasmids were also confirmed by agarose gel 
electrophoresis (0.9%) using the GelDoc 1000 (Bio-Rad Laboratories, Hercules, CA, 
USA). 
 
2.2.5 DNA Sequencing and Mutation Verification 
The desired DNA was confirmed by sequencing the whole gene of interest using 
appropriate primers. Samples of plasmid DNA (600-1000 ng) with primer (0.8 
pmol/μL) and sterile distilled water up to 12 μL final volume were sent to the Australian 
Genome Research Facility Ltd. (AGRF, Westmead Millennium Institute, Westmead, 
Australia). 
  
2.2.6 Linearization and Purification of DNA 
ρ1 and ρ2 GABAC plasmids DNA were linearized by incubation with Xba1 and EcoRV 
enzymes respectively for 2 hours at 37 
0
C. The linearized plasmid DNA was purified by 
QIAquick PCR purification Kit (Qiagen, VIC, Australia). In brief, five volumes of 
buffer PB was added and mixed thoroughly with the reaction mixture. This mixture was 
then transferred to a QIAquick column and it was centrifuged at 13000 rpm for 1 minute 
to pellet the linearized DNA. The flow through was discarded and the column was 
washed by adding PE washing buffer (750 μL; 10 mM Tris-HCl (PH 7.5) and 80% 
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ethanol) and centrifuged at 13000 rpm for 1 minute. The flow through was then 
discarded and the column was spun for an additional minute at 6000 rpm to remove the 
excess washing buffer that may be trapped in the column. Linearized plasmids DNA 
were eluted by adding elution buffer (30 μL; 10Mm Tris-HCl, PH 8.5) to the center of 
column and let stand for 1 minute before centrifuging it over a microcentrifuge tube for 
1 minute to collect the eluent. 
An agarose gel electrophoresis (0.9%) using the Gel Doc 1000 (Bio-Rad Laboratories, 
Hercules, CA, USA) was performed to ensure linearization of the plasmids DNA. 
 
2.2.7 In Vitro Transcription (cRNA Synthesis) 
ρ1 and ρ2 cRNA were synthesized from linearized plasmid DNA using the T7 
Transcription mMESSAGE mMACHINE Kit (Ambion, Austin, TX, USA). The 
transcription reaction mixture contains linearized DNA (≈ 1 μg) in addition to reaction 
buffer (2 μL; salts, buffer, dithiothreitol and other ingredients), ribunucleotide mix (10 
μL; 15 mM ATP, 15 mM CTP, 15 mM UTP, 2 mM GTP, 8 mM Cap Analog) and the 
enzyme mix (2 μL; T7 RNA polymerase and placental RNAse inhibitor in 50% 
glycerol). The total reaction volume was kept at 20 μL and was then incubated for two 
hours at 37 
0
C. The produced RNA was purified with lithium chloride precipitation 
methods by mixing thoroughly the reaction mixture with 30 μL of Nuclease-free water 
and 30 μL of LiCl precipitation solution and then it was chilled for at least 30 minutes at 
–80 0C. The mixture was then centrifuged at 4 0C for 15 minutes (14000 rpm; 
Eppendorf Centrifuge 5417R, Hamburg, Germany) to pellet the RNA. The supernatant 
was carefully removed and the pellet of RNA was then washed with 250 uL 70% 
ethanol. Then, the mixture was again centrifuged for 15 minutes at 14000 rpm to 
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remove unincorporated nucleotides. The supernatant; ethanol was carefully discarded 
and the pellet of RNA was incubated at 37 
0
C for 5 minutes to remove any traces of 
ethanol. Finally, RNA pellet was re-suspended in 10-25 uL of Nuclease-free water. 
The quantity and quality of synthesized CRNA was determined by absorbance at 260-
280 nm using Nanodrop Spectrophotometer (Thermo Scientific, Wilmington, DE, 
USA). The purity of CRNA was checked by the ratio of absorbance at 260-280 nm 
(Thermo Scientific T042 technical Bulletin), a ratio of ≈ 2.0 is generally accepted as 
pure. The purity of synthesized cRNA was confirmed by agarose gel electrophoresis 
(0.9%) using the GelDoc 1000 (Bio-Rad Laboratories, Hercules, CA USA). 
  
 Experimental Methods 
  
32 
 
2.3 Electrophysiology 
2.3.1 Oocytes Preparation and RNA Injection 
Lobes of ovaries were removed from female Xenopus laevis (South Africa clawed 
frogs) which were anaesthetized with tricane (850 mg/ 500 ml) and were harvested in 
accordance with the national health and medical research council (NHMRC) of 
Australia’s ethical guidelines and approved also by the University of Sydney’s animal 
ethics committee. The lobes were rinsed with oocyte releasing buffer 2 (OR2: 82.5 mM 
NaCl, 2 mM KCl, 1 mM MgCl2.6H2O, 5 mM HEPES) and separated evenly by 
tweezers. 
The separated lobes were then incubated with Collagenase A (Boehringer Manheim, 
Germany) (3 mg/mL in 10 mL of OR2) for one hour at 18 
0
C to release and 
defolliculate the oocytes. Collected oocytes were first washed with OR2 buffer then 
washed and stored with frog Ringer buffer (ND96: 96 mM NaCl, 1 mM MgCl2.6H2O, 
1.8 mM CaCl2.2H2O, 5 mM HEPES supplemented with 2.5 mM sodium pyruvate, 0.5 
mM theophylline) with shaking at 18 
0
C. 
A microprocessor-controlled micropipette puller (PUL-100, World precision 
Instruments, Inc. FL, USA) was used to make micropipettes and their tips were blunted 
to diameter 10 – 20 um. These micropipettes were filled with mineral oil (Sigma 
Chemical Co. Ltd) and the cRNA was then pulled up into the micropipette by a 
positive-displacement using micro-injector (Nanoliter micro-injector, World Precision 
Instruments, Inc. FL, USA). Oocytes were sorted and only healthy ones were injected 
with 35-50 ng of ρ cRNA. The oocytes were then incubated at 18 0C with constant 
oscillation in ND 96 solution supplemented with 2.5 mM sodium pyruvate, 0.5 mM 
theophylline, gentamycin (50 μg/ml) and tetracycline (2.5 mg/ml). 
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2.3.2 Two-electrode Voltage-clamp (TEVC) Electrophysiology 
The two-electrode voltage-clamp experiment was used to test the activities of GABA 
and other ligands of interest at ρ GABAc wild type receptors and to study the effect of 
mutant of interest on the function of ρ1 GABAc receptors. 
The injected oocytes were incubated for between one and four days after injection with 
desired RNA. Later, to measure the various activities on the receptors expressed by 
these oocytes undertaken using two-electrode voltage clamp instrument; Geneclamp 
500 amplifier (Axon Instrument, Sydney, NSW, Australia) and chart version 5.5.6 
Program. The oocytes were placed in a cell bath and clamped at –60 mV with 
continuous flow of ND96 buffer. The recording microelectrodes were prepared by 
pulling using PUL-100 micropipette puller (World precision Instruments, Inc. FL, USA) 
and filled with 3 M KCl.  
The cell bath was continuously perfused with ND96 and switched to solutions 
containing required to screen ligands solubilized in ND96 solution. The stock solutions 
of ligands were prepared using either milliQ water or DMSO according to the solubility 
of molecules.  
Stock solutions during experiments were used to make various desired ligand 
concentration as required with ND96 buffer. The level of receptor expression was 
determined during recording by the application of maximum concentration of GABA 
that produces maximum current (ECmax) (e.g. GABA ECmax for ρ1 GABAC wild type 
receptors is equal to 100 uM) in this case, if GABA ECmax produced at least 100 nA of 
current receptor expression is considered sufficient to carry out the experiment. In order 
to detainees agonist dose-response curves, known concentrations of compounds were 
applied until maximum responses were obtained and no increase in current was 
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observed by increasing concentration. When the inhibitory dose response curves were 
screened, the antagonist effects were tested in the presence of GABA concentration 
which effectively activates 50% of the maximal response (EC50). 
Solutions containing ligand/s were superfused until a steady baseline was achieved. The 
washing intervals depended on the nature of receptors and compounds tested each time. 
The washing interval between doses was generally performed for 7-10 minutes in both 
ρ1 and ρ2 homomeric wild type and mutant receptors. 
 
2.3.3 Data Analysis  
Current responses were normalized to the maximum GABA-activated current recorded 
in the same cell and expressed as a percentage which was fitted by least squares to Hill 
equation (Equation 1). GABA dose response curves (DRC) were generated using 
GraphPad PRISM 5.02 (GraphPad Software san Diego, CA). The responses of other 
agonists that tested at ρ1 and ρ2 GABA receptors were normalized by GABA ECmax 
concentrations in order to calculate concentration response curves of these ligands. 
I = Imax [A]
nH
 / (EC50
nH
 + [A]
nH
)  Equation 1 
Where I is the current response refer to a known concentration of agonist, Imax is the 
maximum current obtained, [A] is the agonist concentration, EC50 is the concentration 
of agonist at which current response is half maximal and nH is the Hill coefficient. 
The inhibitory concentration curves were generated using GraphPad PRISM 5.02 and 
IC50 values were calculated using equation 2. 
I = Imax [A]
nH 
/ (IC50
nH
 + [A]
nH
)  Equation 2 
 Experimental Methods 
  
35 
 
I is the peak current at a given concentration of agonist, Imax is the maximal current 
generated by the concentration of agonist, [A] is the concentration of GABA, IC50 is the 
antagonist concentration which inhibits 50% of the maximum GABA response and nH 
is the Hill coefficient. 
 
2.3.4 Statistical Analysis 
Student’s t-test was performed to determine the statistical significance of the change in 
EC50 and IC50 at ρ1 GABAc WT and mutant receptors. Two-tailed distributions, 
unequal variance and log EC50 and/or IC50 values for ρ1 GABAc WT and mutant 
receptors with various ligands were used when required calculating p-value.
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3. Homology Modelling of the Orthosteric Binding Site of ρ1 
GABAC Ion Channel Receptors via Comparison of Multiple Templates 
X-ray crystallography or nuclear magnetic resonance structural studies of the ρ GABAC 
receptor have been hampered due to the difficulty in overexpressing and purifying the 
protein.
163
 Thus, homology modelling based on available templates affords the best 
method to gain knowledge about the structure of ρ GABAC receptors. There are three 
homology models of the GABAC extracellular domain based on the acetylcholine 
binding protein (AChBP) template.
95-97
  This soluble protein is found in the snail 
Lymnaea stagnalis and was the only structural reference for LGICs for many years until 
the structural determination of the prokaryotic homologues from Erwinia chrysanthemi 
(ELIC),
164
 Gloeobacter violaceus (GLIC)
165
, the Caenorhabditis elegans glutamate-
gated homopentameric chloride channel α (GluCl)166 and most recently human GABAA 
β3 homopentameric receptor.167 These proteins are unified ‘full’ ion channels with the 
extracellular and transmembrane domains present and they vary in the percentage of 
conserved residues with ρ GABAC. In this study five sets of homology models were 
generated based on the five available templates. The four novel templates and the 
previously used template were aligned with the ρ1 protein (Figure 3.1 and 3.3), the 
structures of the generated models were tested and the best models selected. The ρ1 
models were then used to study the receptor’s structure in terms of structural sequence 
alignment, conserved residues between templates and the target protein and the 
conformation of GABA in the binding site. We focused on the orthosteric binding site 
of the homology models by studying the conformation of GABA in the binding pocket 
and residues that are believed to line the binding site in order to explore further of 
interactions of GABA in the binding pocket. 
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Figure 3.1 Amino acid sequence alignment of ρ1 GABAC subunit with ELIC, GLIC, GluCl and GABAA 
β3 subunits. The prediction of secondary structure of the studied ion channel receptors is predicted by 
maestro according to the templates and the generated model. The highlighted residues with dark red color 
are conserved in all templates under this study. The highlighted residues with fair red color are conserved 
residues in two or more of the studied templates, but not all. Note: th intracellular loop between the TM3 
and TM4 is not shown.  
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3.1 Homology modelling of ρ1 GABAC Receptors  
Sets of five GABA bound ρ1 GABAC homology models were generated based on the 
previously used template (AChBP) and four novel templates (i.e. ELIC, GLIC, GluCl 
and GABAA R β3) in open conformations. A set of TPMPA bound ρ1 GABAC 
homology models was also generated based on the GluCl template in the apo state.  
In each set of the generated models, the 6 models were chosen according to potential 
energy-OPLS_2005 and RMS derivative-OPLS_2005. The structures of selected 
models were carefully inspected with focus directed at the orthosteric binding site 
region and the amino acids in the binding site. Stereochemical and energetic properties 
and the packing environment of the residues were confirmed by Ramachandran plot 
analysis (Figure 3.2).  
Figure 3.2 Ramachandran plots of the five GABA bound ρ1 GABAC models based on A. AChBP, B. 
ELIC, C. GLIC, D. GABAA β3 and E. GluCl.   F. Ramachandran plot of the TPMPA bound ρ1 GABAC 
model based on GluCl in apo state. 
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All the selected models have good geometry properties with at least 90% of residues 
situated in the most favoured region and 97.5% in the allowed region (Table 3.1). None 
of the residues found in the generously allowed or disallowed regions are located in the 
binding pocket or recognized as an important residue for any vital role in the binding or 
gating processes.  
Calculating the MM-GBSA free energy of GABA in the binding site of the generated 
models were interestingly showing that GABA capable  to form many interactions in 
the binding site of models based on GluCl and GABAA β3 templates (-25.5 Kcal/mol 
and -23.5 Kcal/mol, respectively), while moderate interactions in models based on 
AChBP (-17.1 Kcal/mol) and very lesser interactions that GABA forms with either 
models based on ELIC or GLIC templates (42.62 Kcal/mol and -4 Kcal/mol, 
respectively) (Table 3.1). 
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Table 3.1. LGIC proteins used as templates in generating ρ1 GABAC homology models: Sequence identity, sequence similarity and gap percentages according to Prime 3.2. 
Note: Proteins used in this study were co-crystalized with ligands that are bound at the orthosteric binding site except the GluCl in the apo state. The MM-GBSA free energy 
of GABA binding in the generated models based on each template was determined. 
Template PDB 
code 
Resolution 
Å 
R-
value 
R-
free 
Co-crystalized 
Ligand 
% 
Sequence 
Identity 
% 
Sequence 
Similarity 
‘Positive’ 
% 
Gaps 
MM-GBSA 
kcal/mol 
 
AChBP 1UV6
168
 2.50 0.227 0.265 Carbamylcholine 16 38 4 -17.1 
ELIC 2YOE
169
 3.90 0.188 0.230 GABA 16 36 13 42.62 
GLIC 4F8H
170
 2.99 0.189 0.219 Ketamine 20 41 8 -4 
GluCl 3RIF
166
 3.35 0.249 0.271 Glutamic Acid 36 60 1 -42.5 
GABAA 
R β3 
4COF
167
 2.97 0.206 0.226 Benzamidine 44 64 2 -23.5 
GluCl 
‘apo 
state’ 
4TNV
171
 3.60 0.262 0.283 - 36 59 2 -25.5 
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Moreover, the results obtained with MolProbity4 (Table 3.2) showed that backbone and 
side chain conformations, bond lengths and angles are within the established criteria for 
reliable structures and are of very good quality.
172
 The best ρ1 GABAC models selected 
based on the five available crystalized proteins were also validated by experimental 
findings and other mutational studies as described throughout this chapter. 
Table 3.2. Models validation by all atom contact ‘steric interactions’ and geometric analyses.172 
Template 
used for 
model 
generating 
Ramachandran 
‘favor’ (%) 
Ramachandran 
‘disallowed’ 
(%) 
Cβ 
deviations 
˃0.25 Å (%) 
Bad 
backbone 
bonds (%) 
Bad 
backbone 
angles (%) 
AchBP 96 1.2 0.9 0.21 0.7 
ELIC 90.5 2.4 2.25 1.04 1.32 
GLIC 90.1 2.5 3.32 0.3 1.23 
GluCl 94.2 1.4 0.7 0.23 0.67 
GABAA R 
β3 
95.4 1.2 1.1 0.2 0.8 
GluCl ‘apo 
state’ 
94.1 1.6 1.2 0.27 1.17 
 
The question of the conformation of GABA in the binding site at the extracellular 
domain of the ion channel receptors has not yet been fully answered. To assist with 
understanding the GABA conformation in the orthosteric binding site we have 
generated ρ1 GABAC ‘GABA bound’ homology models based on all templates which 
are available and compared the GABA conformations with those predicted by 
experimental mutational studies. In a previous study using a ρ1 GABAC model built 
based on the AChBP template, some GABA conformations with many predictions 
about interactions in the binding pocket were discussed.
96
 Although there was an 
abundance of mutational data available at the time, the AChBP template based model 
could not reasonably interpret some of the experimental findings due to the low 
homology between the two proteins, such as the crucial role of loop C residue Thr244, 
which is involved in interactions with GABA during the gating processes. 
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3.2 AChBP Based Modelling of the GABA Binding Pocket 
The crystal structure of the ACh-binding protein was first reported in 2001.
18
 Since that 
time this protein has been used as a template to model the structure of the extracellular 
‘orthosteric’ binding site of many ion channel receptors. There are currently many 
GABAC extracellular domain homology models reported in the literature which have 
been generated in the last ten years based on this template protein.
95-97
  
Throughout the years, the AChBP protein has been crystalized from Lymnaea stagnalis, 
Capitella teleta and Aplysia californica organisms. The amino acid sequence alignments 
of AChBP proteins from those organisms are not exact identical, however there are no 
significant differences in terms of the conserved residues in the orthosteric binding site 
region with ρ1 GABAC subunit. In the current study, the co-crystalized structure of 
AChBP with carbamylcholine in Lymnaea stagnalis was used to generate a set of ρ1 
GABAC extracellular domain models in order to study the GABA binding site along 
with the molecular basis of GABA in the site. 
After the sequence alignment of the extracellular domain of the two proteins, the amino 
acids were found to be only 16% homologous and the gaps were just 4% (Table 3.1). 
By careful inspection of the alignment of both proteins, we noted that the AChBP is a 
good template for modelling the aromatic residues of ρ1 that potentially lines the 
binding pocket, as these residues are conserved with the exception of Phe138 which is 
an alanine in AChBP. Many of the acidic and basic residues that are close to the binding 
site and are believed to have role in GABA binding or protein stability are not 
conserved with the exception of Asp136 and Arg158. Interestingly, the acidic residue 
Asp204 in ρ1 GABAC receptors is aligned with a glutamic acid in AChBP (Figure 3.3). 
This acidic residue was previously studied along with Arg158 by means of the double 
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mutation Asp204Arg and Arg158Asp which restored function that was eliminated by a 
single mutation suggesting an inter-subunit salt bridge between Arg158 and Asp204 in 
wild-type ρ1 GABAC receptors. In the same way, glutamic acid and arginine residues 
may form a salt bridge in ACh binding protein.  
AChBP was aligned with ρ1 GABAC extracellular domain because it only has the 
extracellular domain and was studied before, so studying AChBP in this thesis is to 
show the advantages and disadvantages of the previous published works. 
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Figure 3.3 Amino acid sequence alignment of the extracellular domain of ρ1 GABAC subunit and AChBP 
template. The prediction of secondary structure of transmembrane is predicted by maestro according to 
the generated model. 
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Glu196 in the ρ1 GABAC subunit is a conserved acidic residue in the α1 GABAA 
subunit. This residue is believed to form a salt bridge with the ammonium functional 
group of GABA. This residue aligns with a glycine residue in the AChBP and models 
based on AChBP suggest that GABA favours hydrogen bonds with Ser197 and the 
Tyr198 backbone carbonyl groups rather than a salt bridge. This may explain why the 
GABA conformation is less extended in this model (Figure 3.4). Re-docking of GABA 
after forming a grid has generated a ρ1 GABAC model which still favours hydrogen 
bonds with the backbone carbonyl groups of Ser197 and Tyr198 rather than the salt 
bridge. This example demonstrates how different ligand-protein interactions may result 
in different conformations of a ligand, and an interaction with a single residue may lead 
eventually to an incorrect pose.  
 
 
 
Figure 3.4 GABA docking results 
in the orthosteric binding site of ρ1 
GABAC model based on AChBP 
template. Residues highlighted in 
orange color are potential and 
discussed in the model.  
 
 
 
 
 
 
 
The aliphatic hydrophilic residues Ser168, Ser243 and Thr244 are believed to line the 
binding site with their side chains oriented toward the GABA binding pocket except 
Ser243 which has its side chain partially oriented towards the binding site. These 
hydrophilic residues have been studied experimentally and are believed to be involved 
in interactions with the ligand when it is bound in the orthosteric binding site.
94
 The 
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sequence alignment of ρ1 with AChBP (Figure 3.3) reveals that Ser243 and Thr244 are 
aligned with cysteine residues whereas Ser168 is aligned with a methionine. The 
methionine and cysteine residues have sulfur groups in their side chains, which form 
different interactions to those formed by the hydroxyl groups of serine and threonine. 
The model predicts a direct interaction of Ser168 and Ser243 residues with GABA in 
the orthosteric binding site. However, in this model the side chain of Thr244 does not 
face the orthosteric binding site of the ρ1 GABAC receptor and this model did not 
predict a potential role for Thr244 (Figure 3.4), despite the reported role of Thr244 in 
agonist activity.
100
 Additionally, loop F is not conserved between ρ1 GABAC and 
AChBP subunits. Although significant sequence alignment editing was undertaken in 
order to find a better agreement with experimental results, none of the models based on 
the AChBP template were of good quality in terms of the protein 3D structure, 
particularly in the modelling of loop C. 
 
3.3 ELIC Based Modelling of the GABA Binding Pocket 
The ELIC protein has recently been reported as the first protein to have GABA co-
crystalized in the orthosteric binding site at the interface of two subunits in a LGIC 
receptor.
169
 Prior to the models based on ELIC being generated, the residues interacting 
with GABA in the orthosteric binding pocket of ELIC were compared with those in ρ1 
receptors. Two of the aromatic amino acids that stabilize the ammonium group of 
GABA in ρ1 GABAC receptors are conserved in ELIC (Phe133 and Phe188 in ELIC are 
homologous with Tyr198 and Tyr247, respectively, in ρ1 GABAC) (Figures 3.5A and 
3.5B). However, the hydrophilic residues believed to interact with GABA in ρ1 GABAC 
receptors are absent from the binding pocket of ELIC. Finally, the acidic residues 
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Glu129 and Glu131 in ELIC are conserved in ρ1 GABAC receptors and homologous to 
Glu194 and Glu196, respectively. Unlike the ammonium group of GABA that is 
believed to form a salt bridge with an acidic amino acid in ρ1 GABAC and GABAA 
receptors, GABA in ELIC’s binding pocket does not form a salt bridge. 
 
 
Figure 3.5 ELIC protein and 
GABA docking results. A: 
GABA-protein interactions in 
the orthosteric binding site of 
ELIC. B:  GABA co-
crystalized in ELIC (2YOE, 
table 1). In image B, the 
highlighted residues in orange 
color are the potential 
aromatic residues in the 
orthosteric binding site of 
ELIC. 
 
 
 
 
 
 
 
 
The ELIC protein co-crystalized with GABA (PDBID: 2YOE, Table 3.1) was used as a 
template to generate a set of ρ1 GABAC homology models. GABA was retained in the 
orthosteric binding pocket as a reference ligand during model generation. The built 
models showed defects in modelling many residues in essential loops in particular loop 
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C. The large loop C in ELIC leads to an increase in gaps between the two aligned 
proteins. Due to the length of loop C in the template protein and the conformation of 
GABA in ELIC’s orthosteric binding site, the generated model was not successful in 
providing a representative GABA binding pocket. In this model, GABA could not form 
any of the interactions believed to be essential for GABA binding, due to the docked 
GABA location being located further down the extracellular domain (Figure 3.6).  
 
 
Figure 3.6 GABA docking 
results in the orthosteric 
binding site of ρ1 GABAC 
model based on ELIC 
template where GABA is left 
as a reference ligand during 
modelling. The highlighted 
residues in orange colors are 
potential in the binding site. 
 
 
 
 
 
 
 
Therefore, we generated a grid at the interface between two ρ1 subunits with GABA 
absent. The grid was defined by residues believed to be critical in GABA binding 
including Tyr198, Arg104 and Glu196.
95,97
 When GABA is docked in this manner it 
forms many important and expected interactions, including salt bridges with Arg104 
and Glu196. However, the ammonium group of GABA is not stabilized by the residues 
in what is an aromatic box (Figure 3.7). The carboxylate of GABA forms a hydrogen 
bond with Gln83, a residue in loop G that aligns to the unconserved Phe19 in ELIC, 
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with its side chain oriented towards the binding site, close to the carboxylate group of 
GABA in the orthosteric binding site of ELIC (Figure 3.5A). The functionality of Gln83 
in the ρ1 GABAC receptors has not yet been studied experimentally, so the significance 
of this interaction is at present unknown. Additionally, the GlideScore of GABA in this 
pose is -5 kcal/mol, may indicates that GABA is forming only moderate interactions 
with the residues in the binding site. 
 
Figure 3.7 GABA 
docking results in the 
orthosteric binding site 
of ρ1 GABAC model 
based on ELIC. GABA 
docking results in ρ1 
GABAC homology 
model using interface 
between two subunits 
where GABA was not 
docked at that interface 
during the model 
generating. The 
highlighted residues in 
orange color are 
potential in the binding 
site. 
 
 
 
 
 
3.4 GLIC Based Modelling of the GABA Binding Pocket 
 
GLIC is a prokaryotic LGIC receptor that does not require activation by a ligand in the 
orthosteric binding site. These channels are activated upon lowering of the pH but can 
also be activated in response to general anesthetics, similar to nACh receptors.
173
 
Recently, GLIC receptors were co-crystalized with the anaesthetic ketamine and 
interestingly the ligand binding site overlaps with the conventional orthosteric binding 
sites in LGIC receptors.
170
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A set of ρ1 models was generated using GLIC as a template protein with ketamine 
selected as a reference ligand in the orthosteric binding site. After selecting the best 
model according to previously mentioned criteria, a grid defined by the coordinates of 
the co-crystallised ketamine was generated and GABA docked into it (Figure 3.8A). 
GABA was found to bind in the exact pocket occupied by ketamine with an orientation 
opposed to what is conventionally found in studies using the AChBP template, i.e. in 
the GLIC model, the ammonium group is oriented towards the complementary  (–) ρ1 
subunit and carboxylate is towards the principal (+) ρ1 subunit (Figure 3.8A). In this 
pose the carboxylate of GABA forms a salt bridge with Arg249 and is not surrounded 
by any of the tyrosine residues believed to have a potential role in stabilizing GABA in 
the orthosteric binding pocket (Figure 3.8A).   
Figure 3.8 The ρ1 GABAC homology model based on GLIC. A: GABA redocked into ketamine binding 
site after generating a grid defined by ketamine. B: GABA docked into orthosteric binding site after 
generating a grid defined by the potential residues The244, Tyr198 and Glu196. The highlighted residues 
in orange color are potential in the orthosteric binding site of GABAc model based on GLIC. 
 
 
A grid was placed in the ketamine-free interface defined as a centroid formed by the 
major binding residues; Thr244, Glu196 and Arg104. Due to errors that occur in the 
grid generation when the standard size (20 Å) was used, a slightly larger grid of 24 Å 
was applied. When GABA is docked into this grid it forms a number of interactions 
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with residues previously studied and believed to be involved in binding or receptor 
functionality (such as Ser243 and Tyr247). In addition, the carboxylate of GABA is 
pointed toward the side chains of residues at loop G (Gln83 and Glu85) and loop F 
(Lys217). The ammonium of GABA is oriented toward the side chains of Glu196 and 
Arg170 (Figure 3.8B).  
The GABA pose at the ketamine-free interface of the model based on GLIC resembles 
to a certain extent the one in the model based on ELIC ‘GABA-free interface’. Both 
conformations share interactions that have not previously been reported or studied, such 
as Gln83 with the carboxylate of GABA. 
 
3.5 GABAA Receptor β3 Subunit Based on Modelling of the GABA 
Binding Pocket 
The human homomeric GABAA β3 subunit receptor is the most recently crystallised 
LGIC receptor. These homomeric receptors were co-crystalized with the novel ligand 
benzamidine in the orthosteric binding site. This template aligned with ρ1 GABAC 
showed the highest amino acid sequence identity and similarity of 46% and 64% 
respectively (Figure 3.1 and Table 3.1), in the orthosteric binding site this template 
shares slightly higher than 50% amino acid sequence identity with ρ1.  
The sequence similarity in the orthosteric binding site between GluCl and ρ1 GABAC 
was manually calculated considering only the amino acids that line the binding sites. 
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Figure 3.9 Docking studies of GABAA β3 template. A. The co-crystalized benzamidine in the template 
surrounded by the crucial residues. B. The reference ligand during modelling, benzamidine docked in the 
ρ1 GABAC homology model based on the template surrounded by the crucial residues. C. GABA 
redocked in in the benzamidine pocket of ρ1 GABAC model surrounded by the crucial residues. D. The 
reference ligand during modelling, GABA docked in ρ1 GABAC homology model based on the GABAA 
β3 template surrounded by the crucial residues. The highlighted residues in orange color are potential in 
the binding site.  
Benzamidine was first studied in the GABAA receptor β3 template’s orthosteric binding 
site (Figure 3.9A). The ligand is surrounded by four aromatic residues forming the 
aromatic box (Tyr62, Tyr157, Phe200 and Tyr205). The amidine group is not pointed 
toward Glu155 and there is no interaction between the hydrophilic residue side chains 
in loop C or E and the ligand. The loop G residue, Asp43, an equivalent to Gln83 in ρ1 
GABAC, points to the orthosteric binding site.  
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GABA was docked into one of the benzamidine binding pockets in the template 
receptors before modelling, and both GABA and benzamidine were chosen as reference 
ligands during modelling. The best model was selected according to previous criteria. 
Benzamidine was studied in the ρ1 GABAC receptor orthosteric binding site (Figure 
3.9B). The ligand is stabilized by four aromatic tyrosine residues (102, 198, 241 and 
247) forming an aromatic box, and the aromatic ring of benzamidine forms π-π 
stacking interactions with Tyr102. The amidine forms two interactions with Arg104 
and Glu196; it also forms H-bond interactions with the backbone carbonyls of Ser197 
and Tyr198. Hydrophilic residues (Ser168, Ser243 and Thr244) are not implicated in 
any interaction with benzamidine. A docking grid was defined by benzamidine, and 
GABA was then docked demonstrating stabilization by four tyrosine residues (102, 
198, 241 and 247), which form the aromatic box (Figure 3.9D). The carboxylate of 
GABA forms H-bonds with Arg104 and the backbone carbonyl of Ser242, and the 
ammonium of GABA forms H-bonds with Glu196 and the backbone carbonyl of 
Ser197. This GABA conformation does not suggest any interaction with aliphatic 
hydrophilic residues (Ser168, Ser243 and Thr244). 
When GABA was docked in the benzamidine pocket of the template (and used as 
reference ligand during modelling), it was stabilized in the model (Figure 3.9C) by four 
tyrosine residues (102, 198, 241 and 247) forming the aromatic box. Although the 
carboxylate of GABA was predicted to form interactions with the hydrophilic residues 
Ser168, Ser243 and Thr244, it did not form the critical salt bridge with Arg104 because 
the side chain of this residue, which is not conserved in the β3 subunit, is not oriented 
towards the GABA binding pocket in this model. Additionally, multiple grids were also 
produced at the ‘ligand free’ interface. These grids were defined by critical residues in 
The ρ1 GABAC ‘Orthosteric Binding Site’ Homology Modelling 
54 
 
the orthosteric binding site, however none of the predicted binding conformations of 
GABA formed all experimentally observed interactions in the orthosteric binding site.    
GABAA β3 subunits form heteromeric receptors in vivo, in combination with GABAA α 
and γ subunits. However, the in vivo existence of GABAA β3 homomeric receptors is 
still a matter of speculation, although these homomeric receptors can be experimentally 
expressed and studied in vitro.
174
 In heteromeric receptors the orthosteric binding site is 
located between the β subunit on the principal (+) side and α subunit on the 
complementary (–) side. However, in the orthosteric binding site of the β3 homomeric 
receptor the complementary (-) side lacks an arginine residue, that is conserved in all α 
and ρ subunits, and forms a critical salt bridge with the carboxylate of GABA. The 
absence of Arg104 in the β3 homomeric receptor and the fact that the protein was 
crystalized in the presence of a ligand that has little resemblance to the endogenous 
neurotransmitter, may explain the inability of this template to produce an excellent 
model representing homomeric receptors such as ρ1.174  
 
3.6 GluCl Based Modelling of the GABA Binding Pocket 
GluCl is the first anion-selective LGIC receptor to be crystallised. This template 
protein was co-crystalized with both ivermectin, and the endogenous ligand L-
glutamate in the orthosteric binding site. Both ivermectin and glutamate are required 
for glutamate activation of homomeric GluClα receptors.
166
 The crystal structure shows 
that the α-carboxylate group of glutamate forms a salt bridge with Arg37 and the other 
carboxylate group forms a salt bridge with Arg56. The ligand in the binding site is 
stabilized by only two aromatic residues (Tyr152 and Tyr200) while the other two 
aromatic resides (Tyr102 and Tyr241) present in the ρ1 GABAC binding site are 
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replaced by threonine residues (Thr54 and Thr195) in the GluCl protein. The modelling 
of these two aromatic residues was confirmed by the best model based on GABAA β3 
template as the aromaticity is conserved at these two sites. Loop C of GluCl has three 
hydrophilic residues with functional groups oriented toward the binding site (Thr195, 
Asn196 and Thr197). Ser121 in loop F of the GluCl protein, equivalent to Ser168 in the 
ρ1 GABAC protein, forms an H-bond with the side chain carboxylate of glutamate. As 
the GluCl protein lacks an equivalent acidic residue to that present in the ρ1 GABAC 
protein, no salt bridge is formed with the ammonium of glutamate and the GluCl 
protein. 
A set of ρ1 GABAC homology models were generated based on GluCl where GABA 
was docked into the glutamate binding pocket prior to generating the model to study the 
possible GABA poses in the binding site and compare those poses in terms of Glide 
score and interactions with residues in the orthosteric binding site.
166
 Interestingly, the 
orthosteric binding site in GluCl receptors strongly resembles that of the ρ1 GABAC 
receptors. The sequence alignment of the two proteins shows that GluCl shares 36% and 
60% amino acid sequence identity and similarity, respectively with ρ1 GABAC, and in 
the neurotransmitter binding site the amino acid sequence identity is up to 50% which is 
just slightly lower than for GABAA β3. 
The best model was chosen according to criteria stated above. The reference ligand 
GABA, which remained in the binding site during model generation, is found to form 
all expected interactions with the protein. These interactions have been either 
experimentally studied or predicted through homology with GABAA receptors to have a 
potential role in ligand binding such as: the two salt bridges with Arg104 and Glu196, 
interactions with the aliphatic hydrophilic residues (Ser168 and Thr244) and the 
aromatic residues that are believed to stabilize ligands in the binding site by forming an 
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aromatic box (Tyr198, Tyr241 and Tyr247) surrounding the cationic ammonium ion 
(Figure 3.10). A grid was produced in a ‘ligand free’ interface defined by the critical 
residues Tyr102, Arg104, Glu196 and Thr244. The GABA conformation and 
interactions with proposed binding residues were predicted to be identical to those in the 
model built with the reference ligand in place. 
   
Figure 3.10 The 
GABA bound ρ1 
GABAC  homology 
model based on 
GluCl. Docking 
results of GABA 
when it was left as a 
reference ligand  in 
the orthosteric 
binding site during 
model generation. 
The highlighted 
residues in orange 
color are potential in 
the binding site of 
orthosteric binding 
site of ρ1  GABAc. 
 
 
The ρ1 GABAC homology model based on GluCl was found to be the best to represent 
the structure of ρ1 GABAC receptors, predicting expected interactions and providing the 
most reasonable explanations for previous experimental findings. Further docking 
studies were carried out on this model, which were used to study the interactions that 
GABA and other ligands of interest form in the orthosteric binding site. 
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4. Molecular Basis of the Orthosteric Binding Site of ρ1 
GABAC Receptors 
4.1 The ρ1 GABAC ‘GABA Bound’ Homology Model  
A receptor grid defined by the reference ligand GABA was generated with the model 
based on GluCl, and GABA was then re-docked in this grid. The new GABA pose 
predominantly resembles the original one (RMSD = 0.6Å), however, the GABA pose 
after re-docking is slightly folded while the original pose of GABA is fully extended. 
QM-polarized ligand docking was also applied to GABA docked in this homology 
model and resulted in 3 poses similar at both poles (ammonium and carboxylate) to the 
one generated by the flexible docking process (Figure 4.1). 
 
Figure 4.1 QM-polarized GABA 
docking results in the binding 
site of ρ1 GABAC homology 
model based on GluCl. 
 
 
 
 
 
 
The best pose was selected for performing molecular interaction studies according to 
GlideScore and Glide Emodel (Figure 4.2).  
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Figure 4.2 Docking of GABA 
in the orthosteric binding site 
of ρ1 GABAC receptors based 
on GluCl, showing the best 
pose of GABA according to 
QM-polarized results. The 
highlighted residues in orange 
color are potential residues in 
the orthosteric binding site of 
ρ1 GABAc.  
 
 
 
The GlideScore and Glide emodel of GABA in this pose are -8.7 and -37.3 kcal/mol, 
respectively, which is considered to be very good model for predicting the interactions 
of GABA with the residues in the binding pocket (Table 4.1). 
Table 4.1: Chemical Structures, ligand poses in the binding site, docking (Glide emodel) and Z scores of 
the ligands in this study.  
Ligand Structure Ligand-
Bound 
Homology 
Model 
Glide emodel 
(kcal/mol) 
Z-scoring 
GABA 
 
GABA - 37.2 0.190 
Muscimol 
 
GABA -36.8 1.16 
Imidazole-
4-Acetic 
Acid 
 
GABA -40.5 0.24 
TPMPA 
 
TPMPA -48.5 - 0.765 
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Additionally, the ability of glutamate to activate and/or modulate recombinant ρ1 
GABAC receptors expressed in oocytes was studied using electrophysiology. High 
doses (mM range) of glutamate activated the ρ1 GABAC receptors. If co-applied with 
GABA, glutamate enhances the GABA EC50 response (Figure 4.3). 
 
Figure 4.3 Sample traces of the effect of glutamic acid co-applied in the presence of GABA EC50 at ρ1 
GABAC recombinant receptors. 
 
 
In order to further study the binding of glutamate in ρ1 GABAC receptors, glutamate 
was re-docked into the orthosteric binding site of ρ1 GABAC homology model based on 
the GluCl template. The extra carboxylic acid in glutamate may prevent the full 
stabilization by the aromatic box and may also perform additional interactions such as a 
salt bridge with Arg170 (Figure 4.4), which may be unfavourable to activation of the ρ1 
receptors. 
 
 
 
 
 
Figure 4.4 Ligand protein interaction diagram 
of glutamate in the orthosteric binding site of 
a ρ1 GABAC model.  
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4.1.1 Molecular Basis of Binding at the Orthosteric Site 
 
The molecular basis of binding at the orthosteric site was studied using the homology 
model based on GluCl. In the previous chapter we have shown that GluCl is currently 
the best available template to represent the structure of the orthosteric binding site of ρ1 
GABAC receptors. Furthermore, our observation of the GABA binding pocket in the 
GluCl-based model shows excellent agreement with previous experimental mutational 
studies. 
 
4.1.1.1 Arginine Residues 
The orthosteric binding site of ρ1 GABAC receptors is surrounded by many arginine 
residues including arginine 104, 158, 170, 221 and 249 (Figure 4.5). Many of these 
arginines in ρ1 GABAC receptors are conserved across the crystallised LGIC proteins. 
Arg170 is conserved in all templates while Arg158 is conserved in GluCl and GABAA 
β3, and Arg249 is conserved in ELIC and GABAA β3. On the other hand, Arg104 is 
conserved only in GluCl and Arg221 is conserved only in GABAA β3 (Figure 3.1). 
 
 
Figure 4.5 GABA docking results in the 
orthosteric binding site of the ρ1 GABAC 
model, showing GABA and arginine 
residues that surround the binding site. The 
highlighted residues in orange color are the 
arginine residues in the orthosteric binding 
site of ρ1 GABAC. 
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It is now known that all GABAA receptors form a salt bridge with GABA via an 
arginine residue located in loop D.
98
  Previous structural studies suggest that in ρ1 
GABAC
 
it is Arg104 which forms this interaction,
96-98
  with mutational studies showing 
a significant decrease in GABA responses when Arg104 is mutated to an alanine or 
aspartic acid.
94
 A molecular dynamics simulation has also suggested a salt bridge 
between the carboxylate group of GABA and the side chain of Arg104.
98
 This lends 
weight to the accuracy of the proposed theoretical structure, with the docking studies 
using our model showing this residue forming a salt bridge with the carboxylate group 
of GABA. 
Arg158 has been previously studied by mutation into several different residues and all 
mutations resulted in non-functional receptors in terms of GABA activity.
94
 This 
residue has also been studied alongside Asp204 through a reverse mutation. The results 
suggest that these residues are implicated in the formation of a salt bridge when the 
agonist is bound in the orthosteric binding site at the time of channel gating, and a 
molecular dynamics simulation study has predicted a partial salt bridge forming 
between Arg158 and the carboxylate of GABA.
97
 These results suggest a potential role 
for Arg158 in either GABA binding, channel gating, or both. Our model predicts 
Arg158 at loop E has its side chain oriented toward the GABA binding pocket, but at a 
greater distance than Arg104 (Figure 4.5), supporting the theory that it may stabilise the 
open state through an intra-subunit salt bridge.
175
  
Mutation of the Arg170 residue in loop E of the complementary subunit to alanine or 
aspartic acid results in the mutated receptors being insensitive to mM concentration of 
GABA, suggesting a critical role of this residue.
94
 According to our model, the side 
chain of this residue is not oriented toward the binding pocket (Figure 4.5). This may 
indicate that this residue also does not form a salt bridge with GABA but is important 
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for inter-subunit interactions and stabilization of the channel in either the apo state or 
open conformation.
94,97,175
      
Arg249 is located further down in loop C and is not seen to have any direct interaction 
with GABA (Figure 4.5) in our model. Mutation of this residue to alanine and aspartic 
acid showed only a 4 and 15 fold decrease in GABA activity at GABAC receptors, 
respectively, suggesting that it does not play a role in binding. Interestingly, mutating 
this arginine to lysine, a similar basic residue, also leads to a 30 fold decrease in GABA 
activity which may indicate the importance of the exact location and size of a positively 
charged residue at this site.
94
  
Arg221, an additional arginine that has been studied experimentally and is located 
further down in loop F (Figure 4.5). Introduction of a cysteine at this site increases 
GABA potency by two-fold, indicating that Arg221 is not involved in binding.
93
  
 
4.1.1.2 Aromatic Residues 
As with all LGIC receptors, the ρ1 GABAC orthosteric binding site is surrounded by 
many aromatic residues. These aromatic residues line the GABA binding pocket, while 
some appear to have a direct interaction with GABA, others are crucial for inter-subunit 
interactions or for stabilizing the protein, or a combination of both. Experimental 
mutational studies have proposed which of these aromatic residues have any critical role 
in ligand binding or channel gating.
99
  
Three tyrosines (Tyr198, Tyr241 and Tyr247) are predicted by the best model in this 
thesis to be responsible for stabilizing GABA when it binds in the orthosteric binding 
site (Figure 4.6). Mutational studies have revealed the importance of the aromatic ring 
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system at these sites, as mutating any of these tyrosine residues to phenylalanine leads 
to only a minor effect on GABA activity while mutation to serine leads to a significant 
decrease in GABA activity. Figure 4.6 shows the GABA docking results in the 
orthosteric binding site and stabilization of GABA by these three tyrosine residues 
which line the pocket with their aromatic side chains oriented toward the GABA 
binding pocket. 
 
 
Figure 4.6 GABA docking results in the 
orthosteric binding site of ρ1 GABAC 
model, showing GABA and aromatic 
residues that surround the binding site. 
The highlighted residues in orange color 
are potential aromatic residues in the 
binding site of the ρ1 GABAC. 
 
 
 
 
A cation-π interaction has been predicted to occur between the ammonium group of 
GABA and an aromatic residue in the orthosteric binding site of LGIC receptors. 
Tyr198 has been proposed as the aromatic residue forming this interaction in ρ1 
GABAC receptors.
99
 In this study, none of the GABA bound models generated, 
including the best one based on GluCl were able to predict a cation-π interaction with 
Tyr198 or with any of other aromatic residues with side chains oriented toward the 
GABA binding pocket. In contrast, our model predicts that Tyr198 forms an intra-
subunit CH-π interaction with Phe138 (Figure 4.6). This is in agreement with the 
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GABAA β3 crystal structure where a CH-π interaction is reported to be formed between 
Tyr157 and Tyr 97.
167
  
In our model, Tyr102 does not appear to be involved in stabilizing GABA in the 
binding site (Figure 4.6). However, mutation of this residue has been reported to lead to 
significant changes in GABA activity. The introduction of a serine at this site leads to a 
constitutively active channel while introducing a phenylalanine results in little change, 
and tryptophan leads to a 600-fold decrease in GABA activity. Consistent with our data, 
this suggests that the hydroxyl group of the tyrosine at this site is not critically 
important for GABA binding or channel activation processes, but rather the presence 
and size of the aromatic ring system play a crucial role in the gating process at these 
receptors.
90,91
 The spontaneously opening channels that occur when serine is introduced 
at this site suggest that Tyr102 may play a role during the conformational changes 
which lead to gating, or it may also have a critical role in stabilizing the protein by 
forming inter-subunit interactions. A recent study on the equivalent residue (Phe64) in 
GABAA α1-subunit containing receptors concluded that this residue may be important 
for linking binding to gating by influencing flipping (the transition state between open 
and close states) during channel activation.
176
 
Phenylalanine 138 and 139 are aromatic residues that lie close to the orthosteric binding 
site. Phe138 has the aromatic ring facing the orthosteric binding site (Figure 4.6), 
however this residue most likely has a role in protein stabilization. Introducing various 
mutations at this site leads to only a few fold decrease in GABA activity.
93,99
 On the 
other hand, the side chain of Phe139 does not line the GABA binding pocket, but when 
mutated to cysteine, the receptor becomes non-functional, suggesting that it is most 
likely involved in receptor trafficking or assembly.
93
 Interestingly, these two 
phenylalanine residues are conserved in GluCl receptors (Figure 3.1), which along with 
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mutational studies improves our understanding of the structure and function of these 
residues. 
Tyr200 is believed to be important for intra-subunit stabilization. Mutation to alanine or 
serine leads to inactive receptors. This indicates that aromaticity at this site is crucial for 
channel integrity.
99,177
 Our model shows that this residue’s side chain is not oriented 
toward the GABA binding pocket. Other aromatic residues which are within 7 Å of the 
orthosteric binding site, such as Tyr106, Tyr167 and Tyr208 have also been studied 
previously. Introducing different residues at these sites did not have a significant effect 
on GABA activity.  
 
4.1.1.3 Hydrophilic Residues 
The hydrophilic residues Ser168, Ser243 and Thr244 line the GABA binding pocket. 
These residues are believed to be implicated in interactions with the carboxylate group 
of GABA (Figure 4.7). Switching of a threonine to serine or serine to threonine at any 
of these sites leads to many fold decreases in GABA activity. Thr244 which is 
conserved in GluCl (Thr197) forms a H-bond with the carboxylate of glutamate.
166
 The 
ρ1 GABAC T244S mutant receptors have recently been studied with various ligands. 
Interestingly, after mutation the agonist activity of the studied ligands was decreased 
many fold, whilst the antagonist activity of the studied ligands was unaffected, 
suggesting that a binding interaction at this site is essential for gating of the receptor.
100
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Figure 4.7 GABA docking results 
in the orthosteric binding site of a 
ρ1 GABAC model. Figure shows 
GABA and hydrophilic residues 
that surround the binding site. The 
highlighted residues in orange color 
are the potential aliphatic residues 
in the orthosteric binding site of the 
ρ1 GABAC. 
 
 
 
The residue Ser168 was first predicted by modelling to play a role in agonist activity of 
GABA and other ligands with a carboxylate moiety such as imidazole-4-acetic acid 
(I4AA). In the current study this hydrophilic residue is predicted to form a direct 
interaction with the carboxylate of GABA. The equivalent hydrophilic residue, Thr129, 
in the α1 subunit of the GABAA receptors has previously been studied by a T129S 
mutation. Decreased GABA potency at GABAC S168T mutant receptors and increased 
GABA potency at GABAA α1T129Sβ2γ2L mutant receptors supports the hypothesis 
that Ser168 in ρ1 GABAC receptors is critical for higher potency of agonists with 
carboxylate moieties.
178
 
Ser197 is another hydrophilic residue that lines the orthosteric binding site, and lies 
within 5 Å of the ammonium group of GABA in the binding pocket. However, the 
hydroxyl group of Ser197 does not face the binding site. Our model predicts an 
interaction between the ammonium group of GABA and the backbone carbonyl group 
of this serine. 
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4.1.1.4 Acidic Residues 
Many acidic residues either line or are close to the orthosteric binding site and have 
been predicted through mutational or molecular dynamics simulation studies to have a 
role in ligand binding or channel activation. Our model indicates that Glu196 and 
Asp136 may form a direct interaction with the ammonium group of GABA (Figure 4.8). 
Glu194 and Asp219 are more distant from the orthosteric binding site, and some 
experimental and modelling data suggest that these residues are important in forming 
inter-subunit interactions.
93,97,179
  
The model predicts a salt bridge between the ammonium group of GABA and the 
Glu196 residue (Figure 4.8). The equivalent residue in the β2 subunit of GABAA 
receptors is Glu155, which has been studied in GABAA α1β2γ2L receptors by mutating 
it into cysteine which results in the channel becoming spontaneously active.
180
 
 
 
Figure 4.8 GABA docking results in the 
orthosteric binding site of ρ1 GABAC 
model, showing GABA and acidic 
residues that surround the binding site. 
The highlighted residues in orange color 
are potential acidic residues in the 
orthosteric binding site of ρ1 GABAC. 
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In a molecular dynamics simulation study of a ρ1 GABAC homology model based on 
the AChBP, the Glu194 residue was predicted to form a partial salt bridge with the 
ammonium group of GABA,
97
 while in another simulation study based on the same 
protein, this residue is not predicted to form any interaction with GABA.
98
 The model in 
figure 4.8 shows that this residue’s carboxylate group is not facing the GABA binding 
pocket. Whether this residue is important for GABA activity or not, this residue may 
also be involved in an inter-subunit interaction. 
Asp204 has been studied by mutation into various residues. The study which predicted 
the salt bridge between Asp204 and Arg158 has been discussed before.
175
 These two 
residues may be implicated in inter-subunit interactions that may contribute to global 
conformational changes that result in channel gating. 
Asp136 is located in loop A with its functional group oriented toward the orthosteric 
binding site (Figure 4.8). In a mutational study, introducing cysteine into position 136 
resulted in a few hundred fold decrease in GABA activity, suggesting that this residue 
has a role in GABA binding.
93
 Asp219 is located further down at loop F, distant from 
the GABA binding pocket. Introducing a cysteine at this site leads to only a few fold 
decrease in GABA activity.
93
 This acidic residue has its side chain facing the 
neighbouring subunit, and may be involved in an inter-subunit interaction. 
 
4.1.1.5 Loops F and G 
Loop F of ρ1 GABAC receptors consists of 15-20 residues that are believed to have 
different roles (Figure 4.9). Loop F can be divided into three regions: upper, middle and 
lower depending on the region’s role in binding or channel activation.181 This loop has 
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been studied and residues in it have been investigated in a variety of mutational and site 
specific fluorescence studies.
181-183
 Although there are many predictions about the 
critical role that loop F may play in ligand binding and gating processes, there is 
currently no concrete evidence to specify the role of loop F in either of these processes. 
The loop is also predicted to have an indirect role in agonist and antagonist actions 
through involvement in the conformational changes that may or may not affect channel 
gating.
93
  
According to our model there are 4 residues in loop F that have their functional groups 
oriented toward the orthosteric binding pocket or facing the neighbouring subunit. 
These residues are Lys210, Ser215, Lys217 and Asp219. Mutational studies have been 
undertaken at these sites by introducing a cysteine at each residue and the GABA EC50 
determined. Only the S215C mutation resulted in any significant change with 30-fold 
decease in GABA activity.
181
 These results suggest that these residues have no direct 
effects on GABA binding, but may be involved in interactions leading eventually to 
channel activation.  
 
 
Figure 4.9 GABA docking 
results in the orthosteric 
binding site of ρ1 GABAC 
model, showing GABA and 
residues within loop F and G 
of the binding site. 
Highlighted residues in 
orange color are potential in 
loops F and G. 
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Loop G was recently identified in ELIC receptors, however residues in this loop have 
not yet been investigated experimentally for any specific role.
169
 We studied this loop in 
our model and three residues within the loop were found to have their functional group 
face the orthosteric binding site: Asp81, Gln83 and Glu85. The model predicts that the 
side chain of Gln83 is within 7 Å, and oriented toward the GABA binding pocket 
(Figure 4.9). 
 
4.1.2 Muscimol and Imidazole-4-acetic Acid 
The partial agonists muscimol and imidazole-4 acetic acid (I4AA) at ρ1 GABAC 
receptors are molecules that occur naturally in mushrooms and human brain tissues, 
respectively.
184
 These ligands are able to activate ρ1 GABAC receptors with a range of 
different potencies and efficacies. Muscimol is very potent and efficacious at ρ1 
receptors (EC50 = 1.4 µM, approximately 85% efficacy relative to GABA maximal 
response) while I4AA is slightly less potent and significantly less efficacious at ρ1 
GABAC receptors (EC50 = 8.6 µM, approximately 10% efficacy relative to GABA 
maximal response).
54,115
  
Muscimol is a GABA analogue in which the carboxylic acid is replaced by the aromatic 
bioisostere hydroxyisoxazole (Table 4.1). Muscimol re-docked into the ρ1 GABAC 
‘GABA bound’ homology model was predicted to form similar interactions to those 
formed by GABA, with additional π-π stacking between the hydroxyisoxazole and 
Tyr247. The five membered ring with the hydroxyl side substituent forms identical 
interactions to the carboxylate group of GABA. The model also shows that both the 
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nitrogen and oxygen in the ring system form hydrogen bonds with Thr244 (Figure 
4.10).  
 
Figure 4.10. Re-
docking results of 
muscimol in the 
orthosteric binding 
site of ρ1 GABAC 
‘GABA bound’ 
homology model 
based on GluCl. The 
highlighted residues 
in orange color are 
potential in the 
orthosteric binding 
site of ρ1 GABAC. 
 
 
 
The ammonium group of muscimol is predicted by the model to form direct interactions 
with the backbone carbonyl group of Ser197 and Tyr198 residues, reducing the 
likelihood of a salt bridge forming with Glu196 as occurs with GABA. 
Although I4AA is able to only weakly activate ρ1 GABAC recombinant receptors with 
low efficacy, it is a very potent antagonist at these recombinant receptors with IC50=900 
nM (Figure 4.11).
115
  
 
Figure 4.11 Concentration response curve of I4AA co-
applied with GABA EC50 at ρ1 GABAC recombinant 
receptors. . (Data = Mean ± SD, n = 3). 
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When I4AA is re-docked at the ρ1 GABAC ‘GABA bound’ model, the carboxylate 
group of I4AA forms similar interactions to the carboxylate group of GABA, including 
a salt bridge with Arg104 and interactions with aliphatic hydrophilic residues (Figure 
4.12). According to I4AA docking results, the imidazole ring system is involved in π-π 
stacking with three aromatic residues (Phe138, Tyr198 and Tyr241). The imidazole ring 
system is also predicted to be involved in H-bond interactions with backbone carbonyl 
groups of Tyr198 and Glu196. 
 
Figure 4.12 Re-docking 
results of I4AA in the 
orthosteric binding site of ρ1 
GABAC ‘GABA bound’ 
homology model based on 
GluCl. The highlighted 
residues in orange color are 
potential in the orthosteric 
binding site of ρ1 GABAC. 
 
 
 
 
 
 
 
4.2 ρ1 GABAC ‘TPMPA Bound’ Homology Model 
A set of models was generated based on the crystal structure of GluCl in the apo state 
using the GABAC competitive antagonist TPMPA as a reference ligand during 
modelling.
115
 The best model was used to study the interactions at the orthosteric 
binding site. This antagonist is potent at ρ1 GABAC recombinant receptors and selective 
over GABAA and GABAB receptors.
184
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4.2.1 TPMPA 
The ρ1 GABAC ‘TPMPA bound’ homology model is showing that the antagonist is able 
to form many of the same interactions as GABA. In contrast to GABA, TPMPA is 
stabilized by four aromatic residues (Tyr102, Tyr198, Tyr241 and Tyr247) that form an 
aromatic box around the molecule (Figure 4.13A). TPMPA also forms the two salt 
bridges with Arg104 and Glu196. Moreover, the phosphinic acid bioisostere of GABA’s 
carboxylic acid maintains interactions with hydrophilic residues (Ser168 and Thr244). 
Additionally, this antagonist forms many hydrophobic interactions that may explain the 
greater stabilization of the binding site (Figure 4.13B) and potential for TPMPA acting 
as an antagonist rather than activating the receptor. 
 Figure 4.13: TPMPA docking results with ρ1 GABAC ‘TPMPA bound’ homology model based on GluCl 
in apo state. (A) TPMPA docked in ρ1 GABAC ‘TPMPA bound’ homology model with potential residues 
forming interactions with the ligand. (B) Hydrophobic interactions of TPMPA and potential hydrophobic 
residues in the binding site. 
 
 
4.3 Open and closed conformations 
Superimposing the ρ1 model generated with GABA bound based on the glutamate 
bound GluCl template and the TPMPA bound model based on the apo GluCl template, 
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predicts significant differences in both loops C and F of the orthosteric binding site 
(Figure 4.14). Movement of loop C
166,168,185,186
 and loop F
181-183
 has been suggested to 
be involved in channel activation after agonist binding and shown experimentally to 
change on agonist and antagonist binding. Compared to the antagonist model based on 
the apo structure, loop C in the GABA bound model is held closer to the ligand. 
Agonist binding generates conformational changes that lead to gating while an 
antagonist is able to bind tightly without generating any conformational changes that 
lead to gating. Outward movement of the lower part of loop F is believed to be coupled 
to the channel activation,
181
 and this model suggests how an antagonist such as TPMPA 
may interact with residues in loop F but avoid the required conformational changes for 
gating. 
 
 
 
Figure 4.14 Superimposed 
homology models of ρ1 
GABAC formed with GABA 
bound based on the glutamate 
bound GluCl templates (dark 
grey) formed with TPMPA 
bound based on GluCl template 
in apo state (green), showing 
structural changes in loops C 
and F. 
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5. Studies Exploring Potential Roles of Hydrophilic Residues 
in the Orthosteric Binding Site of ρ1 GABAC Receptors. 
5.1 Background 
Limited studies have been undertaken on the three hydrophilic residues Ser168, Ser243 
and Thr244, which have their hydroxyl groups oriented toward the GABA binding 
pocket of ρ1 GABAC receptors.
88,93,94,100,116
 Those previous studies were undertaken to 
reveal the receptor’s functionality in the presence of GABA when a single point 
mutation is introduced at one of these sites. Serine 168 and threonine 244 were found to 
be critical for receptor’s functionality. However, serine 243 when mutated to alanine 
resulted in only a two-fold reduction in GABA potency and thus was not identified as 
being essential for either channel functionality or GABA activity.
88,94
 
The modelling and docking studies which are discussed in chapter four of this thesis 
predict that hydroxyl groups of Ser 168, Ser 243 Thr 244 are pointed toward the binding 
site and are within a 5 Å distance of the carboxylate group of GABA (Figure 5.1). To 
further investigate the role of these hydrophilic residues they were mutated into alanine, 
cysteine, threonine or serine and studied in the presence of GABA, three sets of partial 
agonists and some representative antagonists.  
These studies aimed to explore the role of the hydrophilic residues in the orthosteric 
binding site in terms of receptors functionality, and to determine interactions that they 
may form with various ligands, and the implications of these interactions in binding, 
channel activation and overall gating processes. Additionally, the shift in potency and/or 
efficacy of the different ligands was also considered and discussed in terms of how 
different interactions may affect receptor stability in apo state or open conformation. 
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Figure 5.1 GABA docked in the 
orthosteric binding site of ρ1 
GABAC homology model and 
surrounded by the hydrophilic 
residues that have side chains 
toward the binding site. 
 
 
 
The introduced residues were selected to add or delete various side chains at each of the 
sites and then test the modified receptor with a range of structurally varied ligands 
(Figure 5.2). Mutating any of these residues to alanine removes the hydrophilic 
functional group and thus allows investigation of the importance of that residue for 
activity of particular ligands and channel functionality. Introducing a cysteine would 
introduce a less hydrophilic functional group at the site that may allow for different 
interactions to be formed. Switching a threonine and serine adds or deletes an additional 
methyl group in the side chain, which may alter the steric constraints of the free 
hydroxyl group and slightly increase hydrophobic character that may enhance the 
stability of ligands in the binding site within the apo state or open conformation. 
 
Figure 5.2 The chemical 
structures of serine, 
cysteine, alanine and 
threonine residues. Red 
circles mark their side 
chain functional groups.  
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The partial agonists were used in studies are classified into three groups as follows: The 
unsaturated GABA analogues, TACA and CACA; GABA analogues of various carbon 
chain lengths, glycine, β-alanine and 5-aminovaleric acid; and heterocyclic GABA 
analogues, muscimol, isoguvacine and imidazole-acetic acid (I4AA) (Figure 5.3). Many 
of these partial agonists have previously been tested at ρ1 GABAC wild type receptors 
and their activities (EC50) reported, however their antagonist effects on GABA EC50 
responses have rarely been reported. 
The apparent affinities of GABA, TACA, CACA, muscimol, I4AA and isoguvacine 
were previously studied and directly correlated with their efficacies in terms of binding 
affinity and activation of recombinant ρ1 GABAC receptors.
187
 In the current study, we 
compare the binding and channel activation by partial agonists with GABA in terms of 
ligand-residue interactions in the orthosteric binding site of ρ1 WT and the mutant 
receptors and the co-operative/inhibition effects of partial agonist when co-applied with 
GABA EC50 at ρ1 WT and the mutant receptors. 
Figure 5.3 The chemical structures of GABA and other ligands which were used in studies in this chapter. 
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The antagonists in this study are representative of the variety of antagonist structures 
and were carefully selected in order to investigate how their functional groups may 
interact with introduced residues. The potencies of these antagonists were compared 
between the wild type and the mutant receptors to investigate whether these hydrophilic 
residues are involved in interactions that affect the mechanism of channel gating. 
 
5.2 Threonine 244 
5.2.1 Previous studies on threonine 244 
The potential importance of threonine 244 was identified from the role of the 
homologous residue in the β subunit of GABA heteromeric receptors containing α and β 
subunits. Threonine 244 was mutated to a number of other residues, however 
introducing serine at this site was the only mutant which formed functional receptors 
with a shift in the GABA dose response curve to the right by 35-fold.
88
 Recently, ρ1 
GABAC T244S mutant receptors have also been studied with some partial agonists and 
antagonists. This study found that the ρ1 T244S mutant receptors resulted in the studied 
partial agonists being converted to antagonists, whereas the studied antagonists still 
antagonized GABA responses with the same potencies.
100
 
5.2.2 Homology Models and GABA Docking Studies at Threonine 244 
The generated models described in previous chapters predict a hydrogen bond between 
the hydroxyl group of the threonine in loop C and the carboxylate group of GABA. This 
interaction assists in agonist binding and may facilitate the gating due to movement of 
loop C inward, leading to the open conformation and activating the receptor (Figure 5.4) 
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Figure 5.4 The orthosteric binding site of a ρ1 GABAC homology model based on GluCl in the open 
conformation, showing interactions between GABA and Thr244. A. H-bonding between the carboxylate 
group of GABA and the hydroxyl group of Thr244 residue. B. Various interactions between the side 
chains of GABA and the Thr244 residue. 
 
Compared to a serine, the presence of threonine at this site with the additional 
methylene group in the side chain will constrain the freedom of the hydroxyl group 
making it less mobile and more oriented to the binding site (Figure 5.4A). Furthermore, 
the hydrophobic character of the methylene group may enhance GABA stability in the 
binding site more particularly in the open conformation state when loop C moves closer 
to the agonist as an essential step in initiating the channel gating process (Figure 5.4B). 
 
5.2.3 Mutation of Threonine 244 into Serine, Alanine and Cysteine  
GABA was first tested on the receptors with the mutated residues in order to investigate 
the functionality of the mutant receptors. The ρ1 GABAC T244S mutant receptors 
showed a 35-fold decrease in GABA potency, as previously reported.
88,100
  However, ρ1 
GABAC T244A and ρ1 GABAC T244C mutant receptors initially appeared to be 
unfunctional or insensitive to GABA at a concentration of 30 mM. However, increasing 
the concentration of mutant RNA injected into the oocytes from 50-100 ng/µl to 300 
ng/µl resulted in the expressions of receptors that were weakly responsive to GABA at 
high concentrations (Figure 5.5). 
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Figure 5.5 Concentration response curves of GABA at ρ1 GABAC WT, ρ1 T244S, ρ1 T244A and ρ1 
T244C receptors, (Data = Mean ± SEM, n = 5). Note: GABA elicited sub-maximal efficacy compared to 
β-alanine and MTSEA at ρ1 T244A and ρ1 T244C mutant receptors, respectively. 
 
5.2.4 ρ1 GABAC T244S Mutant Receptors 
5.2.4.1 Background 
The functionality of ρ1 T244S mutant receptors has previously been investigated with 
GABA.
88,100
 The 35-fold decrease in GABA potency that occurs at ρ1 T244S mutant 
receptors suggests the importance of the threonine methylene group in restricting the 
position of the hydroxyl group which is predicted by modelling to form a hydrogen 
bond with the carboxylate group of GABA (Figure 4.4). The enantiomers R-(−)- and S-
(+)-GABOB which are full agonists at ρ1 wild type receptors (EC50 = 19 μM and 45 
μM, respectively), exert different pharmacological activities at ρ1 T244S mutant 
receptors. R-(−)-GABOB is converted to a partial agonist (1 mM activates 26% of 
maximal GABA efficacy) while S-(+) - GABOB becomes a competitive antagonist IC50 
= 417.4.
100
 When the partial agonists imidazole-4-acetic acid and muscimol were tested 
at ρ1 T244S mutant receptors, their agonist effects were eliminated by the mutation and 
they acted only as competitive antagonists (muscimol switched from eliciting a pure 
additive effect at ρ1 WT to an antagonist at ρ1 T244S receptors, whereas I4AA has 
approximately a 20-fold increase in IC50 at ρ1 T244S compared to ρ1 WT receptors). 
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Conversely, the activity of four competitive antagonists (3-aminopropyl (methyl) 
phosphinic acid (3-APMPA), 3-aminopropylphosphonic acid (3-APA), S-3-(amino-2-
hydroxypropyl) methylphosphinic acid (S-(−)-CGP44532), R-3-(amino-2-
hydroxypropyl) methylphosphinic acid (R-(+)-CGP44533)) remained unchanged at 
these mutant receptors compared to ρ1 WT receptors.100 
5.2.4.2 GABA, TACA and CACA at ρ1 T244S Mutant Receptors 
5.2.4.2.1 Agonist Effect of TACA and CACA at ρ1 T244S Receptors 
The trans and cis isomers of crotonic acid, TACA and CACA respectively, are 
conformationally restricted unsaturated GABA analogues. TACA is a potent agonist 
(EC50 = 0.6 µM) at ρ1 WT receptors, but shows a 25-fold decrease in activity at ρ1 
T244S mutant receptors (EC50 = 14 µM) (Table 5.1). However, the partial agonist 
CACA (EC50 = 95 µM) at ρ1 WT receptors becomes almost inactive at ρ1 T244S 
mutant receptors, resulting in only a minimal response at 300 µM (Figure 5.6) 
Figure 5.6 Concentration response curves of GABA and the unsaturated analogues, TACA and CACA at 
ρ1 WT and ρ1 T244S receptors, (Data = Mean ± SEM, n = 5). 
 
The efficacy of the unsaturated ligands was also altered as a result of the ρ1 T244S 
mutation. Interestingly, TACA which shows 95% efficacy relative to GABA maximal 
response at ρ1 WT receptors is slightly more efficacious than GABA at ρ1 T244S 
receptors (Figure 5.7). CACA which shows only 60% efficacy relative to GABA 
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maximal response at ρ1 wild type receptors has only 2% efficacy at ρ1 T244S receptors 
(Table 5.1). 
Figure 5.7 Sample traces of the maximal responses of GABA and TACA at ρ1 WT and ρ1 T244S 
receptors. 
 
TACA which has greater distance between the carboxylate and ammonium poles than 
GABA (Figure 5.8) is predicted to be more able to form contacts with the side chain of 
serine residue at the Thr244 site (Figure 5.9).  
Figure 5.8 GABA, TACA and CACA docked in the orthosteric binding site of a ρ1 GABAC homology 
model based on GluCl in the open conformation. A. Docking studies where GABA in grey color, TACA 
in blue, and CACA in red. B. Poses of GABA and TACA in their binding conformations showing 
distances between the two poles. 
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Figure 5.9 Docking results of GABA and TACA in the orthosteric binding site of a ρ1 GABAC homology 
model based on GluCl in the open conformation. Various contacts of the side chain of GABA with the 
side chain of serine at the Thr244 site. B. Various contacts of the side chain of TACA with the side chain 
of serine at Thr244 site. The rotamer of serine shown in the figure has similar Chi1 and Chi2 values to the 
predicted conformation of Thr244 at this site (i.e. Chi = 91 and Chi2 = –179). 
  
This interaction may responsible for the higher efficacy of TACA, further stabilizing the 
open conformation. 
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Table 5.1 Summary of various effects of partial agonists at ρ1 GABAC WT and ρ1 GABAC T244S homomeric receptors. 
Ligand ρ1WT 
EC50 
ρ1WT 
Efficacy 
ρ1WT 
(Additive/inhibition) % 
ρ1T244S 
EC50 
ρ1T244S 
Efficacy 
ρ1T244S 
(Additive/inhibition) % 
TACA 0.6µM 95 % 180 14 µM 110 % 180 
CACA 95 µM 60 % 150 % 95 µM 3 % 125 % 
Glycine 1 mM 25 % 170 % 1.4 mM 8 % (140/100) 
β-Alanine 400 µM 30 % (120/40) 4.4 mM 5 % (115/45) 
5-Aminovaleric 
Acid 
7 mM 3 % (125/3) 600 µM 3 % (120/2) 
Isoguvacine 205 µM 50 % 135 % 0 0 (110/0) 
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5.2.4.2.2 Effects of CACA Co-applied with GABA EC50 at ρ1 T244S Receptors 
The effect of CACA when it was co-applied with GABA EC50 at ρ1 WT and ρ1 T244S 
receptors was also investigated (Figure 5.10) Table 5.1). 
 
Figure 5.10 The effect of co-
applying increasing 
concentrations of CACA in the 
presence of GABA EC50 at ρ1 
WT and ρ1 T244S receptors, 
(Data = Mean ± SEM, n = 5). 
 
 
 
The co-application of CACA has an additive effect on GABA EC50 responses at ρ1 WT, 
reaching up to 150% of GABA EC50 efficacy with 100 µM CACA concentrations. The 
additional effect of CACA is similar in magnitude to the effect of CACA applied alone 
at ρ1 WT receptors (Table 5.1). These results suggest the ability of CACA to bind and 
enhance GABA EC50 responses without competing with GABA for the same binding 
site at the same time (Figure 5.11). 
Interestingly, despite the fact that CACA applied alone is almost inactive at ρ1 T244S 
receptors (Figure 5.6), CACA applied in the presence of GABA EC50 shows a co-
operative effect on GABA EC50 responses at these mutant receptors, the magnitude of 
300 μM CACA applied alone is less than 2% of GABA IMAX, however the GABA EC50 
effect is enhanced by approximate 20% at 100 µM CACA (Figure 5.11).  
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Figure 5.11 The traces of CACA co-applied with GABA EC50 at ρ1GABAC WT and ρ1 T244S receptors. 
  
This suggests that binding and/or activation by GABA may enable CACA to bind in 
sites unoccupied by GABA and further activate the receptor more effectively than when 
CACA is applied alone. 
 
5.2.4.3 Glycine, β-Alanine and 5-Aminovaleric Acid and ρ1 T244S Mutant 
Receptors 
5.2.4.3.1 Agonist Effects of Glycine, β-Alanine and 5-Aminovaleric Acid 
Analogues of GABA with varying numbers of carbon atoms in the backbone, glycine, 
β-alanine and 5-aminovaleric acid, respectively, were tested at both ρ1 WT and ρ1 
T244S receptors. 
Figure 5.12 Concentration response curves of GABA, glycine, β-alanine and 5-aminovaleric acid at ρ1 
WT and ρ1 T244S receptors, (Data = Mean ± SEM, n = 5). 
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At ρ1 WT receptors, all three compounds are weak partial agonists.188,189 Compared to 
their effects on WT receptors, the potencies and efficacies of these partial agonists were 
decreased at the ρ1 T244S mutant receptors. Both glycine and β-alanine showed 
significant decreases in efficacy (8% and 5% efficacies relative to GABA maximal 
response at 30 mM for glycine and β-alanine, respectively) (Table 5.1). The least 
efficacious compound at ρ1 WT receptors, 5-aminovaleric acid showed a large decrease 
in potency, shifting the curve to the right, however the ligand was still able to slightly 
activate the mutant receptors at high concentration (3% efficacy relative to GABA 
maximal response at 30 mM) (Figure 5.12) (Table 5.1). 
 
5.2.4.3.2 Effects of Glycine, β-Alanine and 5-Aminovaleric Acid Co-applied with 
GABA EC50 at and ρ1 T244S Receptors 
The partial agonists, glycine,
189
 β-alanine and 5-aminovaleric acid were co-applied with 
GABA EC50 in order to study their effects on GABA responses at ρ1 WT and ρ1 T244S 
receptors. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13 Concentration response curves of glycine, β-alanine and 5-aminovaleric acid in the presence 
of GABA EC50 at ρ1 WT and ρ1 T244S receptors (Data = Mean ± SEM, n = 5). 
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Glycine displays a co-operative effect on GABA EC50 responses at ρ1 WT receptors 
(180% efficacy relative to GABA EC50 response set to 100%), and also enhances 
GABA EC50 responses at ρ1 T244S mutant receptors but with less magnitude (145% 
efficacy relative to GABA EC50 response set to 100%) and this effect is reduced when 
glycine is applied at concentrations higher than 1 mM (Figure 5.13A) (Table 5.1). These 
results suggest that glycine is able to bind to vacant binding sites in ρ1 WT and ρ1 
S244T receptors and further activate the channel, but does not compete with GABA at 
sites where GABA is bound at ρ1 WT receptors. This is most likely because GABA has 
a much higher binding affinity at ρ1 WT receptors. However, at ρ1 T244S mutant 
receptors the binding affinity of GABA is likely to be reduced and therefore at very 
high concentrations of glycine, some competition between the two ligand for the same 
binding site may occur but without significant displacement of GABA molecules, 
resulting in fewer channels being activated and therefore the cooperative effect by 
glycine is diminished at 10mM (Figure 5.13A).  
In the presence of GABA EC50, β-alanine at lower µM concentrations has additive and 
co-operative effects at ρ1WT receptors (125%) and ρ1 T244S mutant receptors (115%), 
respectively, and acts as an antagonist at both ρ1 WT and ρ1 T244S receptors (β-alanine 
inhibits 60% of GABA EC50 at both receptors), However the IC50 of β-alanine is 
increased 8-fold at ρ1 T244S receptors compared to ρ1 WT (100µM and 1 mM of β-
alanine antagonize GABA EC50 responses at ρ1 WT and ρ1 T244S receptors, 
respectively)(Figure 5.13B) (Table 5.1). 
5-Aminovaleric acid acts as an antagonist at both ρ1 WT and ρ1 T244S receptors in the 
presence of GABA EC50 responses (Figure 5.13C). However, the potency of 5-
aminovaleric acid is increased two-fold with an IC50 = 37 µM and 17 µM at ρ1 WT and 
ρ1 T244S receptors, respectively (Figure 5.13C) (Table 5.1). The additional methylene 
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group of 5-aminovaleric acid may also result in further hydrophobic contacts in the 
binding site that further stabilize the apo state over the open conformation. The 
extended chain length of 5-aminovaleric acid compared to GABA permits 5-
aminovaleric acid to form required interactions with the receptors in the apo state and 
therefore the protein predominantly does not undergo a conformational change to 
activate neither ρ1 WT nor ρ1 T244S receptors (Figure 5.14). The increase in antagonist 
potency of 5-aminovaleric acid at ρ1 T244S receptors is most likely due to the fact that 
the extended chain length results in increased flexibility and allows the carboxylate 
group to form interactions with the side chain of serine at position 244 more so than 
GABA.  
 
Figure 5.14 GABA (white) and 5-
aminovaleric acid (yellow) docked 
in the orthosteric binding site of ρ1 
GABAC homology model based on 
GluCl in apo state.   
 
 
 
 
5.2.4.4 Isoguvacine and ρ1 T244S Mutant Receptors 
5.2.4.4.1 Agonist Effect of Isoguvacine 
The heterocyclic GABA analogue; isoguvacine was tested at ρ1 WT and ρ1 T244S 
receptors. This ligand is weak partial agonist, activating WT receptors with an EC50 of 
200 µM
55
 and 45% efficacy relative to the GABA maximal response. However, at ρ1 
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T244S mutant receptors the potency and efficacy of isoguvacine are abolished at 600 
µM (Figure 5.15) (Table 5.1). 
 
Figure 5.15 Concentration 
response curves of GABA 
and isoguvacine at ρ1 WT 
receptors, (Data = Mean ± 
SEM, n = 5).   
 
 
Docking studies of this ligand with the ρ1 GABAC homology model predict H-bonding 
of the hydroxyl group of Thr244 with the carboxylate group of isoguvacine (Figure 
5.16A). There are also interactions between the side chains of Thr244 and isoguvacine 
(Figure 5.16B). These interactions may possibly further stabilize the ligand in open 
conformation.    
Figure 5.16 Docking studies of isoguvacine in the orthosteric binding site of ρ1 GABAC homology 
model. A. H-bonding of the carboxylate group of isoguvacine with the hydroxyl group of Thr244. B. 
Interactions between the side chains of isoguvacine and threonine 244. 
 
The significant reduction in sensitivity of isoguvacine when serine is introduced at 
Thr244 site suggests the importance of the H-bond and others interactions between the 
side chain of isoguvacine and Thr244 in stabilizing the receptor in open conformation.   
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5.2.4.4.2 Antagonist Effect of Isoguvacine at ρ1 T244S Mutant Receptors 
At ρ1 WT receptors isoguvacine has a moderate additive effect on the GABA EC50 
response of up to 135% (Figure 5.17) (Table 5.1). 
 
Figure 5.17 sample 
trace responses of 
isoguvacine when 
co-applied with 
GABA EC50 at ρ1 
GABAC WT 
receptors.  
 
However, at ρ1 T244S mutant receptors isoguvacine acts as a full antagonist (IC50 = 
25.3 µM) against GABA EC50 (Figure 5.18 and 5.19) (Table 5.1)    
 
Figure 5.18 Concentration 
response curves of the co-
application of isoguvacine with 
GABA EC50 at ρ1 GABAC WT 
and ρ1 T244S receptors (Data = 
Mean ± SEM, n = 5).  
 
These results suggest that isoguvacine binds in the binding site of ρ1 T244S mutant 
receptors however does not stabilize the open conformation at these mutant receptors. 
On the other hand, isoguvacine is switched from a co-operative effect at ρ1 WT 
receptors to antagonist effect at ρ1 T244S mutant receptors. Removing the methylene 
group at the Thr244 site has prevented isoguvacine from moving loop C closer, 
therefore it is not able to stabilize the open conformation.  
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Figure 5.19 
Sample response 
traces of 
isoguvacine 
when co-applied 
with GABA EC50 
at ρ1 T244S 
receptors. 
 
Studying the activity of structurally different partial agonists at ρ1 GABAC T244S 
mutant receptors indicates that the effect of the mutation is determined by the structure 
of the ligand. The efficacy and potency of aliphatic partial agonists (glycine, β-alanine 
and 5-aminovaleric acid) decreased significantly, however they were still able to weakly 
activate ρ1 T244S receptors at very high concentration. However, the heterocyclic 
partial agonist, isoguvacine, was converted to a full antagonist. This suggests that 
structurally different partial agonists form different interactions in the binding site 
leading to channel activation. 
 
5.2.4.5 Antagonists (TPMPA and THIP) 
The GABAC antagonists, TPMPA and THIP were tested in the presence of GABAC 
EC50 at ρ1 WT and ρ1 T244S receptors. Compared to the effect of these antagonists on 
WT
54,57
, the T244S mutation has no effect on the potencies of these ligands (Figure 
5.20).  
Figure 5.20 Concentration response curves of TPMPA and THIP at ρ1 WT and ρ1 T244S receptors, (Data 
= Mean ± SEM, n = 5).  
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Modelling and docking studies with the model based on GluCl in the apo state predict 
that loop C is sterically prevented from moving inward forming a shield-like structure 
above the ligand as an essential step in the open conformation.  The bulkier structure of 
the antagonists may inhibit the movement of loop C closer to the ligand, preventing the 
formation of H-bonds and contacts necessary for channel activation (Figure 5.21). 
Figure 5.21 Docking studies of TPMPA and THIP in the orthosteric binding site of a ρ1 GABAC 
homology model based on GluCl in the apo state. 
 
This may explain why the potencies of competitive antagonists don’t change when 
serine is introduced at the Thr244 site. This also would explain the predominantly 
closed conformation of the channel in the presence of competitive antagonists. 
   
5.2.5 ρ1 GABAC T244A Mutant Receptors 
Substitution of alanine for threonine at the 244 position removes the hydroxyl group at 
this residue. At ρ1 T244A receptors, both the potency and efficacy of GABA was 
significantly reduced (ρ1 WT = 1 µM, ρ1 T244A = 4960 µM). The ρ1 WT agonists, 
TACA and muscimol, and the partial agonists, glycine, β-alanine and 5-aminovaleric 
acid were tested on ρ1 T244A mutant receptors and with the exception of β-alanine, all 
were found to be weaker and less efficacious than GABA. β-Alanine with one carbon 
less than GABA, was found to be more potent (EC50 = 1496 µM) and approximately 
two times more efficacious than GABA at a 30 mM concentration on ρ1 T244A mutant 
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receptors (Figure 5.22 and 5.23). Compared to its effects on ρ1 WT receptors (Figure 
5.11), the potency of β-alanine was reduced only two-fold. 
 
 
 
 
Figure 5.22 
Concentration response 
curves of β-alanine and 
GABA at ρ1 T244A 
mutant receptors, (Data 
= Mean ± SEM, n = 15).   
 
 
 
 
 
Figure 5.23 Response traces of β-alanine and GABA at ρ1 T244A mutant receptors. 
 
Although β-alanine does not form a salt bridge with Glu196 in same manner as GABA, 
the ammonium group of β-alanine may be stabilized by the aromatic box in the binding 
site (Figure 5.24). This may explain the mobility of β-alanine compared to GABA 
allowing it to move slightly closer to and form more contacts between the alanine at 
position 244 and stabilize the open conformation (Figure 5.25). 
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Figure 5.24 GABA and β-alanine docking studies in the orthosteric binding site of GABAC homology 
model based on GluCl in open conformation. A. H-bonds between the side chains of GABA and β-
alanine with side chains of Thr244 and Glu196. B. various contacts between the side chains of GABA and 
β-alanine with side chains of Thr244 and Glu196. 
 
Threonine 244 was also mutated to alanine in silico in the ρ1 GABAC homology model 
which was used for docking studies with GABA and β-alanine. The docking studies 
predict that the carboxylate group of β-alanine forms more contacts with the alanine 
residue than the carboxylate group of GABA. These contacts may provide additional 
stabilization of this ligand in the binding site during gating which may also enhance 
efficacy and potency of the implicated ligands with such contacts in the binding site 
(Figure 5.25). The higher number of contacts of β-alanine with alanine at the Thr244 
site may stabilize the loop C being closer to the ligand, which is essential for channel 
activation. 
Figure 5.25 GABA and β-alanine are docked in ρ1GABAC homology model based on GluCl in open 
conformation, showing the contacts between the side chain of the introduced alanine residue in the Thr 
244 site with the side chains of GABA and β-alanine. 
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The antagonist effects of GABA and TPMPA against the β-alanine (30mM) response at 
ρ1 T244A receptors were also investigated. When 30 mM of GABA was co-applied 
with 30 mM of β-alanine, GABA moderately inhibits the responses elicited by β-alanine 
(Figure 5. 26). These results suggest that GABA is acting as partial agonist at ρ1 T244A 
mutant receptors. On the other hand, the antagonist TPMPA has no effect when applied 
alone, but weakly antagonizes β-alanine responses at 1 mM (Figure 5.26), however, the 
potency of TPMPA was significantly decreased at the mutant receptors in comparison 
with ρ1 WT receptors where it has an IC50 = 2.3 µM (Figure 5.26), indicating that the 
free hydroxyl of either a serine or threonine at the 244 position is important for the 
antagonist potency of TPMPA.  
 
 
Figure 5.26 Response 
traces of β-alanine, 
GABA and TPMPA at 
ρ1 T244A receptors.  
 
 
 
5.2.6 ρ1 GABAC T244C Mutant Receptors 
A cysteine residue was introduced into the Thr244 site and the effect of GABA and 
several ρ1 GABAC receptor ligands on the ρ1 T244C mutant receptors were 
investigated. Initial experiments suggested that T244C mutant receptors did not express, 
however injection of five times the concentration of RNA normally injected resulted in 
a very weak response to GABA (30 mM). Interestingly, the thio-reactive GABA 
analogue 2-aminoethylmethane thiosulfonate (MTSEA) was found to elicit reversible 
responses at ρ1 T244C mutant receptors with greater potency and efficacy than GABA 
(Figure 5.27 and 5.28)  
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Figure 5.27 Concentration response 
curves of MTSEA and GABA at ρ1 
T244C mutant receptors (Data = Mean 
± SEM, n = 15). 
 
 
 
 
Figure 5.28 Sample response traces of MTSEA and GABA at ρ1 T244C mutant receptors. 
 
 
MTSEA was also tested at ρ1 WT receptors in order to investigate the sensitivity of WT 
receptors to this ligand, and its ability to bind in the orthosteric binding site in the 
absence of a cysteine residue. MTSEA activates ρ1 WT receptors with very weak 
efficacy and potency (Figure 5.29). 
 
Figure 5.29 Response traces of MTSEA at ρ1 WT receptors.  
When this ligand is co-applied with GABA, at concentrations below 100 µM it has 
weak additive effects to the GABA EC50 responses, but at concentrations of 100 µM 
and above it weakly antagonizes the GABA EC50 responses (Figure 5.30).  
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Figure 5.30 The response traces of co-application of MTSEA and GABA EC50 at ρ1 WT receptors.  
Docking studies of MTSEA in the orthosteric binding site of the ρ1 homology model 
predict that a H-bond does not form between the sulfonyl oxygen of MTSEA and the 
hydroxyl group of Thr244, Although a number of interactions occur between the side 
chains of MTSEA and Thr244 (Figure 5.31). 
 
 
 
Figure 5.31 Docking studies of MTSEA 
with a ρ1 GABAC homology model 
based on GluCl in the open 
conformation. 
 
 
 
 
 
Moreover, replacing Thr244 with cysteine revealed that the introduced cysteine exists 
predominantly (Chi1 = -64º) as a rotamer in which the thiol is pointed away from the 
binding site, which may explain why an irreversible S-S bond does not form between 
MTSEA and this cysteine (Figure 5.32). However, MTSEA still activates ρ1 T244C 
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receptors with a similar magnitude as it does ρ1 WT receptors, although GABA 
sensitivity with the ρ1 T244C mutant receptors is significantly decreased.  
Additionally, due to the methyl group of the methane thiosulfonate group in MTSEA it 
is predicted by docking studies to have slightly more interactions with the cysteine 
residue at the 244 site than the carboxylate group of GABA. This may confer better 
stability of the open conformation by MTSEA at ρ1 T244C mutant receptors over 
GABA (Figure 5.32). 
 
Figure 5.32 Docking studies of GABA 
(white) and MTSEA (yellow) with ρ1 
T244C homology model based on GluCl 
where the thiol group of Cys244 is 
oriented away from the binding site. 
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5.3. Serine 243 
5.3.1 Background 
Serine 243 is located in loop C of the orthosteric binding site of ρ1 GABAC receptors. 
This residue has been previously studied by a point mutation to threonine. Introducing a 
threonine at this site was reported to result in a 30-fold increase in GABA EC50.
94
 In the 
current study the role of this residue in the binding of studied ligands and during the 
channel gating was explored. Additionally, the effect of introducing different residues at 
this site on efficacies and potencies of a range of ligands was investigated. 
 
5.3.2 Docking studies of GABA and serine 243 
Ser 243 is predicted by the ρ1 GABAC homology model to have the hydroxyl functional 
group oriented partially toward the orthosteric binding site. However, docking studies 
predict no H-bonding between the carboxylate group of GABA and the hydroxyl group 
of this residue. Furthermore, these studies predict no contacts or hydrophobic contacts 
between the side chains of Ser243 and GABA (Figure 5.33).  
 
 
Figure 5.33 GABA docked in the 
orthosteric binding site of the ρ1 
GABAC homology model based on 
GluCl in the open conformation, 
showing Ser243. 
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The ρ1 GABAc homology model in both the apo state and the open conformation in the 
absence of ligands predict many interactions between Ser243 in the (–)-side of the ρ 
subunit and residues in the (+)-side of the adjacent subunit. In the apo state Ser243 has 
interactions with Arg104 in loop D (Figure 5.34A). During channel activation, Ser243 
at loop C is predicted to move forward and form more interactions with Arg104. 
Additionally, Lys210 moves closer to the binding site and forms interactions with 
Ser243 (Figure 5.34B). These conformational changes between apo state and open 
conformation suggest inter-subunit role of Ser243 in the channel stabilization and gating 
process. 
Figure 5.34 Docking results of GABA in the orthosteric binding site of the ρ1 GABAC homology model 
in (A) the apo state and (B) the open conformation, showing interactions between Ser243 with Arg104 
and Lys210. 
 
5.3.3 GABA and Mutant Receptors at the Ser243 Site 
GABA was tested at ρ1 S243A, ρ1 S243T and ρ1 S243C mutant receptors. ρ1 S243A 
receptors were found to be barely sensitive to GABA at high mM concentrations. A 
number of agonists tested at these mutant receptors did not elicit greater responses than 
GABA. This suggests the importance of the hydroxyl functional group at this site.  
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Figure 5.35 Concentration 
response curves of GABA 
at ρ1 WT, ρ1 S243A, ρ1 
S243T and ρ1 S243C 
receptors (Data = Mean ± 
SEM, n = 5). 
 
Introduction of a threonine at the Ser243 site results in an increase in GABA EC50 by 
10-fold, however the introduction of cysteine leads to 60-fold increase in GABA EC50 
(Figure 5.35). This may suggest that the constraint applied by methyl of threonine on 
the hydroxyl group is not the most favorable for GABA activity and that a different 
functional group such as a thiol group does not permit formation of the required inter-
subunit interactions for maximum activity of the agonist. A range of different ligands 
were studied at ρ1 S243T and ρ1 S243C mutant receptors and responses compared to 
those at ρ1 WT receptors. 
 
5.3.4 TACA and Ser243 Mutant Receptors 
TACA was tested at ρ1 S243T and ρ1 S243C receptors in order to study the effect of 
introduced mutations on the response elicited by the unsaturated trans analogue of 
GABA.  
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Figure 5.36. Concentration response curves of GABA and TACA at (A) ρ1 WT, (B) ρ1 S243T and (C) ρ1 
S243C receptors (Data = Mean ± SEM, n = 5). 
 
Mutation of serine 243 has little effect on the activity of TACA. At ρ1 WT receptors 
TACA has EC50 = 600 nM, which was increased to EC50 = 6 µM and 28 µM at ρ1 
S243T and ρ1 S243C mutant receptors, respectively (Figure 5.36) (Table 5.2). These 
results suggest that TACA has effects similar to GABA at the mutant receptors which 
may also suggest that Ser243 is not implicated in direct interactions with this ligand 
(Table 5.2).  
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Table 5.2 Summary of various effects of partial agonists at ρ1 GABAC WT, ρ1 GABAC S243T and ρ1 GABAC S243C homomeric receptors. 
 
 
Ligand ρ1WT 
EC50 
ρ1WT 
Efficacy 
ρ1WT 
(Additive/inhibition) 
% 
ρ1S243T 
EC50 
ρ1S243T 
Efficacy 
ρ1S243T 
(Additive/inhibition) 
% 
ρ1S243C 
EC50 
ρ1S243C 
Efficacy 
ρ1S243C 
(Additive/inhibition) 
% 
TACA 0.6µM 95 % 180 6.6 µM 98 % 175  30 µM 95 % 170 
Glycine 1 mM 25 % 170 % 4.2 mM 2 % (120/95) 15 mM 6 % (180/110) 
β-Alanine 400 
µM 
30 % (120/40) >1 mM 3 % (110/20) >10 mM 7 % (115/7) 
5-
Aminovaleric 
Acid 
7 mM 3 % (125/3) 0 0 (115/0) >3 mM 4 % (120/4) 
Muscimol 1.25 
µM 
85 % 125 55 µM 60 % 125  77 µM 10 % (110/42) 
Imidazole-4-
acetic Acid 
66 µM 10 % (110/4) 160 µM 10 % (115/8) 770 µM 8 % (105/7) 
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5.3.5 Effects of Glycine, β-Alanine and 5-Aminovaleric Acid at Ser243 Mutant 
Receptors  
Glycine, β-alanine and 5-aminovaleric acid were tested on ρ1 Ser243 site mutant 
receptors and results were compared with ρ1 WT receptors in terms of their agonist and 
additive/inhibition effects. 
 
5.3.5.1  Agonist Effects of Glycine at ρ1 S243T and ρ1 S243C Mutant Receptors 
At high concentrations glycine activates ρ1 WT receptors weakly with approximately 
25% efficacy relative to GABA maximal efficacy. Both the potency and efficacy of 
glycine decrease significantly at ρ1 S243T and ρ1 S243C mutant receptors in 
comparison to the ρ1 WT receptors (Figure 5.37) (Table 5.2). 
 
 
 
 
 
 
 
 
 
Figure 5.37 Concentration response curves of GABA and glycine at ρ1 WT, ρ1 S243T and ρ1 S243C 
receptors, (Data = Mean ± SEM, n = 5). 
 
These results show that the efficacy of glycine at the ρ1 S243C mutant receptors is 
slightly greater than at the ρ1 S243T mutant receptors (Figure 5.37). This may suggest 
that methyl group in threonine, which adds extra hydrophobic character is not most 
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favorable in this site however cysteine has significantly decreased both efficacy and 
potency of glycine when it introduced at the site.  
 
5.3.5.2  Effects of Glycine Co-applied with GABA EC50 at ρ1 S243T and ρ1 S243C 
Mutant Receptors 
The co-application of glycine with GABA EC50 was also studied at ρ1 S243T and ρ1 
S243C mutant receptors and compared to effects at ρ1 WT receptors. 
 
Figure 5.38 Concentration 
response curves of glycine co-
applied with GABA EC50 at ρ1 
WT, ρ1 S243T and ρ1 S243C 
receptors, (Data = Mean ± 
SEM, n = 5). 
 
 
Glycine, which has co-operative effects to the GABA EC50 response at ρ1 WT receptors 
(Figure 5.13), also demonstrated similar magnitude (approximately 175%) co-operative 
effects at ρ1 S243C mutant receptors. However at high mM concentrations (˃ 3 mM) of 
glycine, these effects are reduced back to the GABA EC50 baseline (Figure 5.38) (Table 
5.2) in a manner similar to the co-operative effect of glycine on ρ1 T244S mutant 
receptors (Figure 5.13A), unlike at ρ1 WT receptors where they plateau. However at the 
ρ1 S243T mutant receptors the co-operative effect of glycine is significantly decreased 
and glycine may slightly antagonize GABA EC50 at 10 mM concentration and above 
(Figure 5.38) (Table 5.2). This indicates that the presence of the additional methyl 
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group in threonine compared to serine at the 243 position constraining the hydroxyl 
group of threonine is not favorable for the co-operative effect of glycine.  
However these results suggest that while glycine competes with GABA to occupy the 
same binding site at both ρ1 S243T and S243C mutant receptors, it only demonstrates a 
slight displacement of GABA molecules at ρ1 S243T. 
  
5.3.5.3  Agonist Effects of β-Alanine at ρ1 S243T and ρ1 S243C Mutant Receptors 
β-Alanine, at high concentrations, activates ρ1 WT receptors moderately with 30% 
efficacy relative to the GABA maximal response. At both ρ1 S243T and ρ1 S243C 
mutant receptors β-alanine shows a significant decrease in both potency and efficacy 
(Figure 5.39) (Table 5.2). 
Figure 5.39 Concentration response curves of GABA and β-alanine at ρ1 WT, ρ1 S243T and ρ1 S243C 
receptors (Data = Mean ± SEM, n = 5). 
 
These results show that the efficacy of β-alanine is affected by the introduction of a 
cysteine or threonine at Ser243 position, with the effect of threonine being slightly 
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greater than the effect of cysteine. This indicates that the additional methyl of the 
threonine at this site is not favorable for the agonist activity of β-alanine. 
5.3.5.4  Antagonist Effects of β-Alanine at ρ1 S243T and ρ1 S243C Mutant 
Receptors 
β-Alanine was co-applied with GABA EC50 at ρ1 S243T and ρ1 S243C receptors and 
the results were compared with ρ1 WT receptors.  
 
Figure 5.40 Concentration 
response curves of β-
alanine co-applied with 
GABA EC50 at ρ1 WT, ρ1 
S243T and ρ1 S243C 
receptors, (Data = Mean ± 
SEM, n = 5). 
 
 
                               
The IC50 of β-alanine at ρ1 S243T and ρ1 S243C mutant receptors were found 1200 µM 
and 900 µM, respectively (Figure 5.40) (Table 5.2), it’s IC50=300 µM with ρ1 WT 
receptors. The antagonist potency of β-alanine decreased 4- and 3-fold at the ρ1 S243T 
and ρ1 S243C mutant receptors, respectively. 
These results suggest Ser243 is not critical to the antagonist potency of β-alanine. 
However, the ρ1 S243T and ρ1 S243C mutant receptors demonstrated approximately 
85% of GABA EC50 antagonized in contrast to 55% of GABA EC50 only antagonized at 
ρ1 WT receptors. These results suggest the introduced residues at Ser243 site have 
affected the ability of the ligands (i.e. GABA and β-alanine) to stabilize either the apo 
state or the open conformation of the channel.  
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5.3.5.5 Agonist Effects of 5-Aminovaleric Acid at ρ1 S243T and ρ1 S243C Mutant 
Receptors 
5-Aminovaleric acid activates ρ1 WT receptors weakly with 4% efficacy relative to the 
GABA maximal response. The ligand demonstrated a slight decrease in agonist potency 
at ρ1 S243C mutant receptors, whereas this ligand does not activate ρ1 S243T mutant 
receptors even at higher mM concentrations (Figure 5.41) (Table 5.2). 
Figure 5.41 Concentration response curves of GABA and 5-aminovaleric acid at ρ1 WT and ρ1 S243C 
receptors, Results = Mean ± SEM, n = 4. 
 
These results indicate that threonine residue at position 243 would add hydrophobic 
character that may help to abolish the activity of 5-aminovaleric acid by stabilizing the 
apo state only at ρ1 S243T mutant receptors. 
  
5.3.5.6 Antagonist Effects of 5-Aminovaleric Acid at ρ1 S243T and ρ1 S243C 
Mutant Receptors 
5-Aminovaleric acid was co-applied with GABA EC50 at ρ1 S243T and ρ1 S243C 
mutant receptors and the results were compared with those from ρ1 WT receptors. 
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Figure 5.42 
Concentration response 
curves of 5-aminovaleric 
acid co-applied with 
GABA EC50 at ρ1 WT, 
ρ1 S243T and ρ1 S243C 
receptors, Results = Mean 
± SEM, n = 4. 
 
The results show that the inhibition curve of 5-aminovaleric acid has shifted slightly to 
the left when threonine is introduced at Ser243 site while the introduction of cysteine at 
the 243 position results in a 15-fold shift to the right (Figure 5.42) (Table 5.2). These 
findings suggest that the methyl group of threonine enhances the ability of 5-
aminovaleric acid to stabilize the apo state, acting as a full competitive antagonist, 
increasing the potency of 5-aminovaleric acid as an antagonist compared to its effects at 
ρ1 WT receptors. However, when serine is replaced by a cysteine residue at this site, the 
antagonist potency of 5-aminovaleric acid decreased (Figure 5.42), suggesting that the 
presence of thiol group is less favorable for ultimate stability of apo state in the 
presence of 5-aminovaleric acid. 
 
5.3.6 Muscimol and ρ1 Mutant Receptors at Ser243 Site 
The agonist and additive/inhibition effects of muscimol have been investigated at ρ1 
S243T and ρ1 S243C mutant receptors and the results were compared with their actions 
at ρ1 WT receptors. 
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5.3.6.1 Agonist Effect of Muscimol at ρ1 S243T and ρ1 S243C Mutant Receptors 
Muscimol activates ρ1 WT receptors with an EC50 slightly lower than GABA and 82% 
efficacy relative to the GABA maximal response. The ligand demonstrates decreases in 
agonist potency at ρ1 S243T and ρ1 S243C mutant receptors by 10- and 62-fold, 
respectively (Figure 5.43). This is similar to the decreases in potency exhibited by 
GABA at these mutant receptors compared to ρ1 WT receptors. However the efficacy of 
this ligand has only slightly decreased at ρ1 S243T receptors while it significantly 
decreased at ρ1 S243C receptors (Figure 5.43) (Table 5.2). 
Figure 5.43 Concentration response curves of GABA and muscimol at ρ1 WT, ρ1 S243T and ρ1 S243C 
receptors, Results = Mean ± SEM, n = 4. 
 
Docking studies predict that muscimol does not form interactions with the Ser243 
residue at loop C (Figure 5.44). This may also support the hypothesis that Ser243 is 
involved with inter-subunit interactions, more particularly interactions with basic 
residues in the adjacent subunit. 
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Figure 5.44 Docking results of muscimol 
in the orthosteric binding site of ρ1 WT 
homology model based on GluCl in the 
open conformation, showing muscimol 
and the Ser243 residue in the binding site.  
 
 
 
5.3.6.2 Effects of Muscimol Co-applied with GABA EC50 at ρ1 S243T and ρ1 
S243C Mutant Receptors 
Muscimol was co-applied with GABA EC50 at ρ1 S243T and ρ1 S243C mutant 
receptors, and the results were compared with the ρ1 WT receptor results. 
 
 
Figure 5.45 
Concentration response 
curve of muscimol co-
applied with GABA EC50 
at ρ1 WT, ρ1 S243T and 
ρ1 S243C receptors, 
Results = Mean ± SEM, n 
= 4. 
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Figure 5.46 Sample traces showing the effect of co-application of muscimol with GABA EC50 at ρ1 WT, 
ρ1 S243T and ρ1 S243C receptors. 
 
The results show the different responses of mutant receptors in the presence of 
muscimol co-applied with GABA EC50. Muscimol has an additive effect to GABA EC50 
at ρ1 S243T mutant receptors similar to ρ1 WT receptors, however it acts as an 
antagonist at ρ1 S243C mutant receptors. This may suggest that muscimol, which has its 
efficacy significantly decreased at ρ1 S243C mutant receptors, is competing with 
GABA at the binding sites. The presence of a thiol functional group at the Ser243 site 
changes muscimol agonist and co-operative effects which may be interpreted as the 
ligand binding at the site, however the cysteine residue at Ser243 site is not favorable 
for forming inter-subunit interactions and thus although muscimol can compete with 
GABA at the binding sites, the receptor is less stabilized in the open conformational 
(Figure 5.45 and 5.46) (Table 5.2). 
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5.3.7 Imidazole-4-acetic Acid (I4AA) and ρ1 Mutant Receptors at the Ser243 Site 
The agonist and antagonist effects of imidazole-4-acetic acid (I4AA) have been tested 
when threonine and cysteine were introduced at the Ser243 site and the results were 
compared with those at ρ1 WT receptors. 
 
5.3.7.1 Agonist Effects of I4AA at ρ1 S243T and ρ1 S243C Mutant Receptors 
I4AA activates ρ1 WT receptors weakly with 11% efficacy relative to the GABA 
maximal response. The ligand demonstrated decreased potency at ρ1 S243T and ρ1 
S243C mutant receptors, however I4AA is still able to elicit a response at these mutant 
receptors similar to ρ1 WT receptors (Figure 5.47) (Table 5.2). 
 
 
 
 
 
 
 
 
Figure 5.47 Concentration response curves of GABA and I4AA at ρ1 WT, ρ1 S243T and ρ1 S243C 
receptors, Results = Mean ± SEM, n = 4. 
 
The unchanged efficacy of I4AA at the mutant receptors in comparison to ρ1 wild type 
receptors may suggest that I4AA, which has a carboxylate group, acts in a manner 
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similar to GABA at these mutant receptors. However the potency of I4AA at these 
receptors decreased with lesser magnitude than the decrease in potency of GABA, by 3- 
and 13-fold at ρ1 S243T and ρ1 S243C mutant receptors, respectively (Figure 5.47) 
(Table 5.2). 
 
5.3.7.2 Antagonist Effect of I4AA at ρ1 S243T and ρ1 S243C Mutant Receptors 
I4AA was co-applied with GABA EC50 and tested at ρ1 S243T and ρ1 S243C mutant 
receptors and the results were compared with the results at ρ1 WT receptors. 
 
Figure 5.48 Concentration 
response curves of I4AA 
co-applied with GABA 
EC50 at ρ1 WT, ρ1 S243T 
and ρ1 S243C receptors, 
Results = Mean ± SEM, n 
= 4. 
 
 
I4AA which has an IC50 of 850 nM at ρ1 WT receptors, was found to have an IC50 of 8.5 
µM and 51.5 µM at ρ1 S243T and ρ1 S243C mutant receptors, respectively (Figure 
5.48) (Table 5.2). These results show that the antagonist effects of I4AA have shifted 
10- and 60-fold to the right. This shift mimics the shift in the agonist effects of GABA 
at the same mutant receptors in comparison to ρ1 WT receptors. 
  
0.0001 0.01 1 100 10000
0
50
100
150
1 WT
1 S243T
1 S243C
GABA EC50 + I4AA (M)
I/
I
(G
A
B
A
 E
C
5
0
)
Studies Exploring Potential Roles of Hydrophilic Residues 
116 
 
5.3.8 Effect of Antagonists at Ser243 Mutant Receptors 
The antagonists, TPMPA ((1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid), 
THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol), gabazine (6-imino-3-(4-
methoxyphenyl)-1(6H)-pyridazinebutanoic acid hydrobromide) and 3-APPA (3-
aminopropyl phosphonic acid) were tested at ρ1 S243T and ρ1 S243C mutant receptors 
and the results were compared with their effects at ρ1 WT receptors.  
 
5.3.8.1 The antagonist Effect of TPMPA at ρ1 S243T and ρ1 S243C Mutant 
Receptors 
TPMPA demonstrated a 5- and 90-fold decrease in antagonist potency at ρ1 S243T and 
ρ1 S243C mutant receptors in comparison with ρ1 WT receptors57, respectively (Figure 
5.49) 
  
Figure 5.49 Concentration 
response curves of 
TPMPA at ρ1 WT, ρ1 
S243T and ρ1 S243C 
receptors, Results = Mean 
± SEM, n = 4. 
 
 
These results suggest that the shift in the antagonist effect of TPMPA and the agonist 
effects of GABA are quite similar at these mutant receptors. Docking studies of 
TPMPA with the GABAC homology model in the apo state predict that there is no H-
bond or other interactions between this antagonist and Ser243 in the orthosteric binding 
site (Figure 5.50). 
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Figure 5.50. Docking results of 
TPMPA in the orthosteric binding 
site of GABAc homology model 
based on GluCl in apo state, showing 
TPMPA and Ser243 in the binding 
site. 
 
 
5.3.8.2 The Antagonist Effect of THIP at ρ1 S243T and ρ1 S243C Mutant 
Receptors 
Although THIP has demonstrated 7-fold decreases in antagonist potency at ρ1 S243C 
mutant receptors in comparison to ρ1 WT receptors, at ρ1 S243T receptors there are no 
differences in the antagonist effects comparing to ρ1 WT receptors54 (Figure 5.51). 
 
Figure 5.51 Concentration 
response curves of THIP 
at ρ1 WT, ρ1 S243T and 
ρ1 S243C receptors, 
Results = Mean ± SEM, n 
= 4. 
 
 
Introduction of a threonine at this site leads to no change in the potency of THIP which 
may indicate that extra contacts by the methyl group of threonine at this site aren’t 
affecting the potency of antagonists such as THIP. Whereas the introduction of a 
cysteine at the Ser243 site results in a moderate decreases in the potency of THIP. 
Docking studies of THIP with the GABAC homology model in the apo state predicted 
no H-bond or other interactions between this antagonist and the Ser243 residue (Figure 
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5.52). This may suggest that the residue is involved in inter-subunit contacts with 
residues in the adjacent subunit, however the methyl group of threonine is favorable for 
the antagonist effect of THIP. 
 
 
Figure 5.52 Docking results of THIP in 
the orthosteric binding site of a GABAc 
homology model based on GluCl in the 
apo state, showing THIP and Ser243 in 
the binding site. 
 
 
 
5.3.8.3 The antagonist effect of gabazine at ρ1 S243T and ρ1 S243C mutant 
receptors 
Gabazine showed no change in antagonist effects at ρ1 S243C or ρ1 S243T mutant 
receptors in comparison to ρ1 WT receptors101 (Figure 5.53). 
 
Figure 5.53 
Concentration response 
curves of gabazine at ρ1 
WT, ρ1 S243T and ρ1 
S243C receptors, Results 
= Mean ± SEM, n = 4. 
 
 
Gabazine is not affected by introducing a threonine or cysteine at the Ser243 site. This 
may suggest that gabazine is not antagonizing ρ1 receptors similar to other antagonists. 
Moreover, gabazine is a bulky molecule with many functional groups which may 
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stabilize this ligand in the apo state and changes in one residue may be insufficient to 
decrease the antagonist potency of gabazine (Figure 5.54B). 
Figure 5.54 Docking results of gabazine in the orthosteric binding site of a GABAc homology model 
based on GluCl in the apo state. (A) Gabazine and Ser243 in the binding site. (B) Gabazine-binding site 
interactions. 
Docking studies of gabazine in the orthosteric binding site of a GABAc model in the 
apo state predict there are no H-bond or other contacts between gabazine and the side 
chain of Ser243. This may also suggest inter-subunit contacts of Ser243 with residues in 
the adjacent subunit is the major role of Ser243 in the binding site (Figure 5.54) 
 
5.3.8.4 Activation Versus Potentiation Effects of 3-APPA at ρ1 S243T and ρ1 
S243C Mutant Receptors  
Interestingly, the ρ1 S243T and ρ1 S243C mutations convert 3-APPA from an 
antagonist at ρ1 WT receptors55, to a weak partial agonist at the mutant receptors. 
5.3.8.4.1 Activation of 3-APPA at ρ1 S243T Mutant Receptors 
As an antagonist, 3-APPA is only half as potent at ρ1 S243T mutant receptors as it is at 
ρ1 WT, with IC50 of 38 µM and 20μM, respectively. Interestingly, when 3-APPA is 
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applied alone at concentrations of greater than 100 μM, it acts as a weak partial agonist, 
activating the ρ1 S243T mutant receptors (Figure 5.55).  
Figure 5.55 (A) Inhibition and (B) activation curves of 3-APPA at ρ1 WT and ρ1 S243T receptors. A. 
Inhibition curves of 3-APPA co-applied with GABA EC50 at ρ1 WT and ρ1 S243T receptors. B. 
Activation curves of GABA and 3-APPA at ρ1 S243T receptors. Results = Mean ± SEM, n = 6. 
 
These results suggest the ability of 3-APPA to stabilize the open conformation of the 
channel when it binds in the orthosteric binding site of ρ1 S243T mutant receptors 
(Figure 5.56). 
 
Figure 5.56 Sample traces 
show activation of ρ1 
S243T mutant receptors by 
3-APPA.  
 
 
Docking studies of 3-APPA with the GABAC homology models in both the apo state 
and open conformation predict no hydrogen bonding or interactions between the ligand 
and Ser243. However, 3-APPA can adopt two different conformations in the binding 
site of the apo and open states (Figure 5.57). The docking scores (i.e. Emodel score) of 
the different poses in the two different receptor states are quite similar, approximately -
40. 
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Figure 5.57 Docking results of 3-APPA with GABAc homology model based on GluCl. A. 3-APPA with 
GABAc model in open conformation. B. 3-APPA with GABAC model in apo state.  
 
5.3.8.4.2 Additive Effects of 3-APPA at ρ1 S243C Mutant Receptors 
3-APPA was found to very weakly activate (approximately 5%) ρ1 S243C mutant 
receptors. However, when co-applied with GABA EC50, 3-APPA has a co-operative 
effect, enhancing the GABA EC50 response by approximately 20% (Figure 5.58 and 
5.59). 
Figure 5.58 The effect of 3-APPA at ρ1 S243C mutant receptors. A. Dose response curves of GABA and 
3-APPA at ρ1 S243C mutant receptors. B. The additive effect of 3-APPA on GABA EC50 response at ρ1 
S243C mutant receptors. Results = Mean ± SEM, n = 8. 
 
 
Figure 5.59 Sample 
traces showing the 
additive effect of 3-
APPA on the GABA 
EC50 response at ρ1 
S243C mutant 
receptors. 
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The conversion of 3-APPA from an antagonist to partial agonist at ρ1 S243T and ρ1 
S243C mutant receptors may suggest a critical role of Ser243 in the stability of the 
closed and/or the open conformations in channel gating. Furthermore, the aliphatic 
phosphonic acid 3-APPA has features that the other tested ligands do not, allowing it to 
open the channel and stabilize this state. This may suggest that 3-APPA has some 
agonist character in the binding site and when a residue with a role in inter-subunit 
stability of different states has been mutated, the phosphonic acid GABA analogue 
shows mixed effects (i.e. activation, inhibition and additive effects). 
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5.4 Serine 168  
5.4.1 Background 
Serine 168 is located in loop E of the orthosteric binding site of ρ1 GABAC receptors. 
This residue has previously been studied by point mutation to threonine, alanine and 
valine. Introduction of threonine or alanine at this site results in a 13- and 50-fold 
decrease in GABA EC50, respectively. Whereas mutating Ser168 to valine turns 
receptors non-functional.
94
 The Ser168 residue was also studied by mutating to 
threonine which is the equivalent residue in GABAA α1 subunits.
116
 The Ser168 residue 
was suggested by this study to play a major role in selectivity of some imidazole-acetic 
acid analogues at ρ1 GABAC receptors. In the current study the interaction of this 
residue with a range of ligands in the binding site during channel gating is explored. 
The role of this residue in stability of receptors in close or open states will also be 
investigated. 
 
5.4.2 GABA Docking Studies with Serine 168  
Serine 168 is predicted by the ρ1 GABAC homology model to have the functional group 
oriented towards the orthosteric binding site. Docking studies of GABA in the 
orthosteric binding site predict H-bond formation of the carboxylate group of GABA 
with the hydroxyl group of Ser168 (Figure 5.60A). Furthermore, the docking studies 
also predict contacts and hydrophobic contacts between this serine and GABA in the 
binding site (Figure 5.60B). 
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Figure 5.60 GABA docked in the orthosteric binding site of the ρ1 GABAC homology model in an open 
conformation based on GluCl. A. H-bonding of the carboxylate group of GABA with the hydroxyl group 
of Serine 168. B. Various interactions of the side chain of GABA with the side chain of Serine 168. 
   
5.4.3 GABA and ρ1 Receptors Mutated at the Ser168 Site 
GABA was tested at ρ1 S168A, ρ1 S168T and ρ1 S168C mutant receptors and the 
results compared with the results at ρ1 WT receptors.  
 
Figure 5.61 Concentration 
response curves of GABA 
at ρ1 WT, ρ1 S168A, ρ1 
S168T and ρ1 S168C 
receptors. Results = Mean 
± SEM, n = 8. 
 
 
 
GABA was found to activate all the studied Ser168 mutant receptors, however the 
potency of GABA was decreased by 10-, 100- and 600-fold at ρ1 S168T, ρ1 S168A and 
ρ1 S168C mutant receptors, respectively (Figure 5.61). Interestingly, the results show 
that removing the functional group at the Ser168 site decreases the potency of GABA 
less than when a functional group other than a hydroxyl, such as a thiol group is 
introduced at the site. This indicates the importance of the hydroxyl group at position 
168 for maximal GABA activity. When threonine is introduced at the site, the decrease 
of GABA potency suggests that presence of the additional methyl group is not favorable 
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for maximal GABA activity possibly because the extra methyl group may result in a 
constraint of the hydroxyl group leading to a less favorable position, or due to increased 
hydrophobic character.  
Alanine and cysteine were introduced into the Ser168 site in the ρ1 GABAC homology 
model. Docking of GABA with this model predicts that there are various interactions 
between GABA and alanine at position 168 (Figure 5.62A). Cysteine is also predicted 
to form various interactions with GABA and the thiol group forms a H-bond with the 
carboxylate group of GABA (Figure 5.62B). However, thiols form much weaker H-
bonds than hydroxyls and this H-bond may not stabilize the open conformation as well 
as the H-bond in the ρ1 WT. 
 
Figure 5.62 Docking results of GABA in the orthosteric binding site of the ρ1 GABAC homology model 
based on GluCl in the open conformation. A. Various contacts of GABA with S168A. B. Various 
contacts of GABA with S168C. The rotamer of cysteine shown in panel B has similar Chi1 and Chi2 
values to the predicted conformation of Ser168 at this site (i.e. Chi1 = 178 and Ch2 = 179). 
 
The following section describes the studies of partial agonists and antagonists of interest 
at ρ1 S168A and ρ1 S243C mutant receptors and compares the results with those at ρ1 
WT receptors. 
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5.4.4 TACA and Mutant Receptors at the Ser168 Site   
TACA was tested at ρ1 S168A and ρ1 S168C mutant receptors in order to study the 
effect of TACA which has unsaturated carbon restricting this ligand to mimic the 
extended conformation of GABA. 
Figure 5.63 Concentration response curves of GABA and TACA at ρ1 WT, ρ1 S168A and ρ1 S168C 
receptors, results = Mean ± SEM, n = 5. 
 
 
The results show that although the agonist potency of TACA has been affected by 
introducing an alanine or cysteine at position168, the magnitude of increases in EC50 of 
TACA was much less than with GABA. The potency of TACA decreased by 40- and 
100-fold at ρ1 S168A and ρ1 S168C mutant receptors, respectively (Figure 5.63). 
Additionally, TACA which has 95% efficacy relative to GABA maximal response at ρ1 
WT receptors becomes significantly more efficacious than GABA (125% efficacy 
relative to GABA maximal response, P-value ˂ 0.05) at ρ1 S168C mutant receptors 
(Figure 5.64) (Table 5.3).  
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Figure 5.64 Sample traces of maximal responses of TACA and GABA at ρ1 WT and ρ1 S168C receptors. 
 
Docking studies of TACA in the orthosteric binding site of the ρ1 GABAC homology 
model predict interactions between TACA and Ser168 in the binding site (Figure 5.65). 
Moreover, the docking results predict an H-bond between the side chains of TACA and 
Ser168 which may indicate that the hydroxyl group at this site is important, however the 
various contacts between the side chains of TACA and Ser168 are also important for 
stabilizing of ligand in the open conformation (Figure 5.65). On the other hand, 
introducing a thiol group wasn’t favorable for potency of TACA and showed relatively 
the highest decreases in TACA activity. 
 
Figure 5.65 Docking results of 
TACA in the orthosteric binding 
site of the ρ1GABAC homology 
model based on GluCl in an open 
conformation, showing H-bonding 
and various interactions of the side 
chain of TACA with the side 
chain of Ser168 in the binding 
site. 
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Table 5.3 Summary of various effects of partial agonists at ρ1 GABAC WT, ρ1 GABAC S168A and ρ1 GABAC S168C homomeric receptors. 
 
 
Ligand ρ1WT 
EC50 
ρ1WT 
Efficacy 
ρ1WT 
(Additive/inhibition) 
% 
ρ1S168A 
EC50 
ρ1S168A 
Efficacy 
ρ1S168A 
(Additive/inhibition) 
% 
ρ1S168C 
EC50 
ρ1S168C 
Efficacy 
ρ1168C 
(Additive/inhibition) 
% 
TACA 0.6µM 95 % 180 27 µM 98 % 180 55 µM 125 % 180 
Glycine 1 mM 25 % 170 % >1 mM 15 % (180/120) 400 µM 3 % (190/100) 
β-Alanine 400 
µM 
30 % (120/40) >7 mM 7 % (170/35) 2.5 mM 17 % (170/95) 
5-
Aminovaleric 
Acid 
7 mM 3 % (125/3) >10 mM 2 % (145/0) >4 mM 3 % (130/15) 
Muscimol 1.25 
µM 
85 % 125 0 0 (120/80) 82 µM 10 % (155/115) 
Imidazole-4-
acetic Acid 
66 µM 10 % (110/4) 6.8 mM 5 % (120/40) 450 µM 3 % (115/15) 
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5.4.5 Effects of Glycine, β-Alanine and 5-Aminovaleric Acid at Ser168 Mutant 
Receptors  
The GABA analogues with various numbers of carbons in the backbone (glycine, β-
alanine and 5-aminovaleric acid) were re-docked into the ρ1GABAC homology model 
in order to study interactions between the carboxylate groups of these ligands and the 
side chain of Ser168. Ligands were also tested at ρ1 S168A and ρ1 S168C mutant 
receptors and the results were compared with ρ1 WT receptors in terms of their agonist 
and antagonist effects. 
 
5.4.5.1 Docking Studies of Glycine, β-Alanine and 5-Aminovaleric Acid 
Docking results of glycine, β-alanine and 5-aminovaleric acid at ρ1 GABAC homology 
models predict H-bonding of carboxylate groups of these ligands with the hydroxyl 
group of Ser168 (Figure 5.66A). Additionally, there are contacts between the side 
chains of these ligands and the side chain of the serine residue at this site which may 
indicate further stability of these ligands in either states (Figure 5.66B). 
Figure 5.66 Docking results of glycine, β-alanine and 5-aminovaleric acid in the orthosteric binding site 
of a ρ1 GABAC homology model based on GluCl in the open conformation. A. H-bonding of the 
carboxylate groups of these ligands with the hydroxyl group of Ser168 in the binding site. B. Various 
contacts of the side chains of these ligands with the side chain of Ser168 in the binding site. 
 
 
 
Studies Exploring Potential Roles of Hydrophilic Residues 
130 
 
5.4.5.2  Agonist Effects of Glycine at ρ1 S168A and ρ1 S168C Mutant Receptors 
Glycine weakly activates ρ1 WT receptors (EC50 = 9335 µM) with 25% efficacy 
relative to the GABA maximal response. At ρ1 S168C mutant receptors this ligand 
shows a significant decrease in agonist activity (i.e. both potency and efficacy), and a 
lesser decrease in efficacy only at ρ1 S168A mutant receptors in comparison to ρ1 WT 
receptors (Figure 5.67). 
 
Figure 5.67 Concentration response curves of GABA and glycine at ρ1 WT, ρ1 S168A and ρ1 S168C 
receptors. Results = Mean ± SEM, n = 4. 
 
Results show that the absence of a functional group at the Ser168 site leads to 
approximately a 30% decrease in the efficacy, while the presence of a thiol group is not 
favorable at this site and results in a significant decrease in both sensitivity and efficacy. 
This suggests that the hydroxyl group is important for glycine activity, however the 
various interactions with this residue are also important for glycine activity (Figure 
5.66) (Table 5.3). Furthermore, the thiol group at the site, which abolishes glycine 
activity, may form unfavorable contacts with glycine in the binding site.  
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5.4.5.3 Effects of Glycine Co-applied with GABA EC50 at ρ1 S168A and ρ1 S168C 
Mutant Receptors 
The co-application of glycine with GABA EC50 was also tested at ρ1 S168A and ρ1 
S168C mutant receptors and the results were compared with ρ1 WT receptors. 
 
 
Figure 5.68 Concentration 
response curves of glycine 
co-applied with GABA 
EC50 at ρ1 WT, ρ1 S168A 
and ρ1 S168C receptors. 
Results = Mean ± SEM, n 
= 4. 
 
 
 
Glycine has a co-operative effect on the GABA EC50 response at ρ1 WT receptor, and 
also shows co-operative effects at ρ1 S168A and ρ1 S168C mutant receptors. However, 
these effects were decreased when high mM concentrations of glycine were co-applied 
with GABA EC50 (Figure 5.68). The co-operative effect of glycine on the GABA EC50 
response reaches a similar magnitude at ρ1 WT and the mutant receptors (Figure 5.68) 
(Table 5.3). These results suggest the importance of the hydroxyl group at the Ser168 
site for the cooperative effects of glycine at high mM concentration. 
The decrease in the additive effect with increasing concentrations of glycine at ρ1 
S168A and ρ1 S168C mutant receptors may be due to the biphasic effects of 
competition and co-operativity between GABA and glycine for the same binding site as 
the concentrations of glycine reach high mM level. 
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5.4.5.4 The agonist effects of β-alanine at ρ1 S168A and ρ1 S168C mutant receptors 
β-Alanine moderately activates ρ1 WT receptors (EC50 = 395µM) with 30% efficacy 
relative to the GABA maximal response. The ligand has shown significant decreases in 
both agonist potency and efficacy at ρ1 S168A mutant receptors however it shows only 
a moderate decrease in agonist activity at ρ1 S168C mutant receptors (Figure 5.69). 
Figure 5.69 Concentration response curves of GABA and β-alanine at ρ1 WT, ρ1 S168A and ρ1 S168C 
receptors, Results = Mean ± SEM, n = 5. 
 
The results show that replacing Ser168 with alanine has a greater effect on the activity 
of β-alanine than when it is replaced by a cysteine. This may suggest that the absence of 
the functional group at the site isn’t favourable for activity of this ligand, however the 
presence of a functional group other than a hydroxyl group such as a thiol group slightly 
decreases the activity of the ligand. This may predict formation of an H-bond and 
various interactions with the larger cysteine, albeit weaker than with serine. 
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5.4.5.5 Effects of β-Alanine Co-applied with GABA EC50 at ρ1 S168A and ρ1 
S168C Mutant Receptors 
β-Alanine was co-applied with GABA EC50 at ρ1 S168A and ρ1 S168C mutant 
receptors and the results were compared with ρ1 WT receptors. 
 
 
 
Figure 5.70 
Concentration response 
curves of β-alanine co-
applied with GABA EC50 
responses at ρ1 WT, ρ1 
S168A and ρ1 S168C 
receptors, Results = 
Mean ± SEM, n = 3.  
 
 
 
At ρ1 WT receptors β-alanine has a small additive effect (120%), and at concentrations 
greater than 100 µM acts as a moderate antagonist (40%). However at ρ1 S168A and ρ1 
S168C mutant receptors β-alanine shows co-operative effects with the GABA EC50 
response at concentrations up to 1mM with inhibition occurring at higher concentrations 
at ρ1 S168A receptors. At the ρ1 S168C mutant receptors the inhibitory effects of this 
ligand are almost abolished (Figure 5.70) (Table 5.3). These results show that 
introducing an alanine or cysteine leads to more co-operative effects of β-alanine than at 
ρ1 WT receptors (Figure 5.70).  
This indicates that at ρ1 S168C mutant receptors β-alanine co-operates with GABA 
rather than competing for the same binding site. However at high mM concentrations of 
β-alanine, it appears to compete weakly with GABA, reducing the enhancement of the 
GABA response back to GABA EC50 levels. At ρ1 S168A mutant receptors, β-alanine 
also co-operates with the GABA EC50 response, but at high concentrations β-alanine 
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competes with GABA in the binding site and exhibits antagonist activity of similar 
magnitude to that at ρ1 WT receptors. 
 
5.4.5.6 Agonist Effects of 5-Aminovaleric Acid at ρ1 S168A and ρ1 S168C Mutant 
Receptors 
5-Aminovaleric acid weakly activates ρ1 WT receptors with 4% efficacy relative to 
GABA maximal response. At ρ1 S168A and ρ1 S168C mutant receptors the activity of 
5-aminovaleric acid is almost eliminated with very little effect seen at concentrations of 
greater than 10 mM (Figure 5.71) (Table 5.3). 
Figure 5.71 Concentration response curves of GABA and 5-aminovaleric acid at ρ1 WT, ρ1 S243A and 
ρ1 S243C receptors. Results = Mean ± SEM, n = 3. 
 
The results indicate that 5-aminovaleric acid is able to very weakly activate receptors in 
the absence of the hydroxyl functional group or the presence of a thiol introduced in 
place of the hydroxyl group at position 168. 
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5.4.5.7 Effects of 5-Aminovaleric Acid Co-applied with GABA EC50 at ρ1 S168A 
and ρ1 S168C Mutant Receptors 
5-Aminovaleric acid was co-applied with GABA EC50 at ρ1 S168A and ρ1 S168C 
mutant receptors and the results were compared with the ρ1 WT receptor results. 
 
 
 
Figure 5.72 Concentration 
response curves of 5-
aminovaleric acid co-applied 
with GABA EC50 at ρ1 WT, 
ρ1 S168A and ρ1 S168C 
receptors. Results = Mean ± 
SD, n = 3. 
 
 
 
 
The inhibition curves of 5-aminovaleric acid are shifted to the right by 15- and 45-fold 
at ρ1 S168A and ρ1 S168C mutant receptors, respectively (Figure 5.72) (Table 5.3). 
The absence of the functional group or replacement of the hydroxyl group with a thiol 
group decreases the antagonist effects of 5-aminovaleric acid. Interestingly, when 
alanine is introduced at the Ser168 site, the additive effect of the ligand is greater than at 
ρ1 WT receptors. This may indicate that 5-aminovaleric acid, in the hundred 
micromolar range co-applied with GABA EC50, does not compete strongly with GABA 
at the same binding site but rather it co-operates with it, however increasing the applied 
concentration of 5-aminovaleric acid leads to full antagonism of GABA EC50 responses 
(Figure 5.72). 
The magnitude of additive effects of 5-aminovaleric acid at ρ1 S168C mutant receptors 
is similar to that at ρ1 WT receptors (Figure 5.72). Although the ligand has shown a 
significant decrease in potency at these mutant receptors, it still partially antagonizes 
receptors in a similar manner to its antagonist effect at ρ1 WT receptors. 
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5.4.6 The Effect of Muscimol at ρ1 Receptors Mutated at Ser168 
The agonist and additive/inhibition effects of muscimol were tested at ρ1 S168A and ρ1 
S168C mutant receptors and the results compared with ρ1 WT receptors. 
 
5.4.6.1 Agonist Effect of Muscimol at ρ1 S168A and ρ1 S168C Mutant Receptors 
Muscimol is a potent agonist at ρ1 WT receptors with an EC50 slightly lower than 
GABA and 82% efficacy relative to the GABA maximal response. At ρ1 S168C mutant 
receptors this ligand shows a significant decrease in both potency and efficacy (Figure 
5.73) (Table 5.3), and ρ1 S168A mutant receptors were found to be totally insensitive to 
muscimol at 300 µM.  
Figure 5.73 Concentration response curves of GABA and muscimol at ρ1 WT and ρ1 S168C receptors, 
Results = Mean ± SEM, (n = 3). 
 
These results suggest that the presence of a functional group capable of forming H-
bonds at the Ser168 site is critically important for muscimol activity. Removing the 
hydroxyl functional group at this site significantly decreases sensitivity to muscimol at 
relatively high concentrations, whereas introducing different functional groups than 
hydroxyl such as a thiol group significantly decreases both potency and efficacy of 
muscimol (Figure 5.73(Table 5.3). 
Muscimol was redocked into the GABA binding site of the ρ1 GABAC homology 
model in order to study interactions between muscimol and Ser168 in the binding site. 
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Figure 5.74 Docking studies of muscimol in the orthosteric binding site of a ρ1 GABAC homology model 
based on the GluCl in open conformation. A. H-bonding between the amide oxygen of muscimol and the 
hydroxyl group of Ser168 in the binding site. B. Various interactions between the side chains of 
muscimol and Ser168 in the binding site.  
 
The docking results of muscimol in the orthosteric binding site of a ρ1 GABAC 
homology model predict the formation of a H-bond between the hydroxyl group of 
muscimol and the side chain of Ser168. Moreover, the model predicts interactions 
between the side chains of muscimol and Ser168 (Figure 5.74). 
 
5.4.6.2 Effects of Muscimol Co-applied with GABA EC50 at ρ1 S168A and ρ1 
S168C Mutant Receptors 
Muscimol was co-applied with GABA EC50 at ρ1 S168A and ρ1 S168C mutant 
receptors and the results were compared with the results at ρ1 WT receptors. 
 
 
Figure 5.75 Muscimol and 
GABA EC50 were co-
applied at ρ1 WT, ρ1 
S168A and ρ1 S168C 
receptors. Results = Mean ± 
SEM, (n = 4). 
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Muscimol shows different effects at ρ1 S168A and ρ1 S168C mutant receptors in 
comparison to ρ1 WT receptors (Figure 5.75). The magnitude of the co-operative effect 
at ρ1 S168A receptors is only approximately 20% greater than the GABA EC50 
response at a muscimol concentration of 60 µM, however muscimol alone elicits no 
response at a concentration of 300 µM. However, muscimol weakly inhibits the GABA 
EC50 response at ρ1 S168A receptors at concentrations of above 60 µM, suggesting 
biphasic effects of co-operativity and competition for the binding sites at higher 
concentrations (Figure 5.75) (Table 5.3). At ρ1 WT receptors, despite the fact that 100 
µM muscimol alone elicits 82%  of the GABA maximal response (Figure 5.73) (Table 
5.3), when applied in the presence of GABA EC50 response, 100 µM muscimol elicits 
only a 25% increase in the GABA EC50 response (Figure 5.75) (Table 5.3). Introduction 
of a cysteine residue at this site results in muscimol eliciting co-operative effects on the 
GABA EC50 response at concentrations below 60 µM, despite the fact that 300 µM 
muscimol elicits a response of only 10% of the GABA maximum. At concentrations of 
above 100 µM the co-operative effects of muscimol decrease, returning the response to 
the GABA EC50 response (Figure 5.75) (Table 5.3). 
 
5.4.7 Imidazole-4-acetic Acid (I4AA) and ρ1 Receptors Mutated at Ser168 
The agonist and additive/inhibition effects of imidazole-4-acetic acid (I4AA) were 
tested at ρ1 S168A and ρ1 S168C mutant receptors and the results were compared with 
ρ1 WT receptors. 
 
5.4.7.1 Agonist Effect of I4AA at ρ1 S168A and ρ1 S168C Mutant Receptors 
I4AA weakly activates ρ1 WT receptors with 11% efficacy relative to the GABA 
maximal response. The ligand has shown decreases in potency at ρ1 S168A and ρ1 
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S168C mutant receptors, however the efficacy of I4AA at these mutant receptors is still 
similar to ρ1 WT receptors (Figure 5.76) (Table 5.3). 
Figure 5.76 Concentration response curves of GABA and I4AA at ρ1 WT, ρ1 S168A and ρ1 S168C 
receptors. Results = Mean ± SEM, (n = 4). 
 
The slightly decreased efficacies of I4AA at mutant receptors in comparison to ρ1 wild 
type receptors may suggest that I4AA, which has a carboxylate group, is behaving 
similar to the carboxylate group of GABA at these mutant receptors, however the 
magnitude of decreases in potency of I4AA at mutant receptors is less than at ρ1 WT 
receptors. Dose response curves of I4AA were shifted by 100- and 10-fold at ρ1 S168A 
and ρ1 S168C mutant receptors, respectively. These results may suggest that the 
presence of the carboxylate functional group is important activity of this ligand, as it 
would provide further stabilization. 
I4AA was redocked into the TPMPA binding pocket in the orthosteric binding site of 
the ρ1 GABAC homology model based on GluCl in the apo state in order to study 
interactions between the side chains of I4AA and Ser168 in the binding site. 
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Figure 5.77 Docking studies of I4AA in the orthosteric binding site of a ρ1 GABAC homology model 
based on GluCl in apo conformation. A. H-bonding between the carboxylate group of I4AA and the 
hydroxyl group of Ser168 in the binding site. B. Various interactions between the side chains of I4AA 
and Ser168 in the binding site. 
 
Docking results of I4AA in the binding site predict H-bonding between the carboxylate 
group of I4AA and the hydroxyl group of Ser168. Additionally, the model is also 
predicting various interactions between the side chains of I4AA and Ser168 in the 
binding site (Figure 5.77). 
 
5.4.7.2 Effects of I4AA Co-applied with GABA EC50 at ρ1 S168A and ρ1 S168C 
Mutant Receptors 
I4AA was co-applied with GABA EC50 and tested with ρ1 S168A and ρ1 S168C mutant 
receptors and the results were compared with the ρ1 WT receptors. 
 
 
 
 
Figure 5.78 Concentration 
response curves of I4AA co-
applied with GABA EC50 at ρ1 
WT, ρ1 S168A and ρ1 S168C 
receptors. Results = Mean ± 
SEM, (n = 4). 
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I4AA has an IC50 of 850 nM at ρ1 WT receptors and an IC50 of 154 µM at ρ1 S168C 
mutant receptors (1 mM of I4AA does not reach a plateau at ρ1 S168A receptors) 
(Figure 5.78) (Table 5.3). These results show that the antagonist potency of I4AA 
decreases by 900- and 180-fold when alanine and cysteine are introduced at the Ser168 
site, respectively (Figure 5.78) (Table 5.3). These decreases in the antagonist potency of 
I4AA would suggest that the presence of the hydroxyl functional group at this site is 
important for the stability of I4AA in the apo state and the presence of other functional 
groups such as a thiol group that can form contacts but are insufficient for I4AA to fully 
stabilize the apo conformation, leads to decreases in the antagonist effect of I4AA. 
 
5.4.8 Antagonists and ρ1 Receptors Mutated at Ser168 
TPMPA ((1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid), THIP (4,5,6,7-
tetrahydroisoxazolo[5,4-c]pyridin-3-ol) and 3-APPA (3-aminopropyl phosphonic acid) 
were tested at ρ1 S168A and ρ1 S168C mutant receptors and their results were 
compared with the ρ1 WT receptors results. 
 
5.4.8.1 The Antagonist Effect of TPMPA at ρ1 S168A and ρ1 S168C Mutant 
Receptors 
TPMPA was 125-fold less potent at ρ1 S168A and ρ1 S168C mutant receptors in 
comparison to ρ1 WT receptors57 (Figure 5.79). 
 
 
Figure 5.79 
Concentration response 
curves of TPMPA co-
applied with GABA 
EC50 at ρ1 WT, ρ1 
S168A and ρ1 S168C 
receptors. Results = 
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These results suggest that the presence of the hydroxyl group at the Ser168 site is 
important for stabilizing the receptor in the apo state. 
In order to study the interactions between TPMPA and Ser168 in the binding site, 
TPMPA was docked in the orthosteric binding site of a ρ1 GABAC homology model in 
apo state. 
Figure 5.80 Docking results of TPMPA in the orthosteric binding site of a GABAc homology model 
based on GluCl in the apo state. A. H-bonding of the phosphonic acid of TPMPA and the hydroxyl group 
of Ser168 in the binding site. B. contacts between the side chain of TPMPA with the side chain of Ser168 
in the binding site. 
 
Docking studies predict that TPMPA forms a H-bond with the hydroxyl of Ser168 in 
the binding site (Figure 5.80A). Furthermore, TPMPA is also predicted to form various 
interactions with Ser168 in the binding site (Figure 5.80B). 
 
5.4.8.2 The Antagonist Effect of THIP at ρ1 S168A and ρ1 S168C Mutant 
Receptors 
THIP shows 80- and 14-fold decreases in potency at ρ1 S168A and ρ1 S168C mutant 
receptors, respectively, in comparison to ρ1 WT receptors54 (Figure 5.81). 
 
 
Figure 5.81 Concentration 
response curves of THIP 
with ρ1 WT, ρ1 S168A 
and ρ1 S168C receptors. 
Results = Mean ± SEM, 
(n = 4). 
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Removing the hydroxyl functional group at the Ser168 site leads to significant 
decreases in potency, whereas introducing a cysteine residue with a thiol at the site 
resulted in a moderate decrease in potency of THIP. These results indicate the 
importance of a functional group at this site that can form a H-bond, for the binding of 
THIP (Figure 5.81). 
THIP was docked in the orthosteric binding site of the ρ1 GABAC homology model 
based on GluCl in the apo state in order to study interactions between THIP and Ser168 
in the binding site. 
Docking studies predict H-bonds between the amide oxygen of THIP and the hydroxyl 
group of Ser168 in the binding site (Figure 5.82A). Moreover, the model also predicts 
various contacts between the side chains of THIP and Ser168 in the binding site (Figure 
5.82B). 
Figure 5.82 Docking results of THIP in the orthosteric binding site of a ρ1 GABAc homology model 
based on GluCl in the apo state. A. H-bonding of the amide oxygen of THIP and the hydroxyl group of 
Ser168 in the binding site. B. Various contacts of the side chain of THIP with the side chain of Ser168 in 
the binding site. 
 
5.4.8.3 The Antagonist Effect of 3-APPA at ρ1 S168A and ρ1 S168C Mutant 
Receptors  
3-APPA has shown a 25-fold decrease in antagonist effects with ρ1 S168C in 
comparison to ρ1 WT receptors55, however its antagonist effect is abolished with ρ1 
S168A mutant receptors (Figure 5.83). 
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Figure 5.83 Concentration 
response curves of 3-
APPA at ρ1 WT and ρ1 
S168C receptors. Results 
= Mean ± SEM, (n = 3). 
 
 
 
The results suggest that the presence of a functional group able to form H-bonds at the 
Ser168 site is important for 3-APPA activity, with 3-APPA showing reduced potency at 
ρ1 S168C mutant receptors in the presence of a thiol, which may form various contacts, 
which however aren’t stabilizing the apo state as much as the hydroxyl group of serine 
does. However the absence of H-bond forming side chains at this site, such as in the ρ1 
S168A mutant receptors, result in 3-APPA being inactive. 
3-APPA was docked in the ρ1 GABAC homology model in the apo state in order to 
study interactions between 3-APPA and Ser168 in the binding site. 
Figure 5.84 Docking results of 3-APPA with a GABAc homology model based on GluCl in the apo state. 
A. H-bonding of the phosphonic acid of 3-APPA with the hydroxyl group of Ser168 in the binding site. 
B. Various contacts of the side chain of 3-APPA with the side chain of Ser168 in the binding site. 
 
Docking studies of 3-APPA in the ρ1 GABAC homology model predict a hydrogen 
bond between the side chain of 3-APPA and the hydroxyl side chain of Ser168 (Figure 
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5.84A). Moreover, 3-APPA has various contacts with Ser168 that may further stabilise 
the ligand in the apo state (Figure 5.84B). 
In summary, the studies in this chapter revealed different roles of the three hydrophilic 
residues in the orthosteric binding site. Thr244 is essentially an important residue for 
channel activation as it forms a H-bond with the agonist that will initiate conformational 
changes and stabilize the open conformation. The movement of loop C inward to form a 
shield-like over the agonist is a rate limiting step for channel gating. Ser243, in the 
middle of loop C, is critical in stabilizing different channel states, however this is not 
due to the direct interaction with ligands, but rather through inter-subunit interactions 
with residues in the neighboring subunit. The homology modelling in this thesis predicts 
inter-subunit interactions between the side chain of Ser243 and the side chain of only 
the Arg104 residue in the apo state, but of both Arg104 and Lys210 residues in the open 
conformation, suggesting a role in stabilizing the protein in both states.  
On the other hand, Ser168 is predicted to form a H-bond with agonists and antagonists, 
suggesting a role in stabilizing either channel state. The role of Ser168 is not critical for 
functionality of receptors, however it assists the bound ligand in the orthosteric binding 
site to stabilize the apo state or open conformation based on other interactions which 
may retain the apo state or switch the channel into the open conformation.    
Reasonable explanations have been proposed in the discussion (Chapter 7) for the 
additive (co-operative)/inhibition effects of partial agonists on GABA EC50 responses in 
terms of forming particular interactions in the binding site which may result in more or 
less ligand stability in either the apo or the open state. The ability of the ligand to co-
operate or compete with GABA in the orthosteric binding sites and the availability of 
free and/or occupied binding sites in the presence of GABA and partial agonist were 
discussed in detail in chapter 7. 
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6. Modelling and Biomolecular Structural Chemistry of the 
Orthosteric Binding site of ρ2 GABAC Receptors 
6.1 Background 
The ρ2 subunit is the second member of the ρ GABAC receptor family originally cloned 
from human retina.
69
 This subunit is less studied than the ρ1 subunit, having similar 
pharmacological and electrophysiological features to ρ1, however it has additional 
distinctive features.
190
 For example, a recent behavioural pharmacology study suggests 
different in vivo roles for ρ1and ρ2 GABAC receptors in the motor effects of ethanol.
86
 
To reveal the unique characteristics of this subunit, we studied the structure of the 
GABA binding site by generating novel ρ2 GABAC homology models based on the 
GluCl templates in the apo state and the open conformation. GABA and other ligands 
of interest were studied in terms of interactions with potential residues and the results 
were compared to their activation and additive/inhibition effects. 
 
6.2 ρ2 GABAc Homology Model 
Two sets of ρ2 GABAC homology models based on GluCl in the apo state,
171
 and open 
conformation,
166
 were generated using the antagonist (R)-ACPBPA, and GABA as 
reference ligands, respectively. After the sequence alignment, the proteins were found 
to be homologues with 36% amino acid sequence identity, 56% amino acid sequence 
similarity and 3% gaps (Figure 6.1). 
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Figure 6.1 Amino acid sequence alignment of the ρ2 GABAC subunit against the GluCl template. 
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In the sets of GABA and (R)-ACPBPA bound ρ2 GABAC homology models, the best 6 
models were chosen according to potential energy-OPLS_2005 and RMS derivative-
OPLS_2005. The structures of the selected models were carefully inspected with focus 
directed at the amino acids in the orthosteric binding site region. Stereochemical, 
energetic properties and the packing environment of the residues were confirmed 
through Ramachandran plot analysis (Figure 6.2). The selected model was found to 
have good geometry properties with 93.5% of residues situated in the most favored 
region and 97.5% in the allowed region. None of the residues found in the generously 
allowed or disallowed regions are located in the binding pocket or recognized as an 
important residue for any critical role in the binding or gating processes. 
 
 
 
 
 
Figure 6.2 Ramachandran plots of the best generated model of ρ2 GABAC based on GluCl. A. 
Ramachandran plot of selected GABA bound GABAC homology model. B. Ramachandran plot of 
selected (R)-ACPBPA bound GABAC homology model. 
 
Although there have been no mutational studies done on the extracellular domain of the 
ρ2 GABAC subunit, the high amino acid homology between this subunit and the ρ1 
subunit facilitates the study of the GABA conformation in the orthosteric binding site 
of the ρ2 GABAC model, and the various interactions of GABA and other ligands of 
interest with residues that are located in this binding site. 
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The main interactions between GABA and the residues in the orthosteric binding site of 
the GABA bound ρ2 GABAC homology model were predicted to be similar to those 
found in the ρ1 GABAC receptor, and verified by the homology model; the two salt 
bridges with Arg83 and Glu177, H-bonds between the aliphatic hydrophilic residues 
Ser149 and Thr225 and the carboxylate group of GABA (Figure 6.3B), and the 
aromatic residues that are believed to stabilize ligands in the binding site by forming an 
aromatic box (i.e. Tyr179, Tyr222 and Tyr228) surrounding the cationic ammonium 
group of GABA (Figure 6.3A). 
Figure 6.3 GABA docking results with ρ2 GABAC homology model based on GluCl in open 
conformation. A. GABA in the orthosteric binding site surrounded by aromatic residues. B. Various 
interactions of GABA with residues in the binding site. 
 
6.3 Effects of GABA at ρ1 and ρ2 Homomeric GABAC Receptors 
GABA is slightly more potent at ρ2 GABAC homomeric receptors than at ρ1 GABAC 
homomeric receptors, with EC50 of 800 nM and 1 µM at ρ1 and ρ2 receptors, 
respectively (Figure 6.4). 
 
 
Figure 6.4 Concentration response curves of 
GABA at ρ1 and ρ2 GABAC homomeric 
receptors. (Data = Mean ± SEM, n = 4). 
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Comparative mutational studies have been done between ρ1 and ρ2 GABAC 
homomeric receptors in transmembrane domains only, and more particularly TM2.
107
 
The results of these studies were discussed in the introduction chapter, and identified 
two residues in the second transmembrane domain that are not conserved between the 
two subunits. Reverse mutation of these residues to corresponding residues of the ρ2 
subunit TM2 led to a significant decrease in the activity of the non-competitive 
antagonist, picrotoxinin, which is believed to bind in the channel formed by the TM2 
region. 
The amino acid sequence alignment of the extracellular domain of the ρ1 and ρ2 
subunits and more particularly the GABA binding site region of these subunits revealed 
high homology between the two subunits, however there are some unconserved 
aliphatic hydrophobic residues in Loop E (Figure 6.5). 
These residues of loop E may assist in stabilizing GABA in either of the two channel 
states (i.e. apo and open states) and these differences may confer the slightly higher 
potency of ρ2 over ρ1 homomeric receptors. 
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Figure 6.5 Amino acid sequence alignment of the ρ1 and ρ2 GABAC subunits. 
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This study explores the effects of three sets of structurally different partial agonists at 
ρ2 GABAC homomeric receptors. It will also discuss the effects of the selective and 
potent competitive antagonist (R)-ACBPBA at ρ2 GABAC receptors (Figure 6.6). 
 
 
 
 
Figure 6.6 Chemical structures of the 
ligands used in the study. 
 
 
 
 
 
 
 
6.4 TACA and CACA at ρ2 GABAC Receptors 
TACA and CACA, which are GABA analogues with an unsaturated carbon-carbon 
bond, were tested at ρ2 WT receptors in terms of their agonist and additive effects. 
 
6.4.1 Agonist Effects of TACA and CACA 
TACA and CACA are partial agonists at ρ2 GABAC homomeric receptors with relative 
efficacies of 85% and 60%, respectively (Figure 6.7). Although TACA is not a full 
agonist at ρ2 receptors, it is slightly more potent than GABA (EC50 of TACA = 450 
nM), whereas CACA is significantly less potent than GABA and TACA with an EC50 
of 38 µM.
117
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Figure 6.7 Concentration 
response curves of GABA, 
TACA and CACA at ρ2 
GABAC homomeric 
receptors. (Data = Mean ± 
SEM, n = 4). 
 
 
 
Docking studies of GABA, TACA and CACA in the orthosteric binding site of the ρ2 
GABAC homology model predict a common interaction between these ligands in the 
binding site and the Arg85 residue. The ammonium groups of TACA and CACA are 
not close enough to Glu177 to form the salt bridge as with the ammonium group of 
GABA (Figure 6.8A and B). Although GABA was predicted to form H-bonds with 
Thr225 and Ser149, TACA is predicted to form a H-bond with Ser149 only, while 
CACA is predicted to form a H-bond with Thr225 only (Figure 6.8B). 
Figure 6.8 Docking results of GABA and TACA (yellow) and CACA (dark grey) in the orthosteric 
binding site of a ρ2 GABAC homology model based on GluCl in the open conformation. (A) Docking of 
GABA in the binding site. (B) Docking of TACA (yellow) and CACA (dark grey) in the binding site. 
 
Additionally, the unsaturated carbon atoms of TACA and CACA may be implicated in 
hydrophobic interactions with residues in loops D and E which are different to those of 
GABA with in the binding site. The predicted conformations of TACA and CACA in 
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the binding site are different to that predicted for GABA, which may effect their ability 
to stabilize the binding site during the apo state or the open conformation. 
 
6.4.2 Additive Effects of TACA and CACA at ρ2 GABAC Receptors 
Co-applying TACA and CACA with GABA EC50 at ρ2 GABAC homomeric receptors 
revealed that TACA elicits an additive effect on GABA EC50 responses, whereas 
CACA does not show any significant effect on the GABA EC50 responses (Figure 6.9). 
 
 
Figure 6.9 Concentration response 
curves of TACA and CACA co-
applied with GABA EC50 at ρ2 
GABAC receptors. (Data = Mean ± 
SEM, n = 5). 
 
 
 
These results suggest that GABA and TACA are additive in the gating process of ρ2 
ion channels. The GABA EC50 response demonstrates an increase in response to 
increasing concentrations of TACA (140 % of GABA EC50 when co-applied with 10 
µM of TACA). This increase is similar in magnitude to the response elicited by 10 μM 
TACA alone and indicates that TACA is either activating unactivated ion channels or is 
binding at vacant sites in receptors where GABA is already bound to some binding 
sites and along with GABA resulting in an increased response. In contrast, the co-
application of CACA does not result in a significant increase in the GABA EC50 
responses (P-value > 0.05). However at concentrations of up to 1000 μM, it also does 
not result in inhibition of the GABA EC50 responses. 
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6.5 Glycine, β-Alanine and 5-Aminovaleric Acid at ρ2 GABAC 
Receptors 
GABA analogues with various numbers of carbon atoms (glycine, β-alanine and 5-
aminovaleric acid) were tested at ρ2 GABAC homomeric receptors in terms of their 
agonist effects and in co-application with GABA EC50. 
 
6.5.1 Agonist Effects of Glycine, β-Alanine and 5-Aminovaleric Acid at ρ2 GABAC 
Receptors 
5-Aminovaleric acid is found to activate ρ2 GABAC receptors in a moderately potent 
and efficacious manner, while β-alanine and glycine activate these receptors with low 
potency but are highly efficacious (Figure 6.10). 
 
 
 
Figure 6.10 Concentration 
response curves of GABA, 
glycine, β-alanine and 5-
aminovaleric acid at ρ2 
GABAC homomeric 
receptors. (Data = Mean ± 
SEM, n = 4). 
 
 
Similar to the studies at ρ1 GABAC receptors, docking studies of glycine and β-alanine 
in the orthosteric binding site of the ρ2 GABAC homology model predict that the 
carboxylate groups of these ligands form interactions similar to GABA (Figure 6.11A). 
The ammonium groups of glycine and β-alanine are not close to Glu177 which suggest 
that these ligands are not able to form the salt bridge with the acid residue in the same 
way as GABA does (Figure 6.11A). 
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Figure 6.11 Docking studies of GABA, glycine, β-alanine and 5-aminovaleric acid in the orthosteric 
binding site of a ρ2 GABAC homology model based on GluCl in the open conformation. A. Docking of 
GABA (white color), glycine (yellow color) and β-alanine (red color) in the binding site. B. Docking of 
GABA (white color) and 5-aminovaleric acid (red color) in the binding site. 
 
Docking studies of 5-aminovaleric acid in the binding site predict the negative and 
positive poles of this residue i.e. carboxylate group and ammonium group, respectively 
form similar interactions to GABA, however the extra methylene group in 5-
aminovaleric acid may afford additional flexibility to the ligand and provide additional 
contacts with residues in loops D, E and F of the binding sites which may enhance the 
ability of the ligand to stabilize both the closed state as well as the open conformation 
(Figure 11B). 
 
6.5.2 Effects of Glycine, β-Alanine and 5-Aminovaleric Acid Co-applied with 
GABA EC50 at ρ2 GABAC Receptors 
Co-application of aliphatic GABA analogues glycine, β-alanine and 5-aminovaleric 
acid with GABA EC50 demonstrates different effects at ρ2 WT receptors (Figure 6.12). 
 
Figure 6.12 Concentration 
response curves of glycine, 
β-alanine and 5-
aminovaleric acid co-
applied with GABA EC50 at 
ρ2 GABAC receptors. (Data 
= Mean ± SEM, n = 4). 
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Glycine has a very small additive effect on GABA EC50 responses at μM 
concentrations, which decreases at mM concentration (Figure 6.12) while β-alanine has 
a weak additive effect on GABA responses at nM concentrations, then partially inhibits 
GABA responses at higher concentration (Figure 6.12). 5-Aminovaleric acid is a 
moderate antagonist of GABA responses at μM concentrations, inhibiting to a 
maximum of the GABA EC50 (Figure 6.12). The direct activation responses by β-
alanine and 5-aminovaleric acid and the results of their co-application with GABA 
EC50 suggest that the concentrations of these ligands needed to activate ρ2 receptors are 
the same as the concentrations of these ligands required to antagonize GABA 
responses. Furthermore, the activation magnitude by these two ligands at ρ2 GABAC 
receptors is similar to the magnitude of their inhibition of GABA responses. 
Interestingly, the carboxylate groups of GABA, β-alanine and 5-aminovaleric acid form 
similar interactions with the receptor, which may demonstrate the importance of 
interactions by carboxylate group for the activation of the channel. 
 
6.6 Muscimol, Isoguvacine and Imidazole-4-acetic Acid at ρ2 GABAC 
Receptors 
Heterocyclic GABA analogues muscimol, isoguvacine and imidazole-4-acetic acid 
(I4AA) were tested at ρ2 GABAC homomeric receptors in terms of their agonist effects 
and co-application with GABA EC50 effects. 
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6.6.1 Agonist Effects of Muscimol, Isoguvacine and Imidazole-4-acetic Acid at ρ2 
GABAC Receptors 
Homomeric ρ2 GABAC receptors show different sensitivities to the heterocyclic 
GABA analogues. Muscimol is the most potent and efficacious agonist
117
, followed by 
I4AA
117
 and isoguvacine respectively (Figure 6.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13 Concentration response curves of GABA, muscimol, isoguvacine and imidazole-4-acetic at 
ρ2 GABAC homomeric receptors. (Data = Mean ± SEM, n = 3). 
 
Docking studies of these ligands in the binding site of the ρ2 GABAC homology model 
in the open conformation predict that muscimol forms mainly similar interactions to 
GABA, whereas isoguvacine is predicted to form an additional cation-π interaction 
with Tyr228. I4AA forms π-π stacking interactions with Phe119 and Tyr179 residues in 
the binding site (Figure 6.14). These docking results give some explanation of why 
muscimol with interactions similar to GABA has the highest efficacy, however the 
heterocyclic carboxylate isostere of muscimol is not the most favourable for full agonist 
activity (Figure 6.14A). The ammonium group of isoguvacine is not close enough to 
Glu177 in order to form a salt bridge and instead it is stabilized by the aromatic box of 
Tyr179, Tyr222 and Tyr228 residues (Figure 6.14B), while the imidazole ring in I4AA 
is predicted to form multiple stacking interactions with the tyrosine residues. I-4-AA 
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also forms a salt bridge with Arg85 and a H-bond with Ser149 but not a salt bridge with 
Glu177 (Figure 6.14C). 
Figure 6.14 Docking studies of muscimol, isoguvacine and I4AA in the orthosteric binding site of a ρ2 
GABAC homology model based on GluCl in the open conformation. (A) Docking of GABA (white) and 
muscimol (yellow) in the binding site. (B) Docking of GABA (white) and isoguvacine (yellow) in the 
binding site. (C) Docking of GABA (white) and I4AA (yellow) in the binding site. 
 
6.6.2 Effects of Muscimol, Isoguvacine and Imidazole-4- acetic Acid Co-applied 
with GABA EC50 at ρ2 GABAC Receptors 
Co-application of muscimol, isoguvacine and I4AA with GABA EC50 showed that 
muscimol in µM concentrations slightly potentiates GABA responses. Isoguvacine, on 
the other hand, has a slight co-operative effect on GABA EC50 responses at 
concentrations below 100 µM. I4AA has an additive effect on GABA EC50 responses at 
nM ranges, then slightly antagonizes GABA responses at µM concentrations (Figure 
6.15). 
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Figure 6.15 
Concentration response 
curves of muscimol, 
isoguvacine and I4AA co-
applied with GABA EC50 
at ρ2 GABAC receptors. 
(Data = Mean ± SEM, n = 
3). 
 
 
The results show that muscimol and isoguvacine have a slight co-operative effect on 
GABA EC50 while I4AA has antagonist effects at the same range of concentrations. 
These results may suggest that muscimol and isoguvacine are not competing with 
GABA over the binding sites. I4AA, on the other hand, has shown cooperativity with 
GABA at nM concentrations however increasing concentration to the µM range leads 
to competition between GABA and I4AA over the same binding site which may confer 
the slight antagonism at GABA EC50. 
 
6.7 Competitive Antagonist (R)-ACPBPA with ρ2 GABAC Receptors 
(R)-Aminocyclopentenyl-butyl phosphinic acid ((R)-ACPBPA) is potent and selective 
competitive antagonist at ρ2 GABAC receptors (i.e. IC50 = 6.22 µM ‘data not 
published’). 
The ρ2 GABAC homology model based on GluCl in the apo state with (R)-ACPBPA as 
the reference ligand predicts that the ligand forms the common interactions of other 
agonists and antagonists at this site, with additional interactions as well. 
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Figure 6.16 Docking studies of (R)-ACPBPA in the orthosteric binding site of a ρ2 GABAC homology 
model based on GluCl in the apo state. A. Various interactions of (R)-ACPBPA with residues in the 
binding site. B. Hydrophobic interactions of (R)-ACPBPA with multiple aromatic residues in the binding 
site. 
 
The common interactions predicted to be formed by (R)-ACPBPA and other ligands in 
the binding site are the two salt bridges of the phosphonic acid and ammonium moieties 
with Arg85 and Glu177, respectively, and a H-bond between the hydroxyl of Thr 225 
and the phosphinic oxygen (Figure 6.16A) 
Additional interactions of this ligand in the binding site are H-bonding with Arg151, 
cation-π interaction of the ammonium group with Try222 and cation-cation interaction 
of the ammonium group with Arg230 (Figure 6.16A). Moreover, multiple additional 
hydrophobic interactions of the unsaturated five-membered ring system of (R)-
ACPBPA are observed with tyrosine residues that are surrounding the binding site 
(Figure 6.17B). 
Interestingly, the enantiomer of the (R)-ACPBPA antagonist, (S)-ACPBPA, is a fold 
less potent at ρ2 homomeric receptors compared to ρ 1 homomeric receptors (data not 
published), and is predicted by modelling to have an emodel value higher than the R 
isomer (-53.45 and -49.32 kcal/mol for (R)- and (S)-ACPBPA, respectively). These 
results may indicate that the binding affinity of the (R) isomer for the binding site of 
the ρ2 protein is higher than that for the (S) isomer which may confer the better potency 
of (R) isomer (Figure 7.8). 
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7. General Discussion 
7.1 Ligand-residue Interactions, Binding and Channel Gating 
As agonists bind at their binding site they cause conformational changes in the binding 
site to facilitate the formations of the binding interactions, these changes in the protein 
lead to further conformational changes resulting in activation of the receptor. An 
agonist in the binding site should fit in a specific way in order to result in certain 
changes in the protein. In GABA ion channel receptors, the ligands bind in the 
extracellular domain, and in the case of agonists generate local and global 
conformational changes within the protein, which are relayed through protein-protein 
interactions until they reach the transmembrane domain, leading to many changes in the 
inter- and intra-subunit interactions that result in the channel pore becoming wider and 
allowing selected ions to pass through (Figure 7.1). 
 
Figure 7.1 Second membrane 
domain (TM 2) showing the pore 
in apo state and open 
conformation of ρ1 GABAC 
homology models based on 
GluCl. The apo state is 
represented by in green and the 
open conformation is represented 
by blue.  
 
 
 
Ligands in the orthosteric binding site may form interactions that are considered 
essential either to convert the channel into the open conformation or to stabilize the 
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protein in the inactive apo conformation. Ligands that are partial agonists have a mixed 
action as their efficacies are sub-maximal compared to the agonists due to their ability 
to stabilize the open conformation not being as efficient as a full agonist and during the 
time they are available at the same binding site with another agonist, their ability to co-
operate/compete for these binding sites will effect on the overall magnitude of 
activation. 
GABA docking studies in this thesis predicted the interactions required by agonists to 
switch the channel into the open conformation. These interactions are: the positive 
ammonium and negative carboxylate groups are essentially required to form two salt 
bridges with acidic and basic residues, respectively. The carboxylate group of GABA 
forms two H-bonds with the side chains of two hydrophilic residues that are located in 
the ρ (+) and ρ (-) faces of different subunits, in particular loop C and loop E of the 
interface (Thr244 and Ser168, respectively). The ammonium group of GABA forms a 
H-bond with the backbone carbonyl group of Ser197 in loop B of the ρ (+) face and the 
ligand is mainly stabilized in the binding site by aromatic residues forming an aromatic 
box: Tyr241 and Tyr247 residues in loop C and Tyr198 in loop B of ρ (+), and Tyr102 
in loop D which is predicted to have a role in the coupling of binding to gating during 
the flipping of the channel from closed to open conformations. Furthermore, some 
aliphatic hydrophobic residues in loop E, loop F and loop G either fully or partially line 
the binding site and are likely to provide further stabilization of the ligand in the 
binding site in the open state. An aromatic residue in loop A (Phe138) has its side chain 
oriented toward the binding site and may stabilize the ligand during channel activation, 
however not through the aromatic box, but rather via hydrophobic contacts with the 
side chains of ligands. 
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These interactions are expected to form between GABA and residues in the orthosteric 
binding site. Most structurally similar agonists would be expected to form similar 
interactions to GABA in order to activate the channel. These interactions that occur 
when agonists bind, require the movement of loop C closer to the agonist as an 
essential and initial step for the gating process. The movement of loop C may provide 
the required interactions of the agonist in the binding site along with the aromatic box 
which may initiate the movement of loop F and further conformational changes may 
stabilize the open conformation of the channel. 
Partial agonists are ligands with sub-maximal activity compared to the reference 
agonists that may demonstrate high or low efficacy depending on the interactions that 
form in the binding site, which determine whether they have a greater ability to 
stabilize the closed apo state or the open conformation. Partial agonists form many 
interactions similar to those of full agonists in the binding site, however partial agonists 
are all missing some of the essential interactions which may effect the overall stability 
of the protein and additional interactions may also effect the generated conformational 
changes and relative stability of different states. 
Competitive antagonists essentially stabilize the closed conformation that prevents the 
channel flipping to the open state. GABA is prevented from binding by the location of 
the ligand in the binding site, however competitive antagonists also hold the ion 
channel in the closed conformation. Those ligands which inhibit the agonist responses 
bind tightly in the site and stabilize the receptor in the inactive state. This can be 
achieved in the orthosteric binding site of ρ1 GABAC by forming additional 
hydrophobic contacts with aromatic residues that surround the binding site. These 
interactions stabilize the closed conformation in addition to blocking the site, so that 
GABA or other agonists are prevented from binding and activating the channel. In the 
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case of ρ1 GABAC ion channels, the bulkier and conformationally restricted 
heterocyclic ligand, TPMPA binds in the site and forms hydrophobic contacts with 
Tyr241 located in loop C which prevent the loop from moving forward and thus leads 
to the channel stabilized in the closed conformation (Figure 7.2). 
 
Figure 7.2 TPMPA bound in the ρ1 
GABAC model based on GluCl in the 
apo state. 
 
 
 
 
 
 
 
 
Potent competitive antagonists form multiple interactions in the binding site without 
generating conformational changes that are propagated through the protein and lead to 
opening of the ion channel or they may form interactions that generate different 
conformational changes that do not lead to an open channel. 
 
7.2 Partial Agonism, ρ GABAC Homomeric Receptors and Co-
operative (Additive)/Inhibition Effects 
The co-application of high concentrations of two ligands at ρ homomeric receptors 
would lead to competition between them at the binding site, influenced by the relative 
concentrations, and the relative binding affinities of each ligand. Stabilization of an ion 
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channel in the apo state or the open conformation requires a particular number of 
binding sites within a single ion channel to be occupied in order to retain the channel 
stabilized in either state. When an antagonist is co-applied with an agonist, it may bind 
at an empty site stabilizing it in the apo conformation, or it may displace GABA, 
particular if it has a high binding affinity and then stabilize that subunit in the apo state. 
When a partial agonist is co-applied with GABA, unless the partial agonist is stronger 
than GABA in binding into the binding site, GABA will be the main ligand responsible 
for channel activation, however binding of a partial agonist at a free binding site within 
the same channel along with GABA or activation of another channel by the partial 
agonist would only lead to an additive effect to GABA responses within a range of sub-
maximal GABA efficacy. However, if the partial agonist also shows antagonist effects 
on GABA responses, such as I4AA at ρ1 homomeric receptors, it reasonably suggests 
that both ligands (i.e. GABA and I4AA) are competing for the same site, however the 
partial agonist is able to bind and/or substitute GABA molecules and stabilize the apo 
state of the channel more predominantly. In spite of this, a full antagonist effect will not 
be reached as the partial agonist still has some activation effect that will show some 
response. 
The co-application of partial agonists with GABA at its EC50 concentration at ρ1 and 
ρ2 GABAC homomeric receptors interestingly showed additive or co-operative effects 
on GABA responses when low concentrations of partial agonist were applied. 
Increasing the concentration of the partial agonist may result in increased co-operative 
effects even at very high mM concentrations such as for glycine and muscimol, or 
inhibitory effects, but without complete antagonism of the GABA responses, such as 
with β-alanine and I4AA. These two different effects are mainly due to the partial 
agonist’s interactions in the binding site. Generally, any partial agonist would initially 
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show some additive effect on GABA responses due to the availability of free binding 
sites (Table 7.1). 
In a single ion channel which consists of five subunits there are five identical binding 
sites. According to previous studies with ρ1 GABAC homomeric receptors, GABA or 
any agonist would require binding in three to four of those binding sites in order to 
result in channel gating.
88
 In such a case one to two binding sites may remain vacant 
even with the channel in the open state. Co-application of small concentrations of a 
partial agonist with GABA EC50 will allow for either ligand to fill up all empty binding 
sites rather than competing over the same site. The ligands may lead to increased 
effects to the GABA responses due to the ability of partial agonist to fill up empty 
binding sites of other channels and this may lead to the enhancement in responses of 
GABA. Filling up empty binding sites in channels already occupied by GABA may 
also contribute on the same channel to flip it to the open state, which may enhance 
efficacy as well. If any or both of these cases are happening, the co-application of low 
concentrations of partial agonists with GABA is showing additive effects at ρ1 and ρ2 
GABAC homomeric receptors. 
 
Figure 7.3 Diagram of homomeric ρ1 GABAC 
receptors showing a single ion channel with three 
binding sites occupied by GABA molecules and 
two others that are empty. Diagram is also 
showing a free molecule of GABA and a few of 
the other ligand (i.e. partial agonist). 
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When high concentrations of partial agonist are applied along with GABA then the 
ligand may increase the GABA EC50 response at all concentrations, or the ligand may 
begin to antagonize the GABA EC50 responses (Figure 7.3). A partial agonist that 
maintains an additive or co-operative effect on GABA responses even at higher 
concentrations suggests that this partial agonist is cooperative with GABA without 
competing for the same binding site. This may indicate that the ligand is probably just 
not as strong as GABA at binding in stabilizing apo or open states, however, it would 
occupy other empty binding sites on the same ion channels which lead to enhance 
GABA responses. 
On the other hand, a partial agonist that has antagonist effects on GABA responses at 
higher concentrations would antagonize to a sub-maximal degree compared to a full 
antagonist, suggesting that this partial agonist does not co-operate effectively with 
GABA, but competes with it for the same binding sites. This may indicate that the 
ligand binding is at least as strong as GABA, however, stabilizing apo over open states 
and by competing with GABA for the same binding site would lead to a decrease in the 
overall responses of GABA via greater stabilization of the apo state resulting in a sub-
maximal antagonist effect. 
7.3 Partial Agonists Showing Pharmacological Subunit-selective 
Features between ρ GABAC Receptors 
Partial agonist studies in this thesis have shown pharmacological subunit-selective 
features between ρ1 and ρ2 GABAC homomeric receptors in terms of activation and co-
operative (additive)/inhibition effects and magnitude (i.e. potency and efficacy) of these 
partial agonists at these homomeric receptors (Table 7.1). 
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Table 7.1 Summaries the effects (Agonist effect, Efficacy, Additive/Inhibition effects and Glide Emodel values) of the partial agonists at the ρ1 and ρ2 GABAC 
homomeric receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. GABA has glide emodel values = -37.2 and -35 (kcal/mol) at ρ1 and ρ1 homomeric receptors, respectively. 
Ligands ρ1 
EC50 
ρ1 
Efficacy 
ρ1 
(Additive/inhibition) 
(%) 
ρ1 
Glide 
Emodel 
(kcal/mol) 
ρ2 
EC50 
ρ2 
Efficacy 
ρ2 
(Additive/inhibition) 
(%) 
ρ2 
Glide 
Emodel 
(kcal/mol) 
TACA 600 
nM 
95 % 190 % -32.3 450 
nM 
85 % 140 % -33.93 
CACA 92 
µM 
60 % 160 % -31.1 37 
µM 
60 % 104 % -29.1 
Glycine 9350 
µM 
25 % 170 % -26.844 1150 
µM 
70 % (115 / 104) % -23.5 
β-Alanine 400 
µM 
30 % (120/40) % -34.95 560 
µM 
85 % (120/85) % -28.3 
5-
Aminovaleric 
acid 
600 
µM 
3 % (125/2.5) % -38.8 36 
µM 
45 % (110/50) % -34.1 
Muscimol 1.25 
µM 
80 % 125 % -38.3 0.75 
µM 
65 % 112 % -38 
Isoguvacine 205 
µM 
40 % 135 % -35.43 35 
µM 
25 % 
 
(120/110) % -30.55 
Imidazole-
4-acetic 
acid 
66 
µM 
10 % (115/3.5) % -40.5 0.3 
µM 
40% (110/80) % -36 
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Although TACA and CACA are almost equal in their potency and efficacy at ρ1 and ρ2 
homomeric receptors, they show moderate to significant differences in their additive 
effects (Table 7.1). TACA shows 190% co-operative effects at ρ1 GABAC homomeric 
receptors, however only 140% at ρ2 GABAC receptors. On the other hand, CACA 
shows 160% co-operative effects at ρ1 GABAC homomeric receptors, but no significant 
additive effect (i.e. 104 %) at ρ2 GABAC receptors (Figure 7.4). 
Figure 7.4 Concentration response curves of TACA (A) and CACA (B) at ρ1 and ρ2 GABAC receptors, 
Results = Mean ± SEM, n = 5. 
 
Glycine, β-alanine and 5-aminovaleric acid generally show significantly higher efficacy 
at ρ2 GABAC receptors than at ρ1 GABAC receptors (Figure 7.5) (Table 7.1). However, 
β-alanine has similar potency at both ρ1 and ρ2 homomeric receptors, whereas glycine 
and 5-aminovaleric acid are more potent at ρ2 GABAC receptors (Figure 7.5) 
Figure 7.5 Concentration response curves of GABA, glycine, β-alanine and 5-aminovaleric acid at ρ1 and 
ρ2 GABAC homomeric receptors. Results = Mean ± SEM, n = 5. 
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Although glycine has a 170 % co-operative effect at ρ1 GABAC receptors, it has little 
co-operative effect (115 %) at ρ2 GABAC receptors, which is abolished by increasing 
the concentration above 100 µM (Table 7.1) (Figure 7.6). 
 
 
Figure 7.6 Concentration response 
curves of glycine co-applied with 
GABA EC50 at ρ1 and ρ2 homomeric 
receptors. Results = Mean ± SEM, n = 
5. 
 
 
β-Alanine shows a similar magnitude of additive effect at both receptor sub-types, 
however its antagonist effects at ρ1 homomeric receptors are more than at ρ2 
homomeric receptors. 5-Aminovaleric acid shows greater additive and inhibition effects 
at ρ1 homomeric receptors than at ρ2 homomeric receptors (Table 7.1). 
Muscimol shows similar to slightly different potency and co-operative 
(additive)/inhibition effects at ρ1 and ρ2 homomeric receptors. Although isoguvacine 
shows 6-fold greater potency at ρ2 homomeric receptors, it shows only a slight 
difference in additive effect. Interestingly, isoguvacine which shows additive effects 
even at higher µM concentrations at ρ1 homomeric receptors, exhibits decreased 
additive effects at concentrations greater than 100 µM at ρ2 homomeric receptors 
(Table 7.1). 
Imidazole-4-acetic acid shows significant differences in potency and efficacy between 
ρ1 and ρ2 homomeric receptors. Potency and efficacy of I4AA are 4- and 100-fold 
higher at ρ2 that ρ1 homomeric receptors.115 
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I4AA shows similar very weak enhancement of the GABA EC50 response at both ρ1 
and ρ2 homomeric receptors. However, at ρ1 GABAC receptors, I4AA is a potent 
antagonist but shows only very weak inhibitory effects at ρ2 GABAc receptors. 
 
Figure 7.7 Concentration response 
curves of I4AA co-applied with 
GABA EC50 at ρ1 and ρ2 
homomeric receptors. Results = 
Mean ± SEM, n = 5. 
 
 
The previous results with partial agonists at ρ1 and ρ2 GABAC homomeric receptors 
show subunit selectivity in pharmacological properties. These results may provide a tool 
for generating more ligands that show selectivity at one of these subunits over the other.  
The glide Emodel results of partial agonists are generally predicted to be higher at ρ1 
than at ρ2 homomeric receptors (Table 7.1), values which may indicate that the studied 
ligands are able to form more interactions in the binding site of ρ1 over ρ2 receptors. 
These findings may result from the unconserved residues in loop D of the binding sites 
of the two subunits. 
The glide Emodel results of partial agonists are generally predicted to be higher at ρ1 
than at ρ2 homomeric receptors (Table 7.1), values which may indicate that the studied 
ligands are able to form more interactions in the binding site at ρ1 over ρ2 receptors. 
These results may be explained along with the unconserved residues in loop D of the 
binding sites of the two subunits. 
The enatiomeric antagonists (R)-ACPBPA and (S)-ACPBPA were reported in our lab to 
show subunit selectivity at ρ1 and ρ2 GABAC homomeric receptors,. (R)-ACPBPA has 
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an IC50 = 59.3 µM and 6.22 µM at ρ1 and ρ2 homomeric receptors, respectively. 
Whereas, (S)-ACPBPA has an IC50 = 4.97 µM and 11.24 µM at ρ1 and ρ2 homomeric 
receptors, respectively (Data not published). 
To study these results in terms of ligand binding affinity in the orthosteric binding site 
and interactions that these enatiomeric antagonists may be involved in with residues 
surrounding the binding site, these isomeric antagonists were redocked into the ρ1 and 
ρ2 homology models based on GluCl in the apo state (Figure 7.8). 
Interestingly, the antagonists have generally higher glide emodel values, indicating 
lower affinity of binding due to the overall interactions of antagonists in the orthosteric 
binding site of the ρ2 model compared to the ρ1 model. (R)-ACPBPA has binding 
affinities of -53.5 and -52.1 (kcal/mol) in the binding site of ρ1 and ρ2 models. On the 
other hand, (S)-ACPBPA has binding affinities -58.76 and -49.4 (kcal/mol) in the 
binding site of ρ1 and ρ2 models, respectively. 
Figure 7.8 Docking studies of (R)-ACPBPA and (S)-ACPBPA in the orthosteric binding site of ρ1 and ρ2 
homology models based on GluCl in the apo state. A. Docking studies of (R)-ACPBPA (silver) and (S)-
ACPBPA (yellow) in the binding site of the ρ1 model. B. Docking studies of (R)-ACPBPA (silver) and 
(S)-ACPBPA (yellow) in the binding site of the ρ2 model. 
In terms of interactions, (R)-ACPBPA which is 10-fold more potent at ρ2 than ρ1 
homomeric receptors, is predicted by modelling to form a salt bridge between its 
ammonium group and Glu177 in the binding site of ρ2 receptors. However, at ρ1 
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receptors this side chain is only stabilized by the aromatic box of the Tyr198 and 
Tyr247 (Figure 7.8). This may predict the higher affinity and potency of the R isomer at 
ρ2 homomeric receptors over ρ1 homomeric receptors. 
 
4. Homology Models, GABA Docking and Experimental Structure 
The GABAC models were generated using five templates allowing us to study the 
conserved residues in the binding site and the orientation of their side chains. The 
different templates had differences in terms of their residues that aligned up with the ρ1 
subunit which were useful to predict the role of those residues either through of 
experimental studies or ligand interactions in the binding site. In the final models based 
on GluCl, the unconserved residues in ρ1 subunit that had been predicted by other 
models based on the other templates were fixed accordingly. The final model which was 
refined by other models based on all templates was used for molecular basis studies of 
GABA and TPMPA, helps in predicting the roles of hydrophilic residues in the binding 
sites and studying the binding of the other studied ligands in the binding site. 
GABA docking studies were done with all the generated models and carried out in 
different ways. The GABA docking in the binding site of the crystalized protein is made 
to facilitate the optimization of the generated models and docked GABA during 
modelling process. In the case when docking studies of GABA was not reasonably 
predicting many of experimental findings, GABA was docked after grid generation in a 
free orthosteric binding site. Docking Studies of GABA in the generated models 
facilitates recognizing and predicting most of interactions that agonists may form in the 
orthosteric binding site. These interactions of GABA with residues are also studied and 
refined with the final model. 
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The final model of GABAC is based on an experimental structure of the GluCl structure 
which is optimized according to conserved residues with other templates and is used to 
predict roles of residues in the binding site along with previous experimental results.     
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8. Conclusions 
In the current study, ρ1 GABAC ‘GABA bound’ homology models were generated 
using all available templates for ligand-gated ion channel receptors that had been co-
crystalized with ligands in the orthosteric site. AChBP, ELIC and GLIC have relatively 
low amino acid sequence identity with ρ1, while GABAA β3 and GluCl have 
considerably higher homology. Despite the obvious advantages of GABAA β3 and 
GluCl as templates over others, homology models were generated based on all 
templates and then compared. The model based on the GABAA β3 template was not 
found to fully predict all critical interactions of GABA with residues found to be 
important through experiment, however the model based on the GluCl template was 
found to be in excellent agreement with previous experimental findings and selected as 
the best model of ‘GABA bound’ ρ1 GABAC. This model was used for further study of 
the GABA conformation by performing a QM-polarized GABA docking study. An 
additional advantage of the GluCl template is that a second GluCl structure has now 
been reported with GluCl in the apo state.  
Loop G in ρ1 GABAC receptors has not previously been reported as being potentially 
involved in molecular interactions with GABA in the binding site. Docking studies of 
GABA in the orthosteric binding site of the generated ρ1 model identified three residues 
with their side chains oriented toward the binding site. Gln83 is the closest to GABA 
and in studies with all templates Gln83 was always predicted to form various 
interactions with GABA. 
Muscimol with a high efficacy relative to the GABA maximal response at ρ1 receptors, 
adopts a conformation similar to GABA, while I4AA which has a low efficacy relative 
to the GABA maximal response, adopts a conformation different to GABA (Table 4.1). 
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In addition, the imidazole ring system is predicted by docking be involved in π-π 
stackings with aromatic residues in the protein which is likely to result in much greater 
stabilization of the apo state allowing this ligand to compete strongly with GABA for 
binding sites and effectively antagonizing EC50 responses of GABA.  
Not surprisingly, the best model for the antagonist TPMPA based on GluCl in the apo 
state is different to the models generated for GABA in the open conformation, with 
differences mainly in the positions of loop C. While TPMPA formed many similar 
binding interactions to GABA, it also formed many additional hydrophobic interactions 
with aromatic residues, and between the methyl group on its phosphinic acid moiety 
with the aromatic ring of Tyr102. Our model predicts that TPMPA is able to stabilize 
the binding site in the apo conformation very well which may explain the high potency 
of TPMPA.  
The best models of GABA and TPMPA based on GluCl in open and apo states, 
respectively, may be use for future studies towards a deeper understanding of the 
molecular basis of these receptors, to identify more ligands which may bind in the 
orthosteric binding site and to provide hypotheses for future studies. 
Hydrophilic residues with their functional group side chains oriented toward the binding 
site were first identified by homology model and GABA docking studies. These studies 
highlight two residues Thr244 and Ser243 located in loop C and Ser168 located in loop 
E of the orthosteric binding site. Additionally, GABA docking studies predicted that 
Thr244 and Ser168 form H-bonds with the carboxylate group of GABA. These two 
residues are also predicted to have various contacts with GABA that may provide 
essential stability during the gating process. Modelling studies in this thesis predict a 
role for Ser243 in stabilizing the closed and open conformations. The hydroxyl side 
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chain of Ser243 is not fully oriented toward the binding site, but rather partially facing 
the adjacent subunit, suggesting inter-subunit interactions between this residue and 
residues in the adjacent subunit may form. 
The study of these hydrophilic residues by rational point mutations and testing against 
GABA, some representative partial agonists and antagonists was able to identify 
essential roles of these hydrophilic residues in the closed/open conformations and 
during channel gating. 
Threonine 244 is predicted by GABA docking studies to form a H-bond with the 
agonist during the gating process. Formation of the H-bond is postulated to require the 
movement of loop C forward closer to the agonist as an essential step for flipping to the 
open conformation. The activation effect by GABA moderately decreases when serine 
was introduced at the site. Although GABA was also able to activate mutant receptors 
with alanine and cysteine at the site, the concentrations of mutant receptor that were 
injected into the oocytes were increased many times. This suggests that the expression 
level may have significantly decreased with these mutant receptors. The partial agonists 
studied demonstrated significant decreases in their potencies and efficacies at ρ1 
GABAC T244S mutant receptors. The additive/inhibition effects of these partial 
agonists were also shown to moderately decrease at the same mutant receptors, however 
the tested aliphatic partial agonists retained their agonist/antagonist effects, while the 
tested heterocyclic partial agonists became inactive at these mutant receptors, fully 
antagonizing GABA EC50 responses. These results suggest that structural differences of 
partial agonists may result in the formation of different interactions leading to the 
partial agonist effect, however their partial agonism has similar features.  The studied 
competitive antagonists did not show changes in the potency at T244S mutant receptors 
in comparison to wild type receptors. The bulkier structure of these antagonists may 
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prevent the movement of loop C closer as the two aromatic residues (Tyr 241 and Tyr 
247) in loop C could stabilize the ligand in the binding site without moving the loop 
forward which may explain what the model predicted, and that is the antagonists do not 
form the H-bond with Thr244.  
When the side chain has been removed at the Thr244 site through the T244A mutation, 
GABA demonstrated lower efficacy compared to β-alanine. β-Alanine demonstrated the 
highest efficacy of all agonists and partial agonists tested at ρ1 GABAC T244A mutant 
receptors. Homology model studies predicted that β-alanine forms more contacts with 
the alanine residue at position 244 than GABA. At ρ1 GABAC T244A receptors, β-
alanine exhibited decreased responses when GABA or TPMPA were co-applied with it. 
These results suggest that TPMPA is binding at the orthosteric binding site of these 
mutant receptors, however a significant decrease in its potency was noticed. 
GABA elicited very small responses at ρ1 GABAC T244C mutant receptors. MTSEA 
with a thiosulfonate side chain demonstrated greater efficacy than GABA. Docking 
studies predict that MTSEA will not form an S-S covalent bond with either cysteine at 
position 244, or with other residues. MTSEA, which shows only weak activation and 
additive/inhibition effects at ρ1 GABAC WT receptors, still has the same magnitude of 
activation effects at ρ1 T244C mutant receptors however GABA is the ligand that 
shows significant decrease in sensitivity as it appears unable to stabilize the open 
conformation as at ρ1 wild type receptors.  
Serine 243 is predicted by the model generated in this thesis to face the opposite subunit 
and to form contacts with Arg104 and Lys210 residues that stabilize either the closed 
state or the open conformation. GABA and other tested ligands were predicted by 
docking studies not to form H-bonds with the hydroxyl side chain of Ser243. Due to the 
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significant decrease in GABA potency at the mutant receptors when the hydroxyl group 
is removed, this serine at the middle of loop C is suggested to be critically important for 
stabilization of the open conformation. The effect of applying a constraint to the 
hydroxyl group through mutation to a threonine or introducing another functional group 
at position 243 was investigated with GABA, some partial agonists and some 
representative antagonists. While GABA and TACA demonstrated weak to moderate 
decreases in potency with the mutant receptors, the partial agonists showed significant 
decreases in their activation (both potency and efficacy) effects at the same mutant 
receptors. The co-operative (additive)/inhibition effects of the studied partial agonists 
were also decreased with theses mutant receptors. The effects of partial agonists which 
show pure additive effects at ρ1 WT receptors shifted to the right, however this additive 
effect was decreased by increasing applied concentrations of these ligands, suggesting 
the ability of these ligands to effectively bind and compete with GABA into the same 
binding site, which may also suggest that GABA became slightly less stabilized in the 
binding site. Muscimol in particular at ρ1 S243C mutant receptors showed an antagonist 
effect suggesting a competition between muscimol and GABA over the same binding 
site. The studied antagonists were found to be affected differently by the introduced 
mutants, apparently due to the most likely overall interactions those antagonists form in 
the binding site. TPMPA and THIP demonstrated decreases in their antagonist effects 
however the structurally different gabazine was unaffected, which may suggest that the 
effect of the Ser243 residue depends on the overall interactions that an antagonist forms 
in the binding site. Mutant receptors at the Ser243 site converted the full competitive 
antagonist 3-APPA to a partial agonist with a mix of activation and potentiation effects 
when co-applied with GABA EC50. 
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Serine 168 in loop E is predicted by modelling and docking studies to form H-bonds 
with GABA and all the tested partial agonists and antagonists. These ligands are also 
predicted to form various contacts with the side chain of Ser168. ρ1 GABAC mutant 
receptors at position 168 that were studied included S168A with the hydroxyl group 
removed, and S168C where the hydroxyl side chain was converted to a thiol. Both 
mutants demonstrated decreases in the potency of GABA by 100- and 600-fold, 
respectively. The results suggest a role of this residue in stabilizing ligands in the 
binding site which would stabilize either the apo or open states. Interestingly, TACA 
demonstrates greater efficacy than GABA by 25-30% at ρ1 S243C mutant receptors 
which may be due to the longer distance between the carboxylate and ammonium 
groups of TACA that may allow contacts leading to the higher efficacy compared to 
GABA as predicted by the model (Figure 5.8). 
The activation and co-operative (additive)/inhibition effects of partial agonists were 
decreased at both ρ1 S168A and ρ1 S168C mutant receptors, however the magnitude of 
the co-operative (additive) effects of many of the studied ligands were higher than at ρ1 
WT receptors. Interestingly, removing the functional group at position 168 reduces 
muscimol sensitivity by several hundred µM, however it still has some additive effect to 
the GABA EC50 response and shows weak antagonist effect as well at higher 
concentrations. The studied antagonists showed moderate decreases in their potencies, 
however 3-APPA becomes inactive when the functional group was removed at position 
168. 
The ρ2 GABAC models were generated based on GluCl in apo and open conformations 
to study various interactions of GABA and (R)-ACPBPA in the binding site. GABA 
was predicted to form interactions similar to GABA with the ρ1 homology model. The 
antagonist (R)-ACPBPA was also predicted to form interactions similar to antagonists 
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at ρ1 GABAC, however it is also predicted to form an additional cation-cation 
interaction with Arg230. The studied partial agonists have shown variable potencies and 
efficacies at ρ2 GABAC receptors. The activation and additive/inhibition effects of these 
ligands were discussed along with their docking studies in the ρ2 GABAC homology 
model. 
The studied partial agonists have shown subunit selective pharmacological features 
between the ρ1 and ρ2 subunits in terms of their efficacy and co-operative 
(additive)/inhibition effects. The results of selectivity between the ρ GABAC subunits 
for the partial agonists are listed in Table 7.1. Interestingly, the Emodel values of the 
studied ligands with ρ1 and ρ2 homology models were generally shown to be higher at 
ρ2 than ρ1.  
In this thesis, the GABA binding site was studied in terms of residues potentially 
involved in the mechanism of action. Other binding sites such as those for divalent ions, 
flavonoids and picrotoxinin are also sites to be studied that could be studied in future 
work. Molecular basis of their binding would be of interest and studying these sites 
would also assist in understanding the action of ligands that bind in those sites. 
The residues identified in this study highlights the critically important residues in the 
binding site such as acidic residues and some potential residues that are located at loop 
G. Experimental studies of these residues by site mutations and electrophysiology may 
reveal an important roles in the mechanism of ligand binding and/or channel activation.    
The studies made with Gabazine in this thesis revealed that this ligand is implicated in 
many interactions in the orthosteric binding site. Further studies on the residues 
predicted to form variety of interactions with Gabazine may help in understanding its 
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mechanism of action and in exploring role of those residues in the mechanism of the 
channel gating. 
Studying the intra-selectivity of ρ1 and ρ2 homomeric channel receptors would be of 
interest. This thesis has predicted some unconserved residues in the binding sites of the 
two similar subunits forming homomeric receptors, which could be studied 
experimentally to test the hypotheses that proposed in this thesis. 
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